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ABSTRACT 
 
Increasing evidence from epidemiological studies, retrospective studies, clinical 
observations as well as pre-clinical in vitro and in vivo data suggest that Parkinson’s disease 
(PD) involves both the enteric (ENS) and central nervous system. Notably, along with 
anosmia, intestinal dysfunction is one of the most common prodromal symptoms, which can 
emerge even decades before PD diagnosis. To understand how intestinal inflammation 
affects the enteric nervous system in the context of PD, we conducted studies involving 
multiple mouse models including: a transgenic model of PD (MitoPark), a model of chronic 
exposure to the environmental toxin manganese (Mn) as well as the dextran sodium sulfate 
(DSS) model of colitis. Many neurological diseases, including PD, are gradually being 
recognized as multi-faceted maladies involving genetic predisposition and environmental 
triggers. 
Mn exposure has been implicated in environmentally-linked PD as evidenced by 
epidemiological studies done on humans exposed to Mn during mining, welding, and dry 
battery manufacturing. With the prevalence of high Mn content in the groundwater in many 
regions of the US, we investigated the effect of chronic low-dose exposure to Mn on the GI 
tract. We found that oral administration of Mn does affect the mouse ENS. In particular, Mn 
accumulation in enteric glial cells (EGC) induces mitochondrial dysfunction and ultimately 
cell death. In an in vivo model of chronic Mn exposure, we observed that even a low dose of 
Mn was sufficient to decrease gastrointestinal (GI) motility, alter the gut microbiome 
population as well as GI metabolism. MitoPark mice, which mimic the adult-onset and 
progressive nature of PD, showed mild intestinal inflammation and spatial differences in GI 
motility. Curiously, when compared to their wild-type littermate controls, these mice have 
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higher motility in the small intestine but lower in the large intestine. Moreover, exposure to 
an environmental toxin potentiated cell death of EGC in the colon with 12-week-old 
MitoParks having increased levels of the pro-apoptotic protein bax compared to non-exposed 
MitoParks. In older MitoPark mice, the ENS showed presence of inflammation with 
increased expression of pro-inflammatory factors, including inducible nitric oxide (iNOS) 
and tumor necrosis factor alpha (TNFα).  
We also found similar results in mice afflicted with DSS-induced colitis. These mice 
showed intestinal inflammation as well as immune cell infiltrations. Intriguingly, the 
lumbosacral region of the spinal cord and the substantia nigra region in the brain of DSS 
mice also showed higher pro-inflammatory (TNFα, iNOS and IL-1β) transcripts. 
Taken together, our data suggest that intestinal inflammation, caused either by a genetic 
predisposition or exposure to environmental toxins can induce neurochemical changes in the 
ENS, and consequently CNS changes, via the gut-brain axis. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Dissertation Organization 
The alternative format was chosen for this thesis and consists of manuscripts that 
have been published, or are being prepared for submission. The dissertation contains a 
general introduction, three research papers and a conclusions/future directions section that 
briefly discusses the overall findings from all chapters. The references for each manuscript 
chapter are listed at the end of that specific section. References pertaining to the background 
and literature review as well as those used in general conclusion section are listed at the end 
of the dissertation. The introduction section under Chapter I provides a brief background and 
overview of Parkinson’s disease (PD). In the Literature review-I section, authors discuss and 
summarize current literature implicating the effect of environmental toxins on the gut 
microbiome and subsequently the gut-brain axis. The Literature Review-II section published 
in Pharmacology & Therapeutics covers current evidence implicating intestinal 
inflammation in the pathogenesis of various neurological disorders including PD and pertains 
to Chapters II and III.  
Chapter II explores how chronic exposure to a low-dose toxin can lead to intestinal 
inflammation. Particularly, it explores the role of Mn toxicity in changing gastrointestinal 
physiology and enteric glial functioning. Chapter III pertains to the characterization of 
gastrointestinal motility symptoms in the MitoPark mouse model of PD. Chapter IV studies 
intestinal inflammation potentiates neuroinflammation in the mid-brain providing evidence 
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of involvement of the gut-brain axis via spinal nerves. Chapters II, III and IV are in the 
process of being submitted for publication. 
This dissertation also contains an appendix section. Appendix I is a paper that was 
published in Nanomedicine: Nanotechnology, Biology and Medicine evaluating the efficacy 
of polyanhydride nanoparticles as a platform for delivery of the antioxidant MitoApocynin to 
neurons.  
This dissertation contains the experimental data and results obtained by the author 
during his Ph.D. study under the supervision of his major professor Dr. Anumantha G. 
Kanthasamy at Iowa State University, Department of Biomedical Sciences. 
 
BACKGROUND 
Parkinson’s disease  
Originally described in Ayurveda as “Kampavata” (Kampa = shaking; vata = affliction), 
Parkinson’s disease (PD) was later described as the “shaking palsy” in AD 175 by the 
physician Galen. The disease received considerable interest as a medical condition in 1817 
after Dr. James Parkinson’s publication titled, “An essay on the Shaking Palsy”. Since then 
and following an increasingly ageing world population, research in the area of PD has gained 
much importance. PD is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD) and is the most common movement disorder in people over the 
age of 65. It affects approximately 1% of individuals older than 65 years and is characterized 
by resting tremor, stiffness (rigidity), slow and decreased movement (bradykinesia), and gait 
and/or postural instability (Hirtz et al., 2007; Shulman et al., 2011). By the time the 
symptoms are manifested, more than 60% of the dopaminergic neurons have already been 
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lost, along with 80% of striatal dopamine (Dauer and Przedborski, 2003). The cardinal 
pathological feature of this disease is a progressive degeneration of neuromelanin-containing 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) along with the 
development of eosinophilic cytoplasmic inclusions termed Lewy bodies and Lewy neurites 
(Dickson et al., 2009). While aging appears to be the greatest risk for the development of PD, 
pathogenesis of the disease is still incompletely understood and remains to be elucidated. 
Various genes have been implicated to PD and can account for about 10% of the PD cases, 
however a majority of PD cases are more likely caused by a complex interplay of genetic and 
environmental factors. Recent epidemiological and clinical studies have suggested potential 
environmental risk factors for PD. These include: repeated head injury, heavy metal 
exposure, exposure to pesticides, dinking well water, farming etc (Ascherio and 
Schwarzschild, 2016).  
Non-motor symptoms of PD 
Till date, diagnosis of PD rests on assessment of a battery of neurological and motor tests. 
However, data from retrospective studies have implicated that PD has a broader impact of the 
nervous system. NMS appear throughout the course of PD, some developing before motor 
symptoms are even recognized. During the asymptomatic phase of the disease, patients 
develop non-motor deficits in cognition, behavioral/neuropsychiatric changes, autonomic 
nervous system, gastrointestinal problems, olfactory impairment and sleep disturbances. 
Importantly, most non-motor symptoms (NMS) show little or no response to dopamine 
replacement and contribute substantially to overall disability, especially late in disease. It has 
been hypothesized that there may be early involvement of autonomic neurons in the spinal 
cord, heart, gastrointestinal and genitourinary tracts and may explain the presence of α-
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synuclein aggregates found in the gastrointestinal tissue of post-mortem PD cases (Grinberg 
et al., 2010). Constipation is one of the most common complaints among PD patients and 
prolonged gastrointestinal transit time is seen in 40-80% of patients. Anosmia – loss of 
olfactory sense or discrimination - is one of the most common and early indicators seen in 
more that 90% of PD cases and increases as the disease advances (Cersosimo and Benarroch, 
2008; Katzenschlager et al., 2004). Other commonly observed symptoms include sleep 
dysfunction that occur in 60–98% of patients, depression which occurs in 40% cases and 
decreased visuospatial, attentional and executive processing (Garcia-Ruiz et al., 2014). Most 
non-motor symptoms vary in different patients. Many patients experience some symptoms 
and not others, and even the pace at which the disease worsens varies on an individual basis. 
However these symptoms are thought to be seen when nigro-striatal degeneration begins to 
occur and by the time the disease is diagnosed based on motor symptoms, about 70% 
dopaminergic neurons are lost rendering most medications mainly symptomatic treatments. 
Thus it is necessary to develop sensitive tests in order to accurately determine early PD 
stages and thus improve a PD patient’s quality of life. 
Manganese neurotoxicity 
In trace amounts, manganese (Mn) is an essential metal found in all body tissues, as it is 
fundamental for many ubiquitous enzymatic reactions, including synthesis of amino acids, 
lipids, proteins, and carbohydrates. It also plays a key nutritional role in bone formation, fat 
and carbohydrate metabolism, blood sugar regulation, and calcium absorption in the body 
(Bowman et al., 2011). Primary route of Mn exposure in humans is through diet, as it is 
present in whole grains, rice, nuts, tea, leafy green vegetables and manganese-containing 
nutritional supplements. However, occupational exposure to Mn can cause a 
5 
 
 
neurodegenerative disorder known as “manganism”, characterized by severe neurological 
deficits that often resemble the involuntary extrapyrimydal symptoms associated with PD. 
Major anthropogenic sources of Mn include the use of methylcyclopentadienyl manganese 
tricarbonyl (MMT) as an antiknock gasoline additive, Mn in fertilizers, in paint and 
cosmetics known as manganese violet (Farina et al., 2013). The other major sources of Mn 
include municipal wastewater discharges, welding, mining and mineral processing, emissions 
from alloy, steel, and iron production, combustion of fossil fuel and dry-cell manufacturing.  
Ulcerative colitis 
Ulcerative colitis (UC) is a chronic condition characterized by sudden, acute flares of 
intestinal inflammation. Particularly, this disease primarily affects the distal colon and 
rectum (Lakhan and Kirchgessner, 2010). Prolonged occurrence of this disease leads to 
ulceration on the intestinal lining and tissue damage occurring even at the sub-mucosa and 
deeper tissue. While the cause of UC is not known, it is thought that genetic predisposition to 
a hyperactive immune system or failure to regulate pro-inflammatory cytokine generation in 
response to gut bacteria or a virus might be the culprit (Brower, 2004).  
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Literature Review I 
 
Environmental toxins, enteric glia and intestinal inflammation: implications on 
progressive neurodegeneration 
 
Introduction 
The nervous system comprising the central (CNS) and peripheral nervous systems (PNS) 
innervates all organs and is one of the first to develop in a growing fetus. With this network 
of nerves present in every body part, there is a bi-directional communication between the 
CNS and the rest of the body. Hence, changes in various organ systems directly reflect in 
biochemical changes in particular regions of the 
CNS. For example, the hypothalamic-pituitary 
axis (HPA) plays a role in satiety and feeding 
behavior. In long-term diabetic patients who have 
autonomic neural imbalance, a hyperactive HPA 
axis with abnormal secretion of cortisol has been 
observed (Chiodini et al., 2007). Since cortisol is 
one of the glucocorticoids involved in satiety 
regulation, a disturbance in normal secretion of 
this important hormone can lead to hypo- or 
hyperphagia. In fact, much research conducted in 
the fields of type-2 diabetes and obesity have found that the CNS in conjunction with the 
autonomic nervous system plays a major role in the chronicity of these metabolic disorders 
Figure 1: 60x image of mouse ileum 
showing enteric neurons (PGP9.5, 
red) and enteric glial cells (GFAP, 
green). The ENS is present in two 
distinct layers- Myenteric plexus 
(MP) and the submucosal plexus. 
(SMP) 
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(Anderson et al., 2016; Miranda et al., 2016; Rosmond, 2003; Rosmond et al., 1998). 
However, not only does diabetes induce an abnormal HPA functioning, it also affects the 
enteric nervous system (ENS) disturbing intestinal motility (Yamamoto et al., 2008).  
The ENS is a part of the PNS and is present throughout the length of the gastrointestinal (GI) 
tract. Unlike the CNS, which is a concerted mass of neurons and glial cells, the ENS is 
present in discrete layers of the gut and consists of i) myenteric (Auerbach’s) plexus that is 
present in between the longitudinal and circular muscles and ii) sub-mucosal (Meissner’s and 
Henle) plexus that is present beneath the mucosal layer (Figure 1). Their location has 
functional relevance with the myenteric plexus mainly regulating GI smooth muscle 
contractions while the sub-mucosal plexus controls GI blood flow and intestinal absorption at 
the villi (Domoto et al., 1990; Hens et al., 2001). Besides neurons, the ENS also constitutes 
the enteric glial cells (EGCs). These cells were once thought to primarily provide a structural 
framework to the enteric neurons but have since emerged as key players in GI physiology 
(Gulbransen and Sharkey, 2012; Neunlist et al., 2014). Unlike enteric neurons that are mainly 
restricted to the two plexi, EGCs are present across all layers of the gut even extending into 
the mucosal villi (Neunlist et al., 2007). These cells act as mediators between enteric neurons 
and other non-neuronal cells.  
The gut encompasses about 100 million neurons with functionally distinct populations 
having individual neurochemical signatures (Benarroch, 2007). Along with interstitial cells 
of Cajal (also called the pacemaker of the gut) and excitable smooth muscle cells, the ENS is 
able to induce spontaneous contractions of the GI tract even in the absence of CNS input 
(Rao and Gershon, 2016).  However, under normal physiological conditions, the there is a 
two-way signaling – through the vagus, pelvic, celiac, superior and inferior mesenteric 
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nerves- between the ENS and the CNS.  Hence, perturbations in either region can lead to 
altered communication and thus physiological dysfunctions in the body.  
 
Neurological disorders and associated gastrointestinal disturbances  
GI dysfunction is a surprisingly common occurrence in many neurological disorders. We 
now know that patients suffering from Parkinson’s (PD), dementia with lewy bodies (DLB) 
and autism have GI dysfunction in the early phase of the disorder. This phenomenon is 
predominantly observed in PD patients with 25-77% patients diagnosed as constipated while 
30% DLB patients show gastrointestinal disturbances (Knudsen et al., 2017; Mishima et al., 
2017; Stubendorff et al., 2012). While these symptoms have long been documented, the 
relation between altered CNS and/or PNS and GI dysfunction has gained much attention only 
in the past decade. In 2003 and 2006 Braak and colleagues showed that aggregated α-
synuclein, a histological hallmark of PD, is observed in the ENS and CNS of post-mortem 
PD patients. Importantly, it appeared that aggregated α-synuclein- positive neurons were 
mainly detected in the olfactory bulb or ENS in early stage patients advancing to the brain 
stem, caudate nucleus, substantia nigra and finally the frontal cortex as the disease 
progressed (Braak et al., 2006; Braak et al., 2003). This evidence - although not universally 
accepted – certainly gave credence to the idea that since the nasal passage and gut are 
continuously exposed to environmental toxins and xenobiotics that can be inhaled or 
ingested, this prolonged exposure could cause oxidative stress and low-grade inflammation in 
the GI tract. The constant presence of oxidative stress and inflammation can lead to 
mitochondrial dysfunction in neurons, an exaggerated response by the resident immune cells 
as well as generation of pro-inflammatory cytokines and chemokines thus leading to 
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misfolding of proteins such as the natively unfolded α-synuclein. A variety of transgenic and 
toxin-based animal models of PD have shown varying degrees of deregulation in intestinal 
motility and aggregated protein inclusions in the ENS (Anderson et al., 2007; Greene et al., 
2009; Kuo et al., 2010; Toti and Travagli, 2014). However, the degree of dysfunction and 
pathology differ when compared to post-mortem histopathological analysis of PD patients. A 
major limiting factor of animal models is that neither toxin models (where a healthy animal is 
given a high or chronic dose of the toxin to induce desired disease) nor transgenic models 
(where the enteric neurons are genetically programmed to undergo dysfunction) can really 
recapitulate the complex etiology of PD. Unlike the results observed in animal models of PD, 
retrospective studies have shown that the prodromal phase of PD- where GI dysfunction is 
first observed – shows negligible loss of enteric neurons. Even at the advanced stages of this 
disease, the percentage of dying enteric neurons is minimal compared to 80% dopaminergic 
cell death observed in the CNS. To explain this observation, Engelender and Isacson 
postulated an alternative theory wherein they speculated that the CNS and ENS had different 
thresholds to insult mainly due to a larger functioning reserve and redundant signaling 
pathways between the dopaminergic neurons in the brain as compared to the dopaminergic 
neurons in the gut (Engelender and Isacson, 2017). While this idea is novel and can explain 
disease onset and progression; the molecular and biochemical signatures that cause such 
distinct thresholds between enteric and mid-brain dopaminergic neurons needs to be 
elucidated. 
Along with PD, other synucleinopathies such as multiple system atrophy (MSA) and 
dementia with lewy bodies (DLB) have also shown intestinal inflammation in concurrence 
with CNS dysfunction. Immunohistochemistry of the sigmoid colon mucosa of a small 
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cohort of MSA patients showed disrupted tight junction protein indicating a “leaky” 
intestinal barrier compared to healthy control subjects (Engen et al., 2017). The study also 
revealed intestinal inflammation and a shift in the gut microbial profile that produces more 
pro-inflammatory factors compared to the healthy cohort. These observations give credence 
to the notion that intestinal inflammation and a dysfunctional motility are closely associated 
with degenerating neurons in the CNS and PNS. In the case of DLB, lewy bodies containing 
protease-resistant α-synuclein is seen at early stages in the ENS and olfactory bulb similar to 
the lewy body progression seen in many PD patients. While no study to our knowledge has 
shown intestinal inflammation or altered motility in DLB patients, nonetheless, given the 
similar disease pathology and progression with PD, it is possible that DLB patients also 
suffer from ENS associated GI dysfunctions. 
In the case of autism spectrum disorder (ASD)- mild, acute or chronic inflammation of the 
colon, rectum, small intestine and stomach as well as increased intestinal permeability is a 
common outcome (de Magistris et al., 2010; Fiorentino et al., 2016). Such children display 
cognitive deficits, fixed behaviors, and impairments in social skills. The relation between 
altered intestinal permeability or “leaky gut” and cognitive or social impairments has been 
shown through various studies where ASD children had increased free amino acids and short 
chain fatty acids (SCFAs) in the feces (De Angelis et al., 2015). Notably, glutamate – a non-
essential amino acid that also functions as an inhibitory neurotransmitter – was found at 
substantially higher amounts in ASD children compared to healthy controls (Adams et al., 
2011; De Angelis et al., 2015; Shimmura et al., 2011). Excess glutamate can lead to 
alterations in neuronal signaling and even apoptosis. Children with ASD also have lower 
amounts of SCFAs in general with the notable exception of propionic acid and acetic acid 
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that are found in larger amounts compared to healthy controls (De Angelis et al., 2013). 
Intraventricular infusions of propionic acid in rats have shown ASD-like behavioral 
abnormalities (MacFabe et al., 2011; Thomas et al., 2010). These rats also showed 
significantly altered acylcarnitine and various phospholipid species in the brain suggesting a 
role played by intestinal metabolites in modifying brain lipid profiles leading to neurological 
impairment (Thomas et al., 2010). Similarly, rodents exposed to valproic acid during prenatal 
development also showed ASD-like behavioral characteristics as well as intestinal 
inflammation (Roullet et al., 2013). This enteric inflammation was associated with higher 
levels of the neurotransmitter serotonin (5-HT) in the intestine. Notably, hyperseretonemia 
(elevated blood serotonin levels) is observed in 30% of children with ASD indicating that 
elevated 5-HT in the intestine might be a potential biomarker in concurrence with behavioral 
tests (Gabriele et al., 2014). Interestingly, children with autism might also suffer from zinc 
deficiency and a Cu/Zn imbalance compared to healthy age-matched children. Particularly, 
zinc deficiency between 0-3 years of age positively correlated with higher incidence of ASD 
(Pfaender and Grabrucker, 2014; Yasuda et al., 2011). While the exact mechanisms are not 
fully understood, nonetheless zinc is known to increase villous height and improve mucosal 
defense against enteric pathogens as well as play a role in memory and cognition in the brain 
(Caine et al., 2009; Tyszka-Czochara et al., 2014). In parallel to increased intestinal 
permeability observed in such patients, an altered blood-brain barrier (BBB) as well as 
neuroinflammation is also observed (Fiorentino et al., 2016). For more information related to 
intestinal inflammation and CNS dysfunction please refer to Rao and Gershon (2016) and 
Ghaisas et al (Ghaisas et al., 2016; Rao and Gershon, 2016). 
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Role of the ENS following intestinal inflammation 
Clinical and histopathological observations have implicated the role of the ENS in intestinal 
inflammation. For example, hypertrophy or hyperplasia of myenteric ganglion cells are 
observed in Crohn’s disease (CD) while neurotransmitter deregulation, particularly 5-HT is 
observed in inflammatory bowel disease (IBD) (Geboes and Collins, 1998; Manocha and 
Khan, 2012). Since the gut is made of different layers each with distinct functions with the 
ENS coordinating these functions, it is necessary to understand the interactions between the 
enteric neurons/glia with other cells during intestinal inflammation. 
 
Role of Enteric Glia in intestinal inflammation 
As the “phenotypical equivalents” of astrocytes in the CNS, EGCs form an important part of 
the ENS (Capoccia et al., 2015). Recently, these 
cells were classified into different groups based 
on their morphology and function (Gulbransen 
and Sharkey, 2012); however despite 
morphological distinctions, much of the functions 
overlap. Similar to astrocytes and Schwann cells, 
EGCs remain in close contact with enteric 
neurons, ensheathing them albeit incompletely, 
allowing the neurons to make contact with other 
cell types such as surveilling immune cells and 
interstitial cells of Cajal (Figure 2) (Gabella, 1972). As mentioned before, EGCs also extend 
in the villi and are present directly beneath the epithelial cells that line the villi (Figure 3). 
Figure 2:  Enteric glia 
communicate with other cells in the 
gastrointestinal tract. 
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Unlike astrocytic end-feet that wrap around endothelial cells and form a unit of the BBB, 
EGCs do not ensheath epithelial cells but regulate the tight junctions mainly via paracrine 
pathways (Savidge et al., 2007b).  
Various toxin and transgenic animal studies have highlighted the importance of EGCs in 
maintaining the epithelial barrier as well as in increasing intestinal permeability. For 
example, EGC knockout mice as well as mice administered the gliotoxin fluorocitrate both 
develop intestinal inflammation and a highly compromised intestinal permeability (Savidge 
et al., 2007a) while patients with slow-transit constipation showed massive loss of EGCs in 
both the small and large intestines (Bassotti et al., 2006). The glial s-nitrosoglutathione 
(GSNO), a molecule mainly produced by EGCs, is critically involved in maintaining tight 
junction proteins and epithelial f-actin. Similarly, glia derived neurotrophic factor (GDNF) 
that helps enterocyte development while TGF-β and 15-deoxy-(12,14)-prostaglandin J2 
produced by EGCs are other important factors involved in maintaining epithelial tight 
junctions (Bach-Ngohou et al., 2010; von Boyen et al., 2011). Thus EGCs control epithelial 
cell proliferation and maturation by regulating transcription factors associated with cell-
Figure 3: Enteric glia extending from the submucosa into the villi. 
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matrix, cell-cell adhesion, lipid and protein metabolism as well as cell survival (Van 
Landeghem et al., 2009).  
During inflammation, upon sensing bacterial products like LPS as well as advanced 
glycation/oxidation products, aggregated proteins etc these cells highly express Toll-like 
receptor 4 (TLR4) as well as RAGE (receptor for advanced glycation end products). 
Increased expression of these receptors renders the cells “reactive”. Patients with ulcerative 
colitis (UC), have a higher expression of EGCs and GDNF in the large intestine compared to 
healthy controls (von Boyen et al., 2011). Higher GDNF expression in the intestine is a 
protective mechanism as GDNF not only confers protection on enterocytes but also promotes 
survival of the EGCs themselves (Steinkamp et al., 2012). Notably, the EGCs have increased 
S100-β immunoreactivity as well as increased nitric oxide production via RAGE signaling 
(Cirillo et al., 2009). However, following GI inflammation, EGCs as well as mucosal 
immune cells release pro-inflammatory factors including TNFα, IL-1β and iNOS (Turco et 
al., 2014). These factors re-arrange junctional adhesion proteins increasing intestinal 
permeability.  
The idea that the CNS can –in part- control EGC functions came from an interesting study 
conducted by Langness and colleagues (Langness et al., 2017). Selective ablation of EGC by 
topical application of Benzalkonium chloride followed by ischemia-reperfusion injury 
resulted in increased intestinal permeability, inflammation and immune cell recruitment. This 
disease state was reduced to a certain extent with vagal nerve stimulation. However in the 
presence of EGCs + vagal nerve stimulation, mice had much lower permeability, 
inflammation and immune cell invasion in the intestine. This study showed that the EGCs in 
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tandem with inputs from the vagus nerve (that arises from the brain stem) are able to control 
intestinal inflammation.  
 
Role of Enteric Neurons in intestinal inflammation 
Since the 1970s when Gabella first observed neuroglial junctions in the ENS; several 
histological and electrophysiology studies have shown the enteric neurons and glia routinely 
communicate with one another. While enteric glial hyperplasia is commonly observed in 
patients with IBD, what is also commonly observed is enteric neuronal cell death. In 2014, 
McClain et al reported that connexin-43 hemichannels mediate neuro-glia crosstalk via 
purinergic signaling (McClain et al., 2014). Using a mouse model of IBD, they found that 
increased nitric oxide production activated connexin-43 channels in EGCs thus releasing 
ATP. This ATP continually drives intracellular [Ca+2] response in adjacent enteric neurons 
leading to neuronal death (Brown et al., 2016). In a similar study, Gulbransen et al observed 
that activating P2X7 receptors and pannexin-1 channels lead to Asc and caspase activation 
concluding in enteric neuronal death (Gulbransen et al., 2012). Inhibition of either P2X7 
receptors or pannexin-1 channels prevented the onset of inflammation. Dying neurons release 
caspases, products of partial nitration and oxidation as well as pro-inflammatory cytokines 
and chemokines. These stimulate intraepithelial lymphocytes to migrate and envelope the 
dead neurons (Tornblom et al., 2002).  
Sensory neurons are enabled to detect molecular signals and environmental cues both from 
luminal contents as well as the intestinal tissue. They are also able to detect pathogenic 
bacteria, bacterial toxins, metabolites and cell components and communicate these findings 
to the patrolling immune cells (Lai et al., 2017). Studies have shown how chemical irritants 
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activate sensory neurons resulting in vasodilation and immune influx (Geppetti et al., 2008). 
Hence acute application of dextran sodium sulfate (DSS) or 2,4,6 trinitrobenzenesulfonic 
acid (TNBS), induces hyperexcitability in the sensory neurons that persists for weeks even 
after the insult is removed inducing visceral hypersensitivity in the area of inflammation 
(Abdrakhmanova et al., 2012). There have been conflicting reports regarding the pro- or anti-
inflammatory role of sensory neuron activation (Engel et al., 2012; Ghia et al., 2006; 
McCafferty et al., 1997; Okayama et al., 2004; Reinshagen et al., 1996). However direct 
comparison between studies is not possible due to the different treatment schedules and toxin 
dosage. Even following natural ageing, there are changes in GI physiology with a shift in the 
immune population from an anti-inflammatory state to a pro-inflammatory state (Becker et 
al., 2017). This means that even low-grade inflammation or a mild acute toxic insult would 
lead to an exaggerated response by the mucosal immune cells leading to a loss in enteric 
neurons and delayed transit time. So how is an “ageing” gut different from a young, healthy  
GI tract? By histological observations, the GI tract of an older individual (≥ 65 years of age) 
has fewer enteric neurons compared to the GI tract of a young and healthy individual (16-25 
Figure 4: (A) Dense a-synuclein staining observed in the myenteric plexus of aged 
Fisher rats (brown) with macrophages (dark blue) seen nearby. (B) Macrophages 
surrounding enteric neurons possibly due to presence of aggregated a-synuclein. 
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years) (Wade and Cowen, 2004). A summary of the changes in myenteric neuronal numbers 
with age has been tabulated in a review by Saffery (Saffrey, 2013). Based on a number of 
histological observations made in both animal models as well as humans, the general 
consensus is that as we age, the number of neurons (mainly myenteric neurons were 
observed) decrease with the largest reduction seen in the large intestine i.e the colon followed 
by the ileum, jejunum and least in the stomach and esophagus. It is hypothesized that the 
aged ENS has a lower threshold for ROS-induced oxidative damage. Coupled with the shift 
in immune cells from an anti- to pro-inflammatory status, it is easy to understand why 
neuronal cell death would occur as an individual gets older. Ageing is associated with 
decreased autophagy; consequently these enteric neurons accumulate products of incomplete 
lysosomal digestion as well as aggregated and protease resistant proteins (Abalo et al., 2007; 
Phillips and Powley, 2007; Phillips et al., 2009).  Phillips et al observed that the small 
intestine of aged rats expressed greater aggregated α-synuclein mainly in the enteric neurons 
(Phillips et al., 2013). In many instances, activated macrophages (indicated by MHCII 
surface expression normally not seen in resident macrophages) were found in close contact 
with neurons exhibiting dense α-synuclein staining (Figure 4a). However, upon ingesting 
aggregated synuclein, most activated macrophages lost their morphological integrity and 
were unable to clear the aggregated proteins (Figure 4b). If the aggregate proteins are not 
efficiently lysed either during lysosomal degradation or by phagocytosing immune cells, they 
contribute to oxidative stress and a pro-inflammatory state in the vicinity. A few studies have 
showed the direct spread of aggregated α-synuclein and prion protein from the gut to the 
brain through the vagus or glossopharyngeal nerve (Breid et al., 2016; Holmqvist et al., 2014; 
McBride et al., 2001). Together these observations give credence to the idea that a disruption 
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in protein quality control leads to the formation of toxic cellular aggregates; if these 
aggregates are not solubilized, they can travel from the gut to the brain via the spinal cord 
nerves leading to development of protein aggregation and neuroinflammation in the CNS. 
Unlike sub-granular zone and sub-ventricular regions of the brain where neurogenesis occurs 
even in aged individuals (albeit at a much slower rate than in healthy young brains), 
neurogenesis has not been demonstrated in the aged gut. This could mean that the enteric 
neurons are more susceptible to age-related loss compared to the neurons in the CNS. This 
premise ties back to the “threshold theory” mentioned previously in this review where the 
authors Engelender and Isacson postulated that even a small loss of enteric neuronal numbers 
during the early stages of PD can lead to decreased gut motility and other GI disorders 
compared to a more than 80% loss of neurons in the substantia nigra pars compacta when the 
disease is actually detected based on motor symptoms (Engelender and Isacson, 2017).  
 
Influence of ingested toxins and xenobiotics on the ENS: consequences on the GI 
physiology and CNS 
It is a well-accepted theory that neurological disorders such as AD, PD, MSA as well as ASD 
are the result of genetic predisposition and exposure to environmental triggers. Multiple sub-
acute exposures or a chronic exposure to water and food pollutants such as heavy metals, 
pesticides, herbicides, neurotoxins, as well as maternal smoking have been linked to 
progressive neurological and associated motor impairment (Belbasis et al., 2015; Bellou et 
al., 2016; Killin et al., 2016; Modabbernia et al., 2017; Yan et al., 2016). Besides the skin, 
which is the largest organ exposed to the environment, the GI and nasal tracts are also 
continuously exposed to environmental factors including toxins and xenobiotics. Pan-
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Montojo and others have shown that the environmental toxin rotenone acts locally on the 
enteric neurons and triggers release of α-synuclein via exosomes (Pan-Montojo et al., 2012). 
Indeed, many animal studies of pesticide exposure have shown that these chemicals - that are 
mainly mitochondrial complex I inhibitors- selectively target enteric neurons causing 
mitochondrial dysfunction and ultimately apoptosis (Greene et al., 2009; Zhu et al., 2012). 
Loss of enteric neurons disrupts the intricate circuitry between the ENS and other cells 
leading to dysmotility, increased permeability and finally intestinal inflammation. With the 
vagus nerve innervating most of the GI tract, changes in GI physiology and motility are 
conveyed to its dorsal nucleus located in the medulla. As mentioned before, this innervation 
also provides a physical link where in theory- aggregated proteins can travel from the gut to 
the brain stem or vice versa. Studies with higher rotenone exposure than the Pan-Montojo 
study have shown neurochemical and behavioral deficits in the brain of exposed rats (Cannon 
et al., 2009; Sherer et al., 2003). Till date, no study has shown conclusive evidence of just 
how ingested neurotoxins cause neurological deficits but it is thought that the absorbed 
neurotoxins cause damage to the ENS thereby deregulating gut motility and increasing 
intestinal inflammation. These inflammatory signals are passed via the blood and across the 
BBB to the CNS. Alternatively the vagus nerve can convey information regarding changes in 
the gut to the brain stem via signaling pathways that have yet to be elucidated.  
Heavy metals and metal mixtures from industrial effluents can contaminate water bodies. 
While few studies have dealt with the effect of metals on human GI physiology, a majority of 
our knowledge on GI metal toxicity comes from research in aquatic animals. A review by 
DeForest comprehensively states that fish given metal-rich food develop intestinal 
dysmotility and impacted abdomens (DeForest and Meyer, 2015). Enterocytes lining the 
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intestine are equipped with a variety of metal ion transporters such as divalent metal 
transporter-1, ferroportin, ZIP8, SLC30A10 etc to regulate the influx and efflux of metals. 
Metals such as copper, iron, manganese, magnesium, zinc, selenium etc are required in trace 
amounts for normal cellular functioning. However in the presence of chronic exposure 
(through drinking water or food containing high amounts of divalent/trivalent metal species) 
the membrane channels and receptors involved in maintaining metal homeostasis become 
overburdened and hence non-functional. A deregulated metal homeostasis may lead to 
bioaccumulation of redox-active metals culminating in free-radical formation and 
mitochondrial dysfunction.  For example, chronic mercury exposure in humans has been 
linked to GI ulcers, fluid accumulation in the intestines as well as diarrhea (McGinnis, 2001; 
Zahir et al., 2005). The fluid accumulation following mercury exposure is caused in part by a 
down regulation of the group of water channels- aquaporins (AQP) especially AQP3, 4 and 
7. With the recent revelation of elevated levels of lead in drinking water at various locations 
in the US and associated GI and neurological problems, the issue of heavy metal poisoning 
and its effect on the gut-brain axis is gaining considerable attention. In the case of chronic 
lead exposure especially through drinking water, stomach cramps, changes in gut motility 
and nutrient absorption have been observed (Begovic et al., 2008; Mongolu and Sharp, 
2013). Particularly, diet deficient in iron, zinc or calcium can lead to lead or cadmium 
poisoning. This occurs because following iron deficiency, there is increased influx of 
cadmium or lead via the divalent metal transporter that is possibly compensating for the lack 
of iron (Goyer, 1996). Cadmium can also induce the enterocytes to become more permeable 
as indicated by an in-vitro model of cadmium exposure on human enterocytes that revealed 
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reduced transepithelial electrical resistance and subsequently increased permeability (Breton 
et al., 2016).   
Another target of toxin or xenobiotic exposure is the gut microbiome. It is now well known 
that the gut microbiome is instrumental in brain and GI tract development (Ghaisas et al., 
2016). Moreover specific microbial communities can detoxify the food we ingest thus 
preventing in their absorption and helping eliminate these toxic compounds. A study 
conducted by Maurice and others have shown that toxicants and host-targeted drugs alter 
microbial gene expression especially those related to xenobiotic metabolism (Maurice et al., 
2013). This change in bacteria gene expression can (depending upon the bacterial species) 
either lead to detoxification and removal of the toxins from the body or conversion of non-
toxic compounds into potential toxins. Long-term exposure to such toxins can significantly 
alter the bacterial population influencing the growth of pathogenic, “inflammatory” bacteria 
over other species leading to an altered GI functioning. For example, Glyphosphate is an 
active component of many herbicides while chlorpyrifos is a pesticide widely used. Exposure 
to either of these compounds either through contact or food consumption (that it was applied 
to) can lead to decrease in beneficial bacteria such as Enterococcus faecalis, Bacillus badius 
and probiotic bacteria such as Bifidobacterium and Lactobacillus sp. with an increase or no 
change in pathogenic species of Salmonella and Clostridium (Joly et al., 2013; Shehata et al., 
2013). Similarly, chronic exposure to even low doses of the heavy metal arsenic lead to a 
reduction in the population of Firmicutes in mice with concurrent alterations in bacterial 
metabolites such as indole derivatives, isoflavones, fatty acids etc (Lu et al., 2014). Increased 
presence of Clostridium, Salmonella sp. or adherent invasive Escherichia coli can lead to 
increased permeability and translocation of gut bacteria from the lumen into the deeper 
22 
 
 
intestinal tissue. This translocation activates surveilling immune cells that mount a response 
to the bacterial cell wall components especially on gram-negative bacteria that have 
lipopolysaccharide. Activated macrophages and dendritic cells recruit circulating monocytes 
to the site of invasion leading to an abundance of activated monocytes that produce pro-
inflammatory cytokines and chemokines. But how does activation of immune cells present in 
the GI tract lead to neuroinflammation in the CNS? 
 
 Changes in CNS following intestinal inflammation 
Following intestinal or systemic inflammation both pro-inflammatory (to activate and recruit 
immune cells and remove the agent of inflammation) and anti-inflammatory factors (wound 
healing, cell re-proliferation etc.) are produced by immune and non-immune cells. Extensive 
evidence links molecules associated with inflammatory conditions, including cytokines, 
reactive oxygen species, matrix metalloproteases, and mediators of angiogenesis, with BBB 
disruption (Wardill et al., 2016). For instance many children with ASD display not only 
intestinal inflammation with associated dysmotility but also presence of activated monocytes 
and perivascular macrophages in the cerebellum (Vargas et al., 2005). CSF and brain 
parenchyma showed a higher levels of macrophage chemoattractant protein 1 (MCP-1), 
which is a potent recruiter of monocytes and macrophages to the site of expression. 
Monocytes are a subset of circulating white blood cells that can further differentiate into 
macrophages and dendritic cells. They mediate host antimicrobial and innate immune 
defense and are implicated in systemic and various organ-specific diseases. Remarkably, 
these cells have the ability to mobilize and traffic to the area of inflammation and further 
differentiate depending on the inflammatory stimuli.	Despite the presence of microglia that 
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are the innate immune cells in the brain and spinal cord, these immune cells are known to 
recruit monocytes in to the brain in response to TNFα produced during peripheral 
inflammation (D'Mello et al., 2009). In another instance, chronic IBD or IBS patients usually 
display “sickness behavior” including increased anxiety and depression. The prevalence of 
cytokines such as IL-1β, IL-6 and TNFα during peripheral inflammation is thought to 
activate the HPA resulting in a depressive mental condition (Figure 5) (Dantzer et al., 2008; 
Dunn, 2006).  
Curiously, most neurological disorders including AD and PD show inflammation and 
immune cell activation in areas closely situated to circumventricular organs (CVOs). CVOs 
are situated adjacent to brain ventricles and are characterized by extensive vasculature and a 
porous blood brain barrier (BBB). These areas receive chemical inputs from the bloodstream 
and relay these inputs to hypothalamus, medulla oblongata and endocrine hypothalamus-
pituitary axis. In doing so, they maintain body fluid homeostasis and cardiovascular 
regulation, and play an important role in the generation of central acute immune and febrile 
responses. The importance of CVOs as possible primary sites of immune invasion came from 
a variety of studies investigating pathogen or peripheral immune invasion following parasitic 
or bacterial infection. In 1988 Schultzburg and colleagues showed that lab rats infected with 
Trypanosoma brucei showed early invasion of the parasite in areas of the brain lacking BBB 
such as the CVOs while Schulz and Engelhardt found that CVOs are a site for the entry of 
immune cells into the CNS and CSF and consequently are involved in the inflammatory 
process in the CNS during experimental autoimmune encephalitis (Schultzberg et al., 1988; 
Schulz and Engelhardt, 2005). Interestingly, disease-associated prion protein (PrPd) 
deposition is found in the CVOs as well as gut-associated lymphoid tissue in preclinical 
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sheep with scrapie (Siso et al., 2010). However it is unknown if the entry of this pathogen is 
via the innervating nerves or via blood-CVO route. A summary of events observed in the 
CNS following peripheral inflammation is given in Table 1.  
  
Conclusions 
Over the years, our understanding of various neurological disorders such as PD, AD, MSA 
and ASD to name a few has expanded from documentation of brain regions primarily 
involved in disease pathogenesis to identification of the biochemical and molecular pathways 
that initiate and propagate these diseases. Strikingly, most of these diseases also display 
altered GI physiology. Common regulatory mechanisms must exist in the development and 
maintenance of a healthy GI tract, immune system and brain since a deregulation in this triad 
commonly results in the symptoms observed in these diseases. Gut microbiome also play an 
important part in the normal development of the nervous, enteric and immune systems. 
Hence focus has now shifted to the role played by the microbiome-gut-brain axis in 
neurodegeneration. He need of the hour is to delineate the specific roles played by each 
system in this triad and the signaling pathways involved following genetic predisposition or 
toxin exposure in order to devise effective therapeutic interventions. 
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1. Abstract 
The gut microbiome comprises the collective genome of the trillions of 
microorganisms residing in our gastrointestinal ecosystem. The interaction between the host 
and its gut microbiome is a complex relationship whose manipulation could prove critical to 
preventing or treating not only various gut disorders, like irritable bowel syndrome (IBS) and 
ulcerative colitis (UC), but also central nervous system (CNS) disorders, such as Alzheimer’s 
and Parkinson’s diseases. The purpose of this review is to summarize what is known about 
the gut microbiome, how it is connected to the development of disease and to identify the 
bacterial and biochemical targets that should be the focus of future research.  Understanding 
the mechanisms behind the activity and proliferation of the gut microbiome will provide us 
new insights that may pave the way for novel therapeutic strategies. 
 
Keyword: microbiome-gut-brain axis, Parkinson’s disease, gut microbiota, neurological 
diseases, Autism, manganese, metals, environmental factors, neurotoxicity 
 
2. Introduction 
Among the many microbial communities colonizing the human body, the gut 
microbiome is emerging as a major player influencing the health status of the host. The 
composition of the gut microbiome is established early during the host’s development and 
can undergo a myriad of changes throughout a lifetime. The complex interaction between 
host physiology and the gut microbiome is a topic of research that is still in its infancy. Yet 
broadening our understanding of this interaction could lead to beneficial therapeutic 
strategies for improving human health. Although we are only in the beginning stages of 
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defining the biomarkers, bacterial species, and diets necessary to manipulate and study the 
human microbiome, we can appreciate the potential implications this research has on the 
future of medicine. The objective of this review is to summarize current findings linking host 
gut microbiome and health and to identify future directions necessary for unraveling the gut 
microbiome’s role in the pathogenesis of chronic metabolic and central nervous system 
diseases.  
 
3. The Gut Microbiome 
The gut microbiome comprises the collective genome of roughly 100 trillion 
microorganisms residing in the gastrointestinal tract (Tsai and Coyle, 2009). The gene 
repertoire of our gut bacteria contains 150 times more unique genes than the human genome 
(Qin et al., 2010).  
The fetal gastrointestinal tract (GIT) is sterile prior to birth with microbial 
colonization first occurring at delivery (Morelli, 2008). In vaginally delivered infants, the 
GIT is primarily colonized by bifidobacteria as well as lactobacilli, Bacteroides, 
Proteobacteria and Actinobacteria. In contrast, infants delivered via cesarean section have 
more Escherichia coli (E. coli) as well as Clostridia, especially C. difficile, and fewer 
Bacteroides and bifidobacteria (Penders et al., 2006). Similarly, breast-fed infants showed a 
higher abundance of bifidobacteria, whereas in formula-fed infants, bifidobacteria and 
Bacteroides as well as Clostridia and Staphylococci were found in equal numbers (Harmsen 
et al., 2000). Conversely, other groups have shown an abundance of Bifidobacterium, 
Actinomyces, and Haemophilus in breast-fed babies while formula-fed babies had an 
abundance of Firmicutes and Bacteroidetes in their gut (Yatsunenko et al., 2012). This 
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discrepancy in estimating the gut microbiome population is possibly due to differences in the 
techniques used to sample and analyze the data. However, despite these discrepancies, most 
studies emphasize that both the type of diet and mode of delivery can preferentially promote 
certain bacterial communities over others. While the mechanism remains unclear, it is known 
that the earliest gut microbiota primarily consists of bacteria that can metabolize the lactose 
absorbed from breast milk or infant formulas made from cow’s milk. However, with the 
introduction of solid food, the gut becomes dominated by bacterial species associated with 
carbohydrate, protein and fat utilization as well as vitamin synthesis (Koenig et al., 2011). 
The host also selectively favors particular bacterial species in different regions of the gut. For 
example, butyrate-synthesizing bacteria such as the Firmicutes are present in higher 
proportions in the colon and are less well represented in the upper small intestine. This is 
beneficial and quite necessary since short chain fatty acids like butyrate are the main source 
of energy for colonic epithelial cells (Hooper et al., 2002; Roediger, 1980; Wong et al., 
2006).  
Not surprisingly, the interaction between an organism and its gut microbes is not 
unidirectional but involves feedback with the host environment affecting the gut microbiotic 
composition and the colonized bacteria, influencing host development. Following bacterial 
colonization, certain physiological changes have been observed in the gut, including 
increased production of neurotransmitters such as serotonin (5-HT) and γ-aminobutyric acid 
(GABA) as well as the expression of various cytokines. These changes are integral to gut 
homeostasis and to programming of the hypothalamic-pituitary-adrenal (HPA) axis, which 
plays an important role in stress responses (Diaz Heijtz et al., 2011; Sudo et al., 2004). As 
shown in Figure 1, early colonization of certain enterotypes can have a long-lasting influence 
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on the health status of the host. For example, infants with a higher prevalence of 
Bifidobacterium and Collinsella at age 6 months showed lower adiposity at 18 months 
(Dogra et al., 2015). In another study, overweight subjects exhibited decreased numbers of 
Bifidobacteria and the Bacteroides (Santacruz et al., 2010).  The gut microbiome 
composition throughout a host’s lifespan is not static, but measuring these changes proves 
difficult due to confounding changes in diet, environment, and disease state throughout life. 
As previously stated, numerous studies have studied gut microbiome composition early in 
life, yet much fewer studies have reported gut microbiome changes in middle-aged and 
elderly subjects. Shifts from Bifidobacterium to Clostridia and Bacteriodetes occur as the 
host develops from a newborn into an adult (Yatsunenko et al., 2012). Decreases in 
Faecalibacterium prauznitzii and its anti-inflammatory relatives occur as young adults 
mature to become elderly or even centenarians (Biagi et al., 2010).  However, determining to 
what extent such changes reflect normal development and maturation versus 
dietary/environmental changes or pathological deficiencies will require further study. 
3.1 The Gut Microbiome and Health 
It was initially thought that gut microbes were mainly commensals whose only 
benefit was controlling the population of pathogenic bacteria. We now know that these 
symbionts play important roles in aiding digestion, in the production of essential metabolites 
and in the development of the immune system (Walker and Lawley, 2013). Gut bacteria play 
a pivotal role in immune modulation and development of the nervous system and are the 
main source of vitamin K, and to a lesser extent the vitamin B complex (Kelly et al., 2007; 
Littman and Pamer, 2011; Resta, 2009). Indeed, germ-free rats require a higher intake of 
exogenous sources of vitamins K, B12 and B6 compared to their conventional counterparts 
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(Gustafsson, 1959; Sumi et al., 1977; Wostmann, 1981). Recognition of the importance of 
the gut microbiota in infant development has been greatly aided by the development of 
gnotobiotic animal models. Germ-free rodents fed sterile chow, identical in all other respects 
to that consumed by their conventional mates, showed decreased basal metabolic rate, 
increased cholesterol in liver and blood as well as structural and functional differences in the 
enteric nervous system (ENS) (Danielsson and Gustafsson, 1959; Dupont et al., 1965; 
Wostmann et al., 1966). Furthermore, systemic T- and B-cell deficiencies in these animals 
are thought to result from the lack of exposure of the naïve immune cells to microbial 
products generally found in animals with normal intestinal microbiota (Falk et al., 1998; 
Mazmanian et al., 2005; Szeri et al., 1976).  
Other studies have shown that seemingly abrupt and chaotic shifts in the gut 
microbiota correspond to changes in the host’s environment, diet and genetic predisposition. 
Dysbiosis of the gut microbiome has been implicated in numerous disorders, ranging from 
intestinal diseases, such as colorectal cancer and inflammatory bowel disease (IBD), to more 
systemic diseases such as diabetes, metabolic syndrome and atopy (Walker and Lawley, 
2013). The gut microbiome also influences various Type-2 Diabetes (T2D)-related 
complications (Fig. 2), including diabetic retinopathy, kidney toxicity, atherosclerosis, 
hypertension, diabetic foot ulcers, and cystic fibrosis (Zhang and Zhang, 2013). Recent 
research has also linked microbial dysbiosis to neurological disorders, such as Parkinson’s 
and Alzheimer’s diseases, multiple sclerosis and autism. The CNS connects with the gut via 
sympathetic and parasympathetic nerves. However, the importance of these connections had 
not been studied in depth until the past decade. Villaran and co-workers reported that 
peripheral inflammation in the form of dextran sodium sulfate (DSS)-induced colitis can 
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aggravate LPS-induced neuroinflammation and neurodegeneration (Villaran et al., 2010) as 
shown by increased mRNA transcripts of TNFα, iNOS and IL-6 in the midbrain. 
Interestingly, even rats with colitis alone (no midbrain injection of LPS) showed increased 
mRNA transcripts of TNFα, iNOS and IL-6 in the midbrain. Other studies have also shown 
that recurring systemic infections can increase the probability of developing multiple 
sclerosis, Alzheimer’s or Parkinson’s disease (Serres et al., 2009; Tilvis et al., 2004). A 
concise summary of the changes seen in the gut and CNS in various diseases is shown in 
Figure 3. 
3.2 Systemic Diseases and Gut Microbiome Dysbiosis  
Multi-disciplinary studies incorporating advances in next generation sequencing 
(NGS), have revealed that various systemic diseases, such as arthritis, atherosclerosis, IBD, 
as well as diabetes and obesity, show significant changes not only in the composition of the 
resident gut microbiota but also in the host’s gut homeostasis and metabolic processes 
(Musso et al., 2011; Scher et al., 2015; Vieira et al., 2015; Yamashita et al., 2015). In 
essence, the gut microbiota influence and even facilitate various metabolic processes such as 
regulating xenobiotic metabolism and energy production. As discussed later in this review, 
diet and environment play an important part in maintaining gut bacterial populations. 
Perturbations in this ecosystem can have negative and prolonged effects on host physiology. 
While there are many such systemic disorders that show an inherent gut microbiota 
dysbiosis, we summarize two common and well-studied diseases- ulcerative colitis and type-
2 diabetes. 
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3.2.1 Ulcerative colitis  
Ulcerative colitis (UC) is a type of IBD characterized by chronic inflammation and 
sores (ulcers) along the lining of the large intestine and rectum. In addition, neuroplastic 
changes in the ENS are observed in UC, including degeneration of ganglion cells and nerve 
hyperplasia (Vasina et al., 2006). UC results from a combination of host genetic risk factors, 
environment, and alterations in gut microbiome composition. Dysbiosis in the gut 
microbiome of UC patients is characterized by a lower proportion of Firmicutes and a higher 
percentage of Gammaproteobacteria, sulfate-reducing Deltaproteobacteria, Actinobacteria 
and Proteobacteria compared to that of healthy hosts (Lepage et al., 2011; Sokol et al., 2007; 
Sokol et al., 2009).  In general, Gram-negative bacteria populations tend to increase, while 
those of Gram-positive bacteria tend to decrease. Increases in Gram-negative bacteria like 
E.coli may lead to increased Lipopolysaccharide (LPS) translocation in the gut and 
consequently to a chronic state of low-grade inflammation as seen in UC. In addition to 
changes in the composition of the gut microbiome in IBD patients, gene expression for 
amino acid metabolism and biosynthesis are greatly downregulated while the expression of 
lysine, histidine, and arginine transport genes is upregulated.  Expression in UC patients of 
transport and metabolism genes for the antioxidant glutathione (a tripeptide synthesized by 
bacterial species) also increases, thus possibly revealing the mechanism by which the gut 
microbiome responds to inflammatory oxidative stress (Gardiner et al., 1993; Morgan et al., 
2012). Besides UC, gut microbiome dysbiosis also occurs in other forms of IBD where it 
causes vast changes in gut microbiome metabolic function and microbiotic reaction to the 
inflammatory response. Neither the extent to which dysbiosis alters GI microbiome function 
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nor the specific consequences of such changes in gut microbiome composition are fully 
understood, and both require further metabolic and genetic study.  
3.2.2 Diabetes 
T2D is a chronic metabolic disorder wherein the body either does not produce enough 
insulin or cannot effectively metabolize glucose despite insulin production. Assessing the gut 
microbiome of healthy and T2D-diagnosed individuals showed that Betaproteobacteria were 
present in higher proportions in T2D individuals (Larsen et al., 2010). This difference 
correlated more with increased glucose plasma levels than with body mass indices (BMI), 
suggesting that this species might be involved in glucose metabolism (Larsen et al., 2010).  
Although research linking PD to diabetes is still in its infancy, preliminary studies 
suggest that individuals with T2D have a higher incidence of PD than do non-T2D 
individuals (Hu et al., 2007; Schernhammer et al., 2011; Sun et al., 2012). During a 9-year 
study, diabetic patients in Taiwan had a significantly increased risk of developing PD in both 
sexes and most age groups. Although the mechanistic link between T2D and PD is not 
known, chronic inflammation and oxidative stress are also linked in the risk of PD. 
Furthermore, insulin plays a role in regulating central dopaminergic signaling, and thus 
insulin dysregulation in T2D patients may contribute to nigro-striatal dopaminergic 
dysfunction. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α) is an important gene involved in mitochondrial biogenesis, regulating energy 
homeostasis relative to environmental stimuli (Knusel et al., 1990; Puigserver and 
Spiegelman, 2003; Wu et al., 1999). PGC-1α and its downstream targets are downregulated 
in both PD and T2D patients (Mootha et al., 2003; Zheng et al., 2010). Recently, it has been 
found that the zinc finger protein Parkin Interacting Substrate (PARIS) binds to the insulin 
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response sequences in the PGC-1α promoter. This interaction represses the expression of 
PGC-1α and Nuclear Respiratory Factor-1 (NRF-1) genes in dopaminergic neurons leading 
to their loss (Shin et al., 2011). Thus, both T2D and PD share common pathophysiological 
mechanisms including oxidative stress, inflammation and mitochondrial dysfunction.  
Since individuals with T2D run an increased risk of developing PD, we need to better 
understand the effect of anti-diabetic drugs on PD.   A patient’s risk of developing PD 
increases 2.2 fold when diagnosed with T2D, but that risk is lowered to only 1.3 fold with 
oral anti-hyperglycemic agent (OAA) therapy, suggesting that OAAs could also protect 
against neurodegenerative diseases like Parkinson’s (Wahlqvist et al., 2012). Metformin is an 
oral anti-hyperglycemic agent prescribed to treat T2D and metabolic syndrome (Knowler et 
al., 2002).  It is a well-tolerated drug that has been extensively used for decades, and thus, 
testing the drug’s efficacy against neurodegenerative diseases seems promising. Metformin’s 
mechanism of action was originally reported to involve activating AMPK through inhibition 
of mitochondrial respiration (El-Mir et al., 2000; Owen et al., 2000). However, recent 
evidence indicates that the metformin induced AMPK activation occurs independent of 
mitochondrial respiration (Bergheim et al., 2006). We found that metformin does not inhibit 
mitochondrial respiration in neuronal cells at therapeutic concentrations. Recent evidence 
suggests that altering the gut microbiome to favor Akkermansia muciniphila, a newly 
discovered mucin-degrading bacterium, in mice fed a high-fat diet (HFD) may contribute to 
the anti-diabetic effects of metformin (Shin et al., 2014). Treatment with A. muciniphila can 
reverse HFD-induced metabolic disorders such as adipose tissue inflammation, weight gain, 
and insulin resistance (Everard et al., 2013).  Metformin also affects host levels of 
methionine and folate, two nutrients essential to human health yet not produced de novo, but 
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instead are synthesized by certain gut microbes. Folates are B-vitamins involved in the 
biosynthesis of purines and pyrimidines as well as the biotransformation of amino acids 
within the host. Interestingly, deficiencies in B-12 vitamins, and folate specifically, have 
been implicated in Alzheimer’s disease patients (Lahiri and Maloney, 2010). Methionine is a 
sulfur-containing amino acid that occurs in proteins with proposed antioxidant activity 
(Levine et al., 1996). Folate and methionine are just two examples of possible gut byproducts 
that influence bacterial and host metabolism and the development of CNS disease.  
3.3 Central Nervous System Disorders and Gut Microbes 
Although not well understood, the gut microbiome could have a significant influence 
on behavior and psychosis. Adult mice that had been separated as neonates from their mother 
for a protracted time showed elevated levels of basal and stress-evoked adrenocorticotropic 
hormone (ACTH) and corticotropic releasing hormone (CRH). This response was inversely 
related to the age of the mice at the time of maternal separation (Schmidt et al., 2002), thus 
development of the HPA axis may have a maturation window influenced and regulated to 
some extent by the gut microbial composition. Sudo and colleagues showed that germ-free 
(GF) BALB/c mice had significantly higher levels of plasma corticosterone and ACTH 
compared to specific pathogen-free (SPF) mice in response to restraint stress (Sudo et al., 
2004). This response was tempered by the presence of Bifidobacterium infantis, which is 
known to be present in the neonate gut. In a highly intuitive experiment, they showed that 
gnotobiotic BALB/c mice colonized with enteropathogenic Escherichia coli (EPEC) 
developed an exaggerated response to stress, much higher than what the GF mice had shown. 
However, another set of mice colonized with the mutant EPEC strain ΔTir, did not display a 
heightened HPA response to stress. ΔTir bacteria lack the intimin receptor, thus preventing 
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microbial adherence and internalization in the intestinal tissue. This study showed that early 
colonization by intestinal bacteria regulates the development of the HPA axis. Colonization 
with commensal bacteria that are known to produce pro-health micronutrients is essential 
because neurodevelopment is impaired if pathogenic bacteria colonize the gastrointestinal 
tract. 
3.3.1 Neurodevelopmental disorders: 
Autism spectrum disorder (ASD) 
Human studies have shown that gut problems in early childhood might contribute to 
autism development. Various disorders, such as Attention Deficit Hyperactive Disorder 
(ADHD) and Autism Spectrum Disorder (ASD) share behavioral abnormalities in sociability, 
communication, and/or compulsive activity (Hsiao et al., 2013). An abnormal HPA response 
and altered microbial and metabolic profiles have been implicated in these disorders (Kaneko 
et al., 1993; King et al., 1998; Ming et al., 2012). Ming and colleagues showed altered amino 
acid metabolism and increased oxidative stress in ASD children relative to age-matched 
controls (Ming, Stein et al. 2012). A sub-group of ASD children with a history of 
gastrointestinal perturbations had an altered microbial profile compared to controls. The ASD 
group showed decreased levels of both 5-amino-valerate, which is thought to act as a weak 
GABA agonist, and 3-(3-hydroxyphenyl) propionic acid, an antioxidant. 
ASD children usually have a higher abundance of Proteobacteria and Bacteroidetes 
and a lower abundance of the Firmicutes and bifidobacteria when compared to healthy 
controls (Finegold et al., 2010; Finegold et al., 2012; Mezzelani et al., 2014). Interestingly, of 
the many classes of bacteria that constitute the Firmicutes, one class in particular, the 
Clostridia, is shown to be present in higher numbers in autistic children with a history of GI 
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problems (Song et al., 2004). Similarly, despite the overall abundance of Bacteroidetes in 
autistic subjects, lower counts of Prevotella are seen. Thus along with quantifying the 
relative increase or decrease in the populations of certain phyla, it is necessary to determine 
the populations of specific gut symbionts in order to understand the significance of certain 
physiological changes in the gut and/or the brain. One of the reasons why Clostridia are 
implicated in ASD is because autistic children subjected to oral Vancomycin treatment 
showed a regression of the characteristic symptoms of this disorder. Vancomycin is not 
absorbed in the intestine but can readily kill Gram-positive bacteria such as Clostridia. 
However, when the treatment was discontinued, the patients reverted back to their autistic 
behavior (Finegold, 2008). It is thought that clostridial spores, which are temperature-, pH- 
and antibiotic-resistant, also sporulate, further multiplying the mucosal populations of 
endotoxin-producing bacteria.  Indeed, according to one current theory, the “leaky gut” 
syndrome, high counts of pathogenic bacteria in the gut impair the intestinal barrier by 
producing neuro- and endotoxins, which then expose the mucosa and sub-mucosa to bacteria. 
The bacterial invasion of this previously aseptic environment causes immune cell activation 
and infiltration as well as up-regulation of pro-inflammatory cytokines such as TNFα and Il-
1β. This inflammatory response further increases barrier permeability thereby perpetuating 
an inflammatory cycle. Sandler et al. (2000) hypothesized that in a subgroup of children, 
disruption of indigenous gut microbiota might promote colonization by one or more 
neurotoxin-producing bacteria, contributing, at least in part, to eliciting autistic signs. These 
same investigators found that with broad-spectrum antimicrobial exposure followed by 
chronic persistent diarrhea, previously acquired skills deteriorated and autistic features 
emerged (Sandler et al., 2000).  In a recent study of offspring exposed to maternal immune 
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activation (MIA), Hsaio et al. revealed that oral treatment with Bacteroides fragillis corrects 
gut permeability, alters microbial composition, and ameliorates defects in communicative, 
stereotypic, anxiety-like and sensorimotor behaviors mainly by altering the HPA axis 
response to stress. This experiment supports a microbiome-gut-brain connection in a mouse 
model of ASD and identifies a potential probiotic therapy for GI disorders and particular 
behavioral symptoms in human neurodevelopmental disorders (Hsiao et al., 2013).  
Besides ASD, there has been considerable interest in understanding the role the gut 
microbiota plays in the development of ADHD and schizophrenia. In one study, infants were 
given either Lactobacillus rhamnosus GG or placebo during the first 6 months of life and gut 
microbiota was assessed over a period of 13 years. The study found a correlation between 
lower counts of Bifidobacterium species and development of ADHD or Asperger’s 
Syndrome (Partty et al., 2015).  
3.3.2 Neurodegenerative Disorders:  
Parkinson’s disease  
The role of the gut microbiome in the pathogenesis of chronic neurodegenerative 
disorders such as Alzheimer’s and Parkinson’s diseases is beginning to emerge. In PD, GI 
dysregulation is often seen several years before the disease is even detected. Braak and 
colleagues hypothesized that the disease begins in the gut and spreads from gut to brain via 
the gut-brain axis, i.e., vagus nerve and spinal cord. Indeed, the parasympathetic fibers of the 
vagus nerve that innervate the intestine among other regions arise from the dorsal motor 
nucleus (DMVX).  Lewy bodies (aggregated proteins, mainly alpha-synuclein and ubiquitin), 
which are the hallmark of PD, were found in the ENS in post-mortem cases of early PD 
(Braak et al., 2006). The presence of these protein aggregates correlated with the increasing 
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stages of PD and was subsequently found in the spinal cord, DMVX, prefrontal cortex and 
finally the mid-brain region of postmortem PD subjects. A recent study demonstrated that 
alpha-synuclein injected in the gut wall of rats migrated to the brain stem via the vagus nerve 
at a rate estimated to be 5-10 mm/day (Holmqvist et al., 2014).  The idea that PD patients 
have a low-grade inflammation of the gut has been around for some time. Indeed, increased 
mRNA expression of pro-inflammatory cytokines has been observed in colonic biopsies of 
PD patients compared to control subjects (Devos et al., 2013). This chronic low-grade 
inflammation might be the trigger that leads to blood brain barrier leakiness, immune cell 
activation and infiltration and ultimately neuro-inflammation in the CNS.  
Investigators are developing considerable interest in understanding the role of the gut 
microbiota in the context of PD.  In one study, fecal microbiota collected from 72 PD 
subjects and age-matched controls showed higher counts of Enterobacteriaceae and reduced 
Prevotellaceae in PD patients. Prevotella is known to break down complex carbohydrates, 
providing short chain fatty acids (SCFA’s) as well as thiamine and folate as byproducts that 
promote a healthy intestinal environment. Decreased Prevotella numbers are likely to result 
in reduced production of these important micronutrients. Unless compensated by dietary 
changes to supply these nutrients exogenously, decreased thiamine and folate might result in 
reduced production of essential vitamins and impaired secretions of gut hormones 
(Scheperjans et al., 2015). However, the study did not evaluate whether or not the patients 
had a history of GI disturbances or significant inflammation. Nevertheless, taken together, 
these results suggest that changes in the gut microbiome could have a direct effect on the 
CNS via the gut-brain axis with chronic mild systemic inflammation possibly driving the 
pathogenesis.  Cyanobacteria present in small numbers in the GI tract are thought to produce 
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β-N-methylamino-L-alanine (BMAA), which is elevated in the brains of AD, PD and 
amyotrophic lateral sclerosis (ALS) patients. BMAA is an excitotoxin that activates 
metabotropic glutamate receptor 5, thereby inducing depletion of the major antioxidant 
glutathione. As a result, neurons and glial cells are unable to effectively control ROS and 
RNS production in the brain. The BMAA protein is also implicated in aiding protein 
misfolding and aggregation typically seen in AD, PD and ALS (Brenner, 2013). However, 
whether patients showing elevated levels of BMAA in their brain also show increased 
cyanobacteria populations in the gut is not clear and needs further study.  
A majority of the clinically diagnosed PD cases are of the sporadic form, which is 
likely caused by a complex interplay of genetic and environmental factors. During the last 
few years, a number of epidemiological and clinical studies have suggested potential 
environmental risk factors for PD, including environmental exposure to certain pesticides and 
fungicides such as paraquat, rotenone and maneb, and some surrogate factors such as living 
in rural areas, drinking well water and farming.  In addition, exposure to heavy metals such 
as iron, lead, mercury, cadmium, arsenic and manganese, as well as to metal-based 
nanoparticles, has also been shown to increase the risk of PD through the accumulation of 
metals in the mid brain and increased oxidative stress-mediated apoptosis (Aboud et al., 
2014; Afeseh Ngwa et al., 2009; Afeseh Ngwa et al., 2011; Harischandra et al., 2015; 
Kanthasamy et al., 2012; Milatovic et al., 2009). Currently, the effect of environmental 
factors on the host gut microbiome is completely unknown.  
Manganese is an essential trace element vital for normal bone development, fat and 
carbohydrate metabolism, blood sugar regulation, and the biological functions of a number of 
enzymes (Aschner and Aschner, 2005; Bowman et al., 2011). However, excessive 
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manganese is considered a neurotoxic pollutant in the environment and recently gained 
importance as a putative risk factor for environmentally-linked PD. Chronic exposure to 
occupational or environmental sources of manganese can cause a neurodegenerative disorder 
known as Manganism, characterized by severe neurological deficits that often resemble the 
involuntary extrapyramidal symptoms associated with PD. Manganism most frequently 
occurs from occupational manganese exposure during mining, welding metals, and dry 
battery manufacturing. Other manganese-containing products presenting a public exposure 
risk include fertilizers, varnish, fungicides, gasoline additives and livestock feeding 
supplements. The growing evidence indicates that manganese primarily causes damage to the 
basal ganglia in humans, where it affects dopamine release and causes GABA dysregulation 
(Brouillet et al., 1993; Erikson and Aschner, 2003; Fitsanakis et al., 2006; Roth et al., 2013).  
Yet, despite its prevalence and potential risk to human health, the mechanisms by which 
manganese exerts its toxic effects on the gut and gut microbiome have yet to be elucidated. 
Preliminary experiments were conducted in our laboratory to assess the impact of 
manganese in altering gut physiology by exposing mice to 15 mg/kg/day MnCl2 for 30 days 
via oral gavage. Manganese-exposed mice displayed increased whole gut transit time and an 
altered fecal metabolic profile. GC-MS studies carried out in stool samples showed that 
manganese exposure decreases butyrate production as well as α-tocopherol, which is 
involved in Vitamin-E synthesis, whereas it increases compounds such as cholic acid, which 
is known to saturate bile salts leading to the development of gall stones (Table 1). Thus, our 
results provide initial evidence that metal toxicity can influence gut motility and key gut 
microbial metabolites.  Thus, it is likely that exposure to environmental toxins can influence 
the gut microbiome profile with potentially unfavorable physiological effects. 
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4. Factors Influencing Microbiome-Gut-Brain regulation 
4.1 Environment 
A recently described epigenetic model of disease development, called the LEARn 
model (Latent Early-Life Associated Regulation), predicts that early-life exposures to 
nutritional imbalances, metals, maternal care variations, or other environmental stressors can 
lead to modified expression of disorder-associated genes over the course of an individual’s 
lifespan (Lahiri and Maloney, 2010). An early environmental influence is the maternal 
environment. The gut microbiota of mouse littermates are more similar than are those of pups 
born to different mothers despite being reared in adjacent boxes in the same animal room 
(Benson et al., 2010). Bacteria present in the mother’s vaginal tract and on her skin serve as 
the first bacteria to colonize the neonate gut. Later, microbes present in the colostrum form a 
part of the gut microbiome, thus increasing the complexity of this environment. Our locality 
also plays an important role in determining individual gut microbiota profiles One study 
noted that ASD patients showed a gut microbiota profile similar to their healthy siblings, 
while unrelated healthy controls had significantly different profiles (Parracho et al., 2005).. 
Besides locality, additional environmental factors affecting the gut microbiome include 
ethnicity and culture (Annalisa et al., 2014; De Filippo et al., 2010; Holmes et al., 2008).   
4.2 Diet, Microbes and Health 
The relative abundance of gut microbiome is dependent upon the energy source 
available to them and their ability to utilize this source. In one study, switching from a low-
fat, plant polysaccharide-rich diet to a high-fat, high-sugar diet shifted the community 
structure of the microbiome within a single day, changed the representation of metabolic 
pathways in the microbiome, and altered microbiome gene expression (Turnbaugh et al., 
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2009). Firmicutes, especially Lactobacillaceae, Veillonellaceae, and Lachnospiraceae, were 
seen in greater proportions in obese individuals. Conversely, a high-fiber, low-fat diet 
decreased the population of Firmicutes (Parnell and Reimer, 2012). 
While individual variations are seen, in general, diets high in animal fat and protein 
are associated with an abundance of Bacteroides, high-fiber diets with Prevotella, while 
plant-based diets are predominated by both Bacteroides and the Firmicutes (David et al., 
2014; Wu et al., 2011). Furthermore, the gut microbiome composition is more complex in a 
host whose diet is primarily plant-based as opposed to animal-based (G. D. Wu, et al., 2011). 
Also, bacteria that can degrade complex carbohydrates are present in high-fiber diets in 
higher numbers, while bacteria that primarily break down proteins predominate in animal-
based diets. However, the fact must be reiterated that while different studies state the overall 
change in bacterial phyla, it is important to understand which species show population 
changes. This is also necessary to know since commensal as well as pathogenic bacteria are 
present in each phylum. Summaries of the factors that potentially affect the host-gut 
microbiome relationship are shown in figure 4. 
Changing one’s diet towards complex carbohydrates such as less processed whole 
grain foods, fermented vegetables, and prebiotic-containing foods has been shown to induce 
weight loss, to reduce blood pressure, cholesterol and heart rate, and to decrease toxin-
producing bacteria while increasing beneficial bacteria in the gut (Hvistendahl, 2012).  
Prebiotics are not digested by the host, but metabolized by the gut bacteria, thereby favoring 
specific changes in the activity and composition of the gut microbiome that benefit host 
health and wellness (Gibson et al., 2004). Preliminary research suggests that the risk of 
developing cardiovascular disease, T2D, obesity, and osteoporosis is reduced with the 
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addition of a prebiotic to the host’s diet (Roberfroid, 2000). One of the first prebiotics an 
infant receives is oligosaccharides present in the mother’s milk (Partty et al., 2015). Unlike 
the sugars found in infant formula, the oligosaccharides present in breast milk are only 
partially digested in the small intestine and so reach the colon where they provide an energy 
source for the development of bifidobacteria. A probiotic, on the other hand, is a microbe 
(bacterial or yeast) that is administered to the host to confer health benefits (Maslowski and 
Mackay, 2011).  They are found in our food (yogurt, fermented vegetables) and have been 
implicated in alleviating lactose intolerance and boosting immune function. Common 
probiotics include Propionibacterium, lactic acid bacteria (LAB), bifidobacteria, and certain 
yeasts to name a few. Numerous studies have investigated the effects of probiotics on 
behavior and intestinal health (Bravo et al., 2011; D'Mello et al., 2015; Ostan et al., 2015; 
Savignac et al., 2014). 
  
5. Biomarkers of interest 
As mentioned before, gut microbiota produce various metabolites, some of which are 
involved in the host’s metabolic processes while others help maintain a healthy gut 
environment. Although the gut residence times of these metabolites differ, they can be 
detected in the host’s blood, urine, feces, or breath. Thus a useful and non-invasive way of 
diagnosing bacterial dysbiosis is by profiling biofluids for such compounds using 
metagenomics technology. For example, using 1H NMR spectroscopy and targeted analysis, 
Schicho and colleagues were able to identify a number of urine, serum and plasma 
metabolites found in higher numbers in colitis patients verses healthy controls (Schicho et al., 
2012). Another method employed to detect gut bacterial dysbiosis is by using selected ion 
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flow tube mass spectrometry [SIFT-MS] to measure volatile compounds in the breath, stool 
or urine of patients. Volatile organic compounds (VOC), such as ethane, methane, pentane, 
dimethyl sulfide, ammonia, dimethylamine, trimethylamine, are produced in part by bacteria. 
These can be measured in biofluids like urine, and saliva or breath and stool. Changes in the 
levels of these compounds could serve as a potential diagnostic tool. For example, elevated 
levels of pentane and ethane are found in individuals diagnosed with asthma and chronic 
obstructive pulmonary disorder (Van Berkel et al., 2010).  
SCFAs are one of the most important gut microbial products. They affect a range of 
host processes, including energy utilization, host-microbe signaling, and colonic pH, with 
consequent effects on gut microbiome composition, gut motility, and epithelial cell 
proliferation (Musso et al., 2011). Butyrate, a common gut microbiome byproduct, and 
propionate can inhibit histone deacetylase (HDAC) enzymes and alter the expression of 
specific genes via conformational changes in the active site of HDAC leading to its 
inactivation (Aoyama et al., 2010; Dashwood et al., 2006).  Microbe-derived butyrate can 
trigger cell cycle arrest and apoptosis in rapidly dividing colonocytes, and thus has proven 
effective at preventing colon cancer (Rooks and Garrett, 2011; Shenderov, 2012; Waby et al., 
2010). In vitro studies have shown that butyrate amplifies the antioxidant properties of 
glutathione-S-transferase (Ebert et al., 2003). Fecalibacterium prausnitzii, Roseburia 
intestinalis, Eubacteria hallii, E.coli and Butyricicoccus pullicaecorum are some of the 
bacteria that produce butyrate in the gut. During ulcerative colitis, the populations of these 
bacteria decline (Kumari et al., 2013). Although gut microbial dysbiosis in T2D patients is 
moderate compared to the dramatic dysbiosis reported in obese patients, a study done by Qin 
et al. revealed that T2D patients exhibit fewer butyrate-producing bacteria and more 
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opportunistic pathogens. They also reported an enrichment of microbial functions conferring 
sulphate reduction and increased oxidative stress, which are indicative of pathogenicity (Qin 
et al., 2012). This promotes the idea that butyrate-producing bacteria protect the host against 
various diseases. Given that other intestinal diseases show a loss of butyrate-producing 
bacteria with a commensurate increase in opportunistic pathogens, it is worth considering 
butyrate as a potential biomarker for intestinal health.  
Regarding the gut microbiome’s influence on neurotransmitters, a recent study has 
shown that patients diagnosed with depression have increased volatile fatty acids such as 
isovaleric acid in their stool (Szczesniak et al., 2015). Isovaleric acid can cross the blood-
brain barrier (BBB) and affect neurotransmitter release in the CNS, thus possibly worsening 
this disorder. This has diagnostic importance since a patient’s stool can be screened for 
increased volatile fatty acids. Factor-S, a sleep promoting substance, accumulates in the brain 
and fluids of sleep-deprived individuals. It is in fact derived from the bacterial cell wall and 
thus released by gut bacteria (Collins and Bercik, 2009) and it provides yet another example 
of how bacterial products can influence brain activity and function. Rats given a strict 
antibiotic regimen exhibited greatly reduced slow-wave sleep and increased sleep onset 
latency (Brown et al., 1990). 
 
6. Current model systems  
Currently, 16s rRNA gene sequence analysis or shotgun sequencing for identifying 
bacteria is widely used. By applying these techniques, changes in the gut microbiome 
composition, from phyla to species level, can be ascertained. To analyze the gut microbial 
content in T2D patients, Qin et al. developed a novel metagenome-wide association study 
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(MGWAS) (Qin et al., 2012). Using deep shotgun sequencing of the gut microbiome of 345 
Chinese individuals, they identified roughly 60,000 T2D markers, thus allowing them to 
establish a linkage group for bacterial species-level analysis. Larsen et al. examined fecal 
content to characterize the composition of the colonic microbiome in adults with T2D using 
qPCR and tag-encoded amplicon pyrosequencing of the V4 region of the 16s rRNA gene 
(Larsen et al., 2010). This hyper-variable V4 region is a bacterial gene segment used for 
distinguishing different bacteria, in this case phyla: Bacteroidetes, Firmicutes, 
Actinobacteria, Verrucomicrobia, and Proteobacteria. This study involved 36 males of 
varying BMIs, half with T2D and half serving as non-diabetic controls. Compared to 
controls, the diabetic group had elevated concentrations of plasma glucose and significantly 
reduced proportions of the phylum Firmicutes and class Clostridia. 
One of the main obstacles in this area is the lack of an animal model system that 
successfully replicates a healthy or a diseased individual’s gut microbiome. Since rodent 
diets differ substantially from the diet of humans, making comparisons between human and 
mouse gut microbiota studies inherently problematic (Flint, 2011; Ravussin et al., 2012). 
While studies have been done using conventional mice as the model organism, in some cases, 
the alterations seen in the intestinal bacterial population in mice are not validated by human 
data. For example, bacteria like Prevotella and Ruminococcus are dominant in the human gut 
but are under-represented in the mouse gut. Also, due to limited sequencing depth, many 
smaller microbial populations in both humans and mice may not be detected (Nguyen et al., 
2015). However, while species differences exist between humans and rodents, the overall 
dominant families are more or less represented similarly between the two. Hence studies 
involving mouse models of different diseases/disorders can be used to understand certain 
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changes in human gut microbiome structure. However, these findings must be validated with 
human gut microbiome sequencing studies. An integrative approach, involving detailed 
epidemiological surveys (e.g., lifestyle, diet, health history), high-throughput sequencing as 
well as the use of advanced analytical tools, is needed to better understand the gut 
microbiome and its role in various biological systems in the body. Furthermore, another 
approach to bridging the translational gap posed by rodent model systems is by making 
“humanized mice” by adding specific bacterial strains common to the human GIT into germ-
free mice (Martin et al., 2008; Turnbaugh et al., 2006; Turnbaugh et al., 2009). 
 
7. Conclusions and Future directions 
Understanding the complex transgenomic metabolic interactions within the gut 
microbiome perhaps poses the ultimate challenge in deciphering and learning how to 
optimize our gut microbiome to promote health and longevity. Understanding the gut 
microbiome has the potential to revolutionize the way human and animal diseases are treated. 
Novel antibiotics, prebiotics, probiotics, and even microbiome transplants could replace 
expensive surgeries or drug treatments. Actively managing the gut microbiome holds 
considerable potential in the realm of preventive medicine as well as the treatment of 
acquired diseases. The most difficult undertaking will be dissecting the complex metabolic, 
environmental, and genomic interactions between the host and its gut microbiome. Some of 
the pertinent areas to be studied are as follows: 
1) The	dynamics	and	 impact	of	maternal	gut	microbiome	transfer	and	the	 influence	of	 infant	
nutrition	on	development	of	the	gut	microbiome	in	early	childhood.		
2) The	 influence	 of	 host	 genome	 variations	 and	 the	 fetal	 environment	 on	 the	 future	 gut	
microbiome	and	the	influence	of	fetal	development	on	the	HMMA.	
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3) The	effects	of	antibiotic	use	on	 the	gut	microbiome	 in	utero,	during	childhood,	and	 in	 the	
elderly	population.	
4) The	 influence	 of	 the	 gut	 microbiome	 on	 metabolism,	 pharmacokinetics,	 and	 the	
biotransformation	of	drugs	and	toxicants.	
5) The	effect	of	drugs	and	toxicants	on	gut	microbiome	population	and	gut	metabolites.	
6) The	influence	of	the	gut	microbiome	and	the	gut-brain	axis	on	repair	and	remodeling	in	the	
CNS	as	well	as	on	the	development	and	progression	of	neurodegenerative	diseases.		
7) Developing	 a	 cost-effective	 technique	 to	map	 an	 individual’s	 complete	 gut	microbiome	at	
any	point	in	time	to	better	help	physicians	create	a	therapeutic	regimen.		
Along with advances in metabolomics and metagenomics, a greater understanding of the 
potential health benefits of our gut microbiome is within reach. Considering the complex and 
dynamic nature of the microbial population and its effect on the individual, collaboration in 
the fields of microbiology, neurobiology, biochemistry, immunology, gastroenterology, 
genetics, epidemiology, pharmacology, and toxicology is warranted to gain a better 
understanding of this important host-bacteria relationship. 
 
Acknowledgements 
The authors acknowledge Gary Zenitsky for his assistance in the preparation of this 
manuscript. This work was in part supported by National Institutes of Health (NIH) [Grants 
ES19267, NS 074443, and ES10586]. The W. Eugene and Linda Lloyd Endowed Chair to 
A.G.K. is also acknowledged.  
 
 
62 
 
 
8. References   
Aboud, A. A., Tidball, A. M., Kumar, K. K., Neely, M. D., Han, B., Ess, K. C., Hong, C. C., 
Erikson, K. M., Hedera, P., & Bowman, A. B. (2014). PARK2 patient 
neuroprogenitors show increased mitochondrial sensitivity to copper. Neurobiol Dis, 
73C, 204-212. 
Afeseh Ngwa, H., Kanthasamy, A., Anantharam, V., Song, C., Witte, T., Houk, R., & 
Kanthasamy, A. G. (2009). Vanadium induces dopaminergic neurotoxicity via protein 
kinase Cdelta dependent oxidative signaling mechanisms: relevance to 
etiopathogenesis of Parkinson's disease. Toxicol Appl Pharmacol, 240, 273-285. 
Afeseh Ngwa, H., Kanthasamy, A., Gu, Y., Fang, N., Anantharam, V., & Kanthasamy, A. G. 
(2011). Manganese nanoparticle activates mitochondrial dependent apoptotic 
signaling and autophagy in dopaminergic neuronal cells. Toxicol Appl Pharmacol, 
256, 227-240. 
Annalisa, N., Alessio, T., Claudette, T. D., Erald, V., Antonino de, L., & Nicola, D. D. 
(2014). Gut microbioma population: an indicator really sensible to any change in age, 
diet, metabolic syndrome, and life-style. Mediators Inflamm, 2014, 901308. 
Aoyama, M., Kotani, J., & Usami, M. (2010). Butyrate and propionate induced activated or 
non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating 
GPR-41/GPR-43 pathways. Nutrition, 26, 653-661. 
Aschner, J. L., & Aschner, M. (2005). Nutritional aspects of manganese homeostasis. Mol 
Aspects Med, 26, 353-362. 
Benson, A. K., Kelly, S. A., Legge, R., Ma, F., Low, S. J., Kim, J., Zhang, M., Oh, P. L., 
Nehrenberg, D., Hua, K., Kachman, S. D., Moriyama, E. N., Walter, J., Peterson, D. 
63 
 
 
A., & Pomp, D. (2010). Individuality in gut microbiota composition is a complex 
polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl 
Acad Sci U S A, 107, 18933-18938. 
Bergheim, I., Guo, L., Davis, M. A., Lambert, J. C., Beier, J. I., Duveau, I., Luyendyk, J. P., 
Roth, R. A., & Arteel, G. E. (2006). Metformin prevents alcohol-induced liver injury 
in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology, 
130, 2099-2112. 
Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkila, J., Monti, D., 
Satokari, R., Franceschi, C., Brigidi, P., & De Vos, W. (2010). Through ageing, and 
beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS 
One, 5, e10667. 
Bowman, A. B., Kwakye, G. F., Herrero Hernandez, E., & Aschner, M. (2011). Role of 
manganese in neurodegenerative diseases. J Trace Elem Med Biol, 25, 191-203. 
Braak, H., de Vos, R. A., Bohl, J., & Del Tredici, K. (2006). Gastric alpha-synuclein 
immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for 
Parkinson's disease-related brain pathology. Neurosci Lett, 396, 67-72. 
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., 
Bienenstock, J., & Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates 
emotional behavior and central GABA receptor expression in a mouse via the vagus 
nerve. Proc Natl Acad Sci U S A, 108, 16050-16055. 
Brenner, S. R. (2013). Blue-green algae or cyanobacteria in the intestinal micro-flora may 
produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be 
related to development of amyotrophic lateral sclerosis, Alzheimer's disease and 
64 
 
 
Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in 
horses. Med Hypotheses, 80, 103. 
Brouillet, E. P., Shinobu, L., McGarvey, U., Hochberg, F., & Beal, M. F. (1993). Manganese 
injection into the rat striatum produces excitotoxic lesions by impairing energy 
metabolism. Exp Neurol, 120, 89-94. 
Brown, R., Price, R. J., King, M. G., & Husband, A. J. (1990). Are antibiotic effects on sleep 
behavior in the rat due to modulation of gut bacteria? Physiol Behav, 48, 561-565. 
Collins, S. M., & Bercik, P. (2009). The relationship between intestinal microbiota and the 
central nervous system in normal gastrointestinal function and disease. 
Gastroenterology, 136, 2003-2014. 
D'Mello, C., Ronaghan, N., Zaheer, R., Dicay, M., Le, T., MacNaughton, W. K., Surrette, M. 
G., & Swain, M. G. (2015). Probiotics Improve Inflammation-Associated Sickness 
Behavior by Altering Communication between the Peripheral Immune System and 
the Brain. J Neurosci, 35, 10821-10830. 
Danielsson, H., & Gustafsson, B. (1959). On serum-cholesterol levels and neutral fecal 
sterols in germ-free rats; bile acids and steroids 59. Arch Biochem Biophys, 83, 482-
485. 
Dashwood, R. H., Myzak, M. C., & Ho, E. (2006). Dietary HDAC inhibitors: time to rethink 
weak ligands in cancer chemoprevention? Carcinogenesis, 27, 344-349. 
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., 
Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., Biddinger, S. B., Dutton, R. 
J., & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut 
microbiome. Nature, 505, 559-563. 
65 
 
 
De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., 
Collini, S., Pieraccini, G., & Lionetti, P. (2010). Impact of diet in shaping gut 
microbiota revealed by a comparative study in children from Europe and rural Africa. 
Proceedings of the National Academy of Sciences of the United States of America, 
107, 14691-14696. 
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., 
Bruley des Varannes, S., Naveilhan, P., Nguyen, J. M., Neunlist, M., & Derkinderen, 
P. (2013). Colonic inflammation in Parkinson's disease. Neurobiol Dis, 50, 42-48. 
Diaz Heijtz, R., Wang, S., Anuar, F., Qian, Y., Bjorkholm, B., Samuelsson, A., Hibberd, M. 
L., Forssberg, H., & Pettersson, S. (2011). Normal gut microbiota modulates brain 
development and behavior. Proceedings of the National Academy of Sciences of the 
United States of America, 108, 3047-3052. 
Dogra, S., Sakwinska, O., Soh, S. E., Ngom-Bru, C., Bruck, W. M., Berger, B., Brussow, H., 
Lee, Y. S., Yap, F., Chong, Y. S., Godfrey, K. M., Holbrook, J. D., & Group, G. S. 
(2015). Dynamics of infant gut microbiota are influenced by delivery mode and 
gestational duration and are associated with subsequent adiposity. MBio, 6. 
Dupont, J. R., Jervis, H. R., & Sprinz, H. (1965). Auerbach's plexus of the rat cecum in 
relation to the germfree state. J Comp Neurol, 125, 11-18. 
Ebert, M. N., Klinder, A., Peters, W. H., Schaferhenrich, A., Sendt, W., Scheele, J., & Pool-
Zobel, B. L. (2003). Expression of glutathione S-transferases (GSTs) in human colon 
cells and inducibility of GSTM2 by butyrate. Carcinogenesis, 24, 1637-1644. 
66 
 
 
El-Mir, M. Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M., & Leverve, X. (2000). 
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the 
respiratory chain complex I. J Biol Chem, 275, 223-228. 
Erikson, K. M., & Aschner, M. (2003). Manganese neurotoxicity and glutamate-GABA 
interaction. Neurochem Int, 43, 475-480. 
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., 
Derrien, M., Muccioli, G. G., Delzenne, N. M., de Vos, W. M., & Cani, P. D. (2013). 
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-
induced obesity. Proc Natl Acad Sci U S A, 110, 9066-9071. 
Falk, P. G., Hooper, L. V., Midtvedt, T., & Gordon, J. I. (1998). Creating and maintaining 
the gastrointestinal ecosystem: what we know and need to know from gnotobiology. 
Microbiol Mol Biol Rev, 62, 1157-1170. 
Finegold, S. M. (2008). Therapy and epidemiology of autism--clostridial spores as key 
elements. Med Hypotheses, 70, 508-511. 
Finegold, S. M., Dowd, S. E., Gontcharova, V., Liu, C., Henley, K. E., Wolcott, R. D., Youn, 
E., Summanen, P. H., Granpeesheh, D., Dixon, D., Liu, M., Molitoris, D. R., & 
Green, J. A., 3rd. (2010). Pyrosequencing study of fecal microflora of autistic and 
control children. Anaerobe, 16, 444-453. 
Finegold, S. M., Downes, J., & Summanen, P. H. (2012). Microbiology of regressive autism. 
Anaerobe, 18, 260-262. 
Fitsanakis, V. A., Au, C., Erikson, K. M., & Aschner, M. (2006). The effects of manganese 
on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochem Int, 
48, 426-433. 
67 
 
 
Flint, H. J. (2011). Obesity and the gut microbiota. J Clin Gastroenterol, 45 Suppl, S128-132. 
Gardiner, K. R., Erwin, P. J., Anderson, N. H., Barr, J. G., Halliday, M. I., & Rowlands, B. J. 
(1993). Colonic bacteria and bacterial translocation in experimental colitis. Br J Surg, 
80, 512-516. 
Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary 
modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr 
Res Rev, 17, 259-275. 
Gustafsson, B. E. (1959). Vitamin K deficiency in germfree rats. Ann N Y Acad Sci, 78, 166-
174. 
Harischandra, D. S., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2015). 
alpha-Synuclein protects against manganese neurotoxic insult during the early stages 
of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci, 143, 
454-468. 
Harmsen, H. J., Wildeboer-Veloo, A. C., Raangs, G. C., Wagendorp, A. A., Klijn, N., 
Bindels, J. G., & Welling, G. W. (2000). Analysis of intestinal flora development in 
breast-fed and formula-fed infants by using molecular identification and detection 
methods. J Pediatr Gastroenterol Nutr, 30, 61-67. 
Holmes, E., Wilson, I. D., & Nicholson, J. K. (2008). Metabolic phenotyping in health and 
disease. Cell, 134, 714-717. 
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Bjorklund, T., Wang, Z. Y., 
Roybon, L., Melki, R., & Li, J. Y. (2014). Direct evidence of Parkinson pathology 
spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol, 128, 805-
820. 
68 
 
 
Hooper, L. V., Midtvedt, T., & Gordon, J. I. (2002). How host-microbial interactions shape 
the nutrient environment of the mammalian intestine. Annu Rev Nutr, 22, 283-307. 
Hsiao, E. Y., McBride, S. W., Hsien, S., Sharon, G., Hyde, E. R., McCue, T., Codelli, J. A., 
Chow, J., Reisman, S. E., Petrosino, J. F., Patterson, P. H., & Mazmanian, S. K. 
(2013). Microbiota modulate behavioral and physiological abnormalities associated 
with neurodevelopmental disorders. Cell, 155, 1451-1463. 
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007). Type 2 diabetes and 
the risk of Parkinson's disease. Diabetes Care, 30, 842-847. 
Hvistendahl, M. (2012). My microbiome and me. Science, 336, 1248-1250. 
Kaneko, M., Hoshino, Y., Hashimoto, S., Okano, T., & Kumashiro, H. (1993). 
Hypothalamic-pituitary-adrenal axis function in children with attention-deficit 
hyperactivity disorder. J Autism Dev Disord, 23, 59-65. 
Kanthasamy, A. G., Choi, C., Jin, H., Harischandra, D. S., Anantharam, V., & Kanthasamy, 
A. (2012). Effect of divalent metals on the neuronal proteasomal system, prion 
protein ubiquitination and aggregation. Toxicol Lett, 214, 288-295. 
Kelly, D., King, T., & Aminov, R. (2007). Importance of microbial colonization of the gut in 
early life to the development of immunity. Mutat Res, 622, 58-69. 
King, J. A., Barkley, R. A., & Barrett, S. (1998). Attention-deficit hyperactivity disorder and 
the stress response. Biol Psychiatry, 44, 72-74. 
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. 
A., Nathan, D. M., & Diabetes Prevention Program Research, G. (2002). Reduction in 
the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J 
Med, 346, 393-403. 
69 
 
 
Knusel, B., Michel, P. P., Schwaber, J. S., & Hefti, F. (1990). Selective and nonselective 
stimulation of central cholinergic and dopaminergic development in vitro by nerve 
growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the 
insulin-like growth factors I and II. J Neurosci, 10, 558-570. 
Koenig, J. E., Spor, A., Scalfone, N., Fricker, A. D., Stombaugh, J., Knight, R., Angenent, L. 
T., & Ley, R. E. (2011). Succession of microbial consortia in the developing infant 
gut microbiome. Proceedings of the National Academy of Sciences of the United 
States of America, 108 Suppl 1, 4578-4585. 
Kumari, R., Ahuja, V., & Paul, J. (2013). Fluctuations in butyrate-producing bacteria in 
ulcerative colitis patients of North India. World J Gastroenterol, 19, 3404-3414. 
Lahiri, D. K., & Maloney, B. (2010). The "LEARn" (Latent Early-life Associated 
Regulation) model integrates environmental risk factors and the developmental basis 
of Alzheimer's disease, and proposes remedial steps. Exp Gerontol, 45, 291-296. 
Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, D. S., Andreasen, A. S., 
Pedersen, B. K., Al-Soud, W. A., Sorensen, S. J., Hansen, L. H., & Jakobsen, M. 
(2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic 
adults. PLoS ONE, 5, e9085. 
Lepage, P., Hasler, R., Spehlmann, M. E., Rehman, A., Zvirbliene, A., Begun, A., Ott, S., 
Kupcinskas, L., Dore, J., Raedler, A., & Schreiber, S. (2011). Twin study indicates 
loss of interaction between microbiota and mucosa of patients with ulcerative colitis. 
Gastroenterology, 141, 227-236. 
70 
 
 
Levine, R. L., Mosoni, L., Berlett, B. S., & Stadtman, E. R. (1996). Methionine residues as 
endogenous antioxidants in proteins. Proceedings of the National Academy of 
Sciences of the United States of America, 93, 15036-15040. 
Littman, D. R., & Pamer, E. G. (2011). Role of the commensal microbiota in normal and 
pathogenic host immune responses. Cell Host Microbe, 10, 311-323. 
Martin, F. P., Wang, Y., Sprenger, N., Yap, I. K., Lundstedt, T., Lek, P., Rezzi, S., Ramadan, 
Z., van Bladeren, P., Fay, L. B., Kochhar, S., Lindon, J. C., Holmes, E., & Nicholson, 
J. K. (2008). Probiotic modulation of symbiotic gut microbial-host metabolic 
interactions in a humanized microbiome mouse model. Mol Syst Biol, 4, 157. 
Maslowski, K. M., & Mackay, C. R. (2011). Diet, gut microbiota and immune responses. Nat 
Immunol, 12, 5-9. 
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., & Kasper, D. L. (2005). An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host 
immune system. Cell, 122, 107-118. 
Mezzelani, A., Landini, M., Facchiano, F., Raggi, M. E., Villa, L., Molteni, M., De Santis, 
B., Brera, C., Caroli, A. M., Milanesi, L., & Marabotti, A. (2014). Environment, 
dysbiosis, immunity and sex-specific susceptibility: A translational hypothesis for 
regressive autism pathogenesis. Nutr Neurosci. 
Milatovic, D., Zaja-Milatovic, S., Gupta, R. C., Yu, Y., & Aschner, M. (2009). Oxidative 
damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl 
Pharmacol, 240, 219-225. 
Ming, X., Stein, T. P., Barnes, V., Rhodes, N., & Guo, L. (2012). Metabolic perturbance in 
autism spectrum disorders: a metabolomics study. J Proteome Res, 11, 5856-5862. 
71 
 
 
Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J., 
Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M. J., 
Patterson, N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander, E. S., 
Hirschhorn, J. N., Altshuler, D., & Groop, L. C. (2003). PGC-1alpha-responsive 
genes involved in oxidative phosphorylation are coordinately downregulated in 
human diabetes. Nat Genet, 34, 267-273. 
Morelli, L. (2008). Postnatal development of intestinal microflora as influenced by infant 
nutrition. J Nutr, 138, 1791S-1795S. 
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. 
A., Shah, S. A., LeLeiko, N., Snapper, S. B., Bousvaros, A., Korzenik, J., Sands, B. 
E., Xavier, R. J., & Huttenhower, C. (2012). Dysfunction of the intestinal microbiome 
in inflammatory bowel disease and treatment. Genome Biol, 13, R79. 
Musso, G., Gambino, R., & Cassader, M. (2011). Interactions between gut microbiota and 
host metabolism predisposing to obesity and diabetes. Annu Rev Med, 62, 361-380. 
Nguyen, T. L., Vieira-Silva, S., Liston, A., & Raes, J. (2015). How informative is the mouse 
for human gut microbiota research? Dis Model Mech, 8, 1-16. 
Ostan, R., Bene, M. C., Spazzafumo, L., Pinto, A., Donini, L. M., Pryen, F., Charrouf, Z., 
Valentini, L., Lochs, H., Bourdel-Marchasson, I., Blanc-Bisson, C., Buccolini, F., 
Brigidi, P., Franceschi, C., & d'Alessio, P. A. (2015). Impact of diet and nutraceutical 
supplementation on inflammation in elderly people. Results from the RISTOMED 
study, an open-label randomized control trial. Clin Nutr. 
72 
 
 
Owen, M. R., Doran, E., & Halestrap, A. P. (2000). Evidence that metformin exerts its anti-
diabetic effects through inhibition of complex 1 of the mitochondrial respiratory 
chain. Biochem J, 348 Pt 3, 607-614. 
Parnell, J. A., & Reimer, R. A. (2012). Prebiotic fibres dose-dependently increase satiety 
hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. 
Br J Nutr, 107, 601-613. 
Parracho, H. M., Bingham, M. O., Gibson, G. R., & McCartney, A. L. (2005). Differences 
between the gut microflora of children with autistic spectrum disorders and that of 
healthy children. J Med Microbiol, 54, 987-991. 
Partty, A., Kalliomaki, M., Wacklin, P., Salminen, S., & Isolauri, E. (2015). A possible link 
between early probiotic intervention and the risk of neuropsychiatric disorders later in 
childhood: a randomized trial. Pediatr Res, 77, 823-828. 
Penders, J., Thijs, C., Vink, C., Stelma, F. F., Snijders, B., Kummeling, I., van den Brandt, P. 
A., & Stobberingh, E. E. (2006). Factors influencing the composition of the intestinal 
microbiota in early infancy. Pediatrics, 118, 511-521. 
Puigserver, P., & Spiegelman, B. M. (2003). Peroxisome proliferator-activated receptor-
gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic 
regulator. Endocr Rev, 24, 78-90. 
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, 
N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., 
Wang, B., Liang, H., Zheng, H., Xie, Y., Tap, J., Lepage, P., Bertalan, M., Batto, J. 
M., Hansen, T., Le Paslier, D., Linneberg, A., Nielsen, H. B., Pelletier, E., Renault, 
P., Sicheritz-Ponten, T., Turner, K., Zhu, H., Yu, C., Li, S., Jian, M., Zhou, Y., Li, Y., 
73 
 
 
Zhang, X., Li, S., Qin, N., Yang, H., Wang, J., Brunak, S., Dore, J., Guarner, F., 
Kristiansen, K., Pedersen, O., Parkhill, J., Weissenbach, J., Meta, H. I. T. C., Bork, 
P., Ehrlich, S. D., & Wang, J. (2010). A human gut microbial gene catalogue 
established by metagenomic sequencing. Nature, 464, 59-65. 
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., 
Peng, Y., Zhang, D., Jie, Z., Wu, W., Qin, Y., Xue, W., Li, J., Han, L., Lu, D., Wu, 
P., Dai, Y., Sun, X., Li, Z., Tang, A., Zhong, S., Li, X., Chen, W., Xu, R., Wang, M., 
Feng, Q., Gong, M., Yu, J., Zhang, Y., Zhang, M., Hansen, T., Sanchez, G., Raes, J., 
Falony, G., Okuda, S., Almeida, M., LeChatelier, E., Renault, P., Pons, N., Batto, J. 
M., Zhang, Z., Chen, H., Yang, R., Zheng, W., Li, S., Yang, H., Wang, J., Ehrlich, S. 
D., Nielsen, R., Pedersen, O., Kristiansen, K., & Wang, J. (2012). A metagenome-
wide association study of gut microbiota in type 2 diabetes. Nature, 490, 55-60. 
Ravussin, Y., Koren, O., Spor, A., LeDuc, C., Gutman, R., Stombaugh, J., Knight, R., Ley, 
R. E., & Leibel, R. L. (2012). Responses of gut microbiota to diet composition and 
weight loss in lean and obese mice. Obesity (Silver Spring), 20, 738-747. 
Resta, S. C. (2009). Effects of probiotics and commensals on intestinal epithelial physiology: 
implications for nutrient handling. J Physiol, 587, 4169-4174. 
Roberfroid, M. B. (2000). Prebiotics and probiotics: are they functional foods? Am J Clin 
Nutr, 71, 1682S-1687S; discussion 1688S-1690S. 
Roediger, W. E. (1980). Role of anaerobic bacteria in the metabolic welfare of the colonic 
mucosa in man. Gut, 21, 793-798. 
Rooks, M. G., & Garrett, W. S. (2011). Bacteria, food, and cancer. F1000 Biol Rep, 3, 12. 
74 
 
 
Roth, J. A., Li, Z., Sridhar, S., & Khoshbouei, H. (2013). The effect of manganese on 
dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected 
HEK cells. Neurotoxicology, 35, 121-128. 
Sandler, R. H., Finegold, S. M., Bolte, E. R., Buchanan, C. P., Maxwell, A. P., Vaisanen, M. 
L., Nelson, M. N., & Wexler, H. M. (2000). Short-term benefit from oral vancomycin 
treatment of regressive-onset autism. J Child Neurol, 15, 429-435. 
Santacruz, A., Collado, M. C., Garcia-Valdes, L., Segura, M. T., Martin-Lagos, J. A., Anjos, 
T., Marti-Romero, M., Lopez, R. M., Florido, J., Campoy, C., & Sanz, Y. (2010). Gut 
microbiota composition is associated with body weight, weight gain and biochemical 
parameters in pregnant women. Br J Nutr, 104, 83-92. 
Savignac, H. M., Kiely, B., Dinan, T. G., & Cryan, J. F. (2014). Bifidobacteria exert strain-
specific effects on stress-related behavior and physiology in BALB/c mice. 
Neurogastroenterol Motil, 26, 1615-1627. 
Scheperjans, F., Aho, V., Pereira, P. A., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, 
E., Kaakkola, S., Eerola-Rautio, J., Pohja, M., Kinnunen, E., Murros, K., & Auvinen, 
P. (2015). Gut microbiota are related to Parkinson's disease and clinical phenotype. 
Mov Disord, 30, 350-358. 
Scher, J. U., Ubeda, C., Artacho, A., Attur, M., Isaac, S., Reddy, S. M., Marmon, S., 
Neimann, A., Brusca, S., Patel, T., Manasson, J., Pamer, E. G., Littman, D. R., & 
Abramson, S. B. (2015). Decreased bacterial diversity characterizes the altered gut 
microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory 
bowel disease. Arthritis Rheumatol, 67, 128-139. 
75 
 
 
Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., & Ritz, B. (2011). Diabetes and 
the risk of developing Parkinson's disease in Denmark. Diabetes Care, 34, 1102-
1108. 
Schicho, R., Shaykhutdinov, R., Ngo, J., Nazyrova, A., Schneider, C., Panaccione, R., 
Kaplan, G. G., Vogel, H. J., & Storr, M. (2012). Quantitative metabolomic profiling 
of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between 
patients with inflammatory bowel disease and healthy individuals. J Proteome Res, 
11, 3344-3357. 
Schmidt, M. V., Oitzl, M. S., Levine, S., & de Kloet, E. R. (2002). The HPA system during 
the postnatal development of CD1 mice and the effects of maternal deprivation. Brain 
Res Dev Brain Res, 139, 39-49. 
Serres, S., Anthony, D. C., Jiang, Y., Broom, K. A., Campbell, S. J., Tyler, D. J., van 
Kasteren, S. I., Davis, B. G., & Sibson, N. R. (2009). Systemic inflammatory 
response reactivates immune-mediated lesions in rat brain. J Neurosci, 29, 4820-
4828. 
Shenderov, B. A. (2012). Gut indigenous microbiota and epigenetics. Microb Ecol Health 
Dis, 23. 
Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., Troconso, J. C., Dawson, 
V. L., & Dawson, T. M. (2011). PARIS (ZNF746) repression of PGC-1alpha 
contributes to neurodegeneration in Parkinson's disease. Cell, 144, 689-702. 
Shin, N. R., Lee, J. C., Lee, H. Y., Kim, M. S., Whon, T. W., Lee, M. S., & Bae, J. W. 
(2014). An increase in the Akkermansia spp. population induced by metformin 
76 
 
 
treatment improves glucose homeostasis in diet-induced obese mice. Gut, 63, 727-
735. 
Sokol, H., Lepage, P., Seksik, P., Dore, J., & Marteau, P. (2007). Molecular comparison of 
dominant microbiota associated with injured versus healthy mucosa in ulcerative 
colitis. Gut, 56, 152-154. 
Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., 
Corthier, G., Marteau, P., & Dore, J. (2009). Low counts of Faecalibacterium 
prausnitzii in colitis microbiota. Inflamm Bowel Dis, 15, 1183-1189. 
Song, Y., Liu, C., & Finegold, S. M. (2004). Real-time PCR quantitation of clostridia in 
feces of autistic children. Appl Environ Microbiol, 70, 6459-6465. 
Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., Kubo, C., & Koga, Y. 
(2004). Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal 
system for stress response in mice. J Physiol, 558, 263-275. 
Sumi, Y., Miyakawa, M., Kanzaki, M., & Kotake, Y. (1977). Vitamin B-6 deficiency in 
germfree rats. J Nutr, 107, 1707-1714. 
Sun, Y., Chang, Y. H., Chen, H. F., Su, Y. H., Su, H. F., & Li, C. Y. (2012). Risk of 
Parkinson disease onset in patients with diabetes: a 9-year population-based cohort 
study with age and sex stratifications. Diabetes Care, 35, 1047-1049. 
Szczesniak, O., Hestad, K., Hanssen, J. F., & Rudi, K. (2015). Isovaleric acid in stool 
correlates with human depression. Nutr Neurosci. 
Szeri, I., Anderlik, P., Banos, Z., & Radnai, B. (1976). Decreased cellular immune response 
of germ-free mice. Acta Microbiol Acad Sci Hung, 23, 231-234. 
77 
 
 
Tilvis, R. S., Kahonen-Vare, M. H., Jolkkonen, J., Valvanne, J., Pitkala, K. H., & Strandberg, 
T. E. (2004). Predictors of cognitive decline and mortality of aged people over a 10-
year period. J Gerontol A Biol Sci Med Sci, 59, 268-274. 
Tsai, F., & Coyle, W. J. (2009). The microbiome and obesity: is obesity linked to our gut 
flora? Curr Gastroenterol Rep, 11, 307-313. 
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. 
(2006). An obesity-associated gut microbiome with increased capacity for energy 
harvest. Nature, 444, 1027-1031. 
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009). 
The effect of diet on the human gut microbiome: a metagenomic analysis in 
humanized gnotobiotic mice. Sci Transl Med, 1, 6ra14. 
Van Berkel, J. J., Dallinga, J. W., Moller, G. M., Godschalk, R. W., Moonen, E. J., Wouters, 
E. F., & Van Schooten, F. J. (2010). A profile of volatile organic compounds in 
breath discriminates COPD patients from controls. Respir Med, 104, 557-563. 
Vasina, V., Barbara, G., Talamonti, L., Stanghellini, V., Corinaldesi, R., Tonini, M., De 
Ponti, F., & De Giorgio, R. (2006). Enteric neuroplasticity evoked by inflammation. 
Auton Neurosci, 126-127, 264-272. 
Vieira, A. T., Macia, L., Galvao, I., Martins, F. S., Canesso, M. C., Amaral, F. A., Garcia, C. 
C., Maslowski, K. M., De Leon, E., Shim, D., Nicoli, J. R., Harper, J. L., Teixeira, M. 
M., & Mackay, C. R. (2015). A Role for Gut Microbiota and the Metabolite-Sensing 
Receptor GPR43 in a Murine Model of Gout. Arthritis Rheumatol, 67, 1646-1656. 
Villaran, R. F., Espinosa-Oliva, A. M., Sarmiento, M., De Pablos, R. M., Arguelles, S., 
Delgado-Cortes, M. J., Sobrino, V., Van Rooijen, N., Venero, J. L., Herrera, A. J., 
78 
 
 
Cano, J., & Machado, A. (2010). Ulcerative colitis exacerbates lipopolysaccharide-
induced damage to the nigral dopaminergic system: potential risk factor in 
Parkinson`s disease. J Neurochem, 114, 1687-1700. 
Waby, J. S., Chirakkal, H., Yu, C., Griffiths, G. J., Benson, R. S., Bingle, C. D., & Corfe, B. 
M. (2010). Sp1 acetylation is associated with loss of DNA binding at promoters 
associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer, 9, 
275. 
Wahlqvist, M. L., Lee, M. S., Hsu, C. C., Chuang, S. Y., Lee, J. T., & Tsai, H. N. (2012). 
Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease 
occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat 
Disord, 18, 753-758. 
Walker, A. W., & Lawley, T. D. (2013). Therapeutic modulation of intestinal dysbiosis. 
Pharmacol Res, 69, 75-86. 
Wong, J. M., de Souza, R., Kendall, C. W., Emam, A., & Jenkins, D. J. (2006). Colonic 
health: fermentation and short chain fatty acids. J Clin Gastroenterol, 40, 235-243. 
Wostmann, B. S. (1981). The germfree animal in nutritional studies. Annu Rev Nutr, 1, 257-
279. 
Wostmann, B. S., Wiech, N. L., & Kung, E. (1966). Catabolism and elimination of 
cholesterol in germfree rats. J Lipid Res, 7, 77-82. 
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y. Y., Keilbaugh, S. A., Bewtra, M., 
Knights, D., Walters, W. A., Knight, R., Sinha, R., Gilroy, E., Gupta, K., Baldassano, 
R., Nessel, L., Li, H., Bushman, F. D., & Lewis, J. D. (2011). Linking long-term 
dietary patterns with gut microbial enterotypes. Science, 334, 105-108. 
79 
 
 
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, 
S., Lowell, B., Scarpulla, R. C., & Spiegelman, B. M. (1999). Mechanisms 
controlling mitochondrial biogenesis and respiration through the thermogenic 
coactivator PGC-1. Cell, 98, 115-124. 
Yamashita, T., Kasahara, K., Emoto, T., Matsumoto, T., Mizoguchi, T., Kitano, N., Sasaki, 
N., & Hirata, K. (2015). Intestinal Immunity and Gut Microbiota as Therapeutic 
Targets for Preventing Atherosclerotic Cardiovascular Diseases. Circ J, 79, 1882-
1890. 
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, 
M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., Heath, A. C., 
Warner, B., Reeder, J., Kuczynski, J., Caporaso, J. G., Lozupone, C. A., Lauber, C., 
Clemente, J. C., Knights, D., Knight, R., & Gordon, J. I. (2012). Human gut 
microbiome viewed across age and geography. Nature, 486, 222-227. 
Zhang, Y., & Zhang, H. (2013). Microbiota associated with type 2 diabetes and its related 
complications. Food Science and Human Wellness, 2, 167-172. 
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. 
C., Zhang-James, Y., Kim, P. D., Hauser, M. A., Grunblatt, E., Moran, L. B., Mandel, 
S. A., Riederer, P., Miller, R. M., Federoff, H. J., Wullner, U., Papapetropoulos, S., 
Youdim, M. B., Cantuti-Castelvetri, I., Young, A. B., Vance, J. M., Davis, R. L., 
Hedreen, J. C., Adler, C. H., Beach, T. G., Graeber, M. B., Middleton, F. A., Rochet, 
J. C., Scherzer, C. R., & Global, P. D. G. E. C. (2010). PGC-1alpha, a potential 
therapeutic target for early intervention in Parkinson's disease. Sci Transl Med, 2, 
52ra73. 
 
80 
 
 
 
Figure 1: Schematic representation of potentially harmful and potentially beneficial 
bacteria present in the gut microbiome. Pro-biotic bacteria such as Lactobacillus and 
Bifidobacteria modulate the gut environment by releasing bioactive compounds that 
enhance enteric epithelial barrier function as well as by competitively binding to the 
epithelium thus outcompeting pathogenic bacteria. Eubacterium rectale and Fusobacterium 
produce fatty acids such as acetic acid, propionate and butyrate that are important as an 
energy source for intestinal epithelial cells as well as for modulating mucosal immune 
responses. In contrast, higher counts of bacteria such as Staphylococcus and Pseudomonas 
are seen in various metabolic disorders such as diabetes and obesity.  Clostridum tetani 
spores are resistant to the acidic environment of the stomach and to regular antibiotic 
treatments. Production of the tetanus toxin by these bacteria is thought to contribute to the 
“leaky gut syndrome” prevalent in autistic children. E.coli is a common commensal of the 
gut microbiome. However, certain serotypes are pathogenic and are known to cause 
gastroenteritis and urinary tract infections. 
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Figure 2: Bacterial species relevant to research on Autism, Parkinson’s disease, Alzheimer’s 
disorder, and Type-2 Diabetes. Clostridia are prevalent in many diseases and notably, 
presence of C. tetani in the gut microbiome of autistic children may contribute the “leaky gut” 
syndrome seen in these children. Lower counts of probiotic bacteria like Lactobacillus are 
also seen in many disorders. Understanding the differences in bacterial species seen in healthy 
and diseased states is crucial to understanding their importance to host health. 
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Figure 3: The Gut-Brain axis: Bidirectional signaling between the gastrointestinal tract 
(GIT) and central nervous system (CNS) occurs through spinal afferents and the vagus nerve. 
This mode of communication is thought to occur through peptides such as Neuropeptide Y 
(NpY), Cholecystokinin (CcK), ghrelin, leptin as well as by neurotransmitters like dopamine 
(DA), serotonin (5-HT), GABA, acetylcholine (Ach) and glutamate. Human and animal 
studies of various diseases demonstrate that these two systems are not exclusive of one 
another but do in fact show some parallels in terms of expression of pro-inflammatory 
cytokines and altered physiological functions.  
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Table 1: The fecal metabolic profile was altered by manganese treatment from day 10 until 
the completion of the study. The table above shows some key compounds that were different 
between treatment and control groups.  Notably, decreased vitamin E and increased 
production of cholic acid were seen in manganese-exposed mice compared to healthy age-
matched controls. 
Compound 
Manganese-
treated 
mice 
Physiological relevance 
α- 
tocopherol 
Decreased 
levels 
Antioxidant, requires proper nerve conduction 
Cholesterol 
Decreased 
levels 
Structural component of cell membranes and an 
important pre-cursor for production of steroids, bile 
acids, etc. 
Cholestane 
Decreased 
levels 
Reduces number of synaptic vesicles, helps regulate 
neurotransmitter release 
Palmitic 
acid 
Higher 
levels 
Induces anxiety-like behavior in mice. Can be a mild 
antioxidant. 
Cholic acid 
Higher 
levels 
Downregulates bile acid synthesis increasing the 
tendency to develop gall stones. 
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Figure 4: Factors affecting gut microbiota composition: The host-microbiota interaction is a 
complex and dynamic symbiosis. While diet and environment are well known factors 
affecting the populations of different phyla in the gut, some reports suggest that the host’s 
genetic composition might pre-dispose the continued growth of certain microbiota 			.	 The	 microbiome	 population	 can	 also	 be	 modulated	 by	 the	 presence	 of	neurotransmitters	and	metabolites	secreted	by	the	host.	
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GASTROINTESTINAL PHYSIOLOGY 
 
Manuscript to be submitted to Environment Health & Perspectives 
 
Shivani Ghaisas*, Dilshan S. Harischandra*, Alexandra Proctor †, Huajun Jin*, Souvarish 
Sarkar*, Monica Langley*, Vellareddy Anantharam*, Arthi Kanthasamy*, Gregory J. 
Phillips†, Anumantha Kanthasamy*‡. 
 
* Department of Biomedical Sciences, Iowa Center for Advanced Neurotoxicology, Iowa State University, 
Ames, Iowa 50011 
† Department of Veterinary Microbiology & Preventive Medicine, College of Veterinary 
Medicine, Iowa State University, Ames, Iowa, 50011, United States of America. 
 
‡Corresponding author:  
Dr. Anumantha G. Kanthasamy, Distinguished Professor and Lloyd Chair,  
Parkinson’s Disorder Research Laboratory,  
Iowa Center for Advanced Neurotoxicology,  
Department of Biomedical Sciences,  
2062 Veterinary Medicine Building,  
Iowa State University,  
86 
 
 
Ames, IA 50011, U.S.A.  
Phone: 1-515-294-2516;  
Email: akanthas@iastate.edu 
 
Abstract:  
Occupational exposure to high level of manganese (Mn) causes debilitating damage to the 
central nervous system. However, its potential toxic effects on the enteric nervous system 
(ENS) have yet to be assessed. We therefore examined the effect of Mn on the ENS using 
both in vitro and in vivo approaches. After exposing a rat enteric glial cell line to Mn, we 
observed a dose-dependent mitochondrial toxicity as measured by decreased mitochondrial 
mass and activity as well as increased circular morphology indicating stressed and dying 
mitochondria. Interestingly, while small doses of Mn induced mitochondrial stress after 24 
hours, only doses of 300 µM and above induced cell death. In a mouse primary enteric mixed 
culture model, Mn increased TNFα and iNOS causing concomitant enteric neuronal cell 
death as revealed by qRT-PCR and Western blot analysis, respectively. Using a mouse model 
of Mn toxicity, a non-toxic dose of Mn (15 mg/kg/day) given daily to mice for 30 days 
increased intestinal transit time compared to littermate controls. These mice also exhibited 
decreased mucopolysaccharide production in the colon as seen by Alcian Blue-Periodic Acid 
Schiff staining. Furthermore, increased production of TNFα and iNOS mRNA indicate 
augmented inflammation and consequently oxidative stress in the colon of these Mn-treated 
mice. Together, these results show Mn-induced mitochondrial dysfunction and subsequent 
inflammation in the ENS leading to altered gut physiology. 
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Introduction:  
Manganese (Mn) is an essential trace metal for many enzymatic reactions, taking part in 
protein, carbohydrate and lipid synthesis. It also plays a key role in bone formation, fat and 
carbohydrate metabolism, blood sugar regulation, and calcium absorption in the body 
(Bowman et al., 2011). Despite its nutritional benefits, chronic exposure to high levels of Mn 
affects functioning in the central nervous system (CNS), demonstrating the role of Mn as 
both an essential nutrient and a toxicant (Claus Henn et al., 2010; Zota et al., 2009). Chronic 
exposure to Mn via welding fumes, pesticides such as Maneb, or well water with high Mn 
content can lead to manganism, a neurological disorder sharing certain features with 
Parkinson’s disease (PD) (Ferraz et al., 1988; Keen et al., 1999; Kondakis et al., 1989). 
Patients suffering from manganism report mild resting tremors, an inclination to fall 
backwards as well as facial and planar dystonia along with hallucinations and psychoses 
commonly referred to as  “manganese madness” (Calne et al., 1994; Huang, 2007). Divalent 
and trivalent forms of Mn are widely used in industrial and agricultural products and high 
Mn exposure in early life is associated with poor cognitive performance, especially in the 
verbal domain of children (Menezes-Filho et al., 2011).  
In the brain, Mn primarily accumulates in the globus pallidus. Upon Mn accretion in this 
region, mitochondrial impairment and loss of cellular functions can follow, resulting in 
neuroinflammation, neurotransmitter dysregulation and synaptic loss (Kraft and Harry, 
2011). One of the early signs of neurological imbalance from chronic Mn exposure is 
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anosmia (Bowler et al., 2007). Curiously, loss of sense of smell, mood swings and sleep 
disturbances have been reported not only in patients suffering from manganism but also from 
PD, multiple system atrophy and dementia with Lewy bodies (Gagnon et al., 2006). These 
non-motor symptoms are thought to be early signs of neurological impairments in the CNS.  
  
Another important non-motor symptom seen in many neurodegenerative disorders is altered 
gastrointestinal (GI) motility. Most PD patients have a history of GI problems – ranging from 
constipation to diarrhea and defecation dysfunction, many years before the disease is even 
detected (Pfeiffer, 2003). While the incidences reported are less, chronic Mn toxicity is also 
known to cause gastritis and peptic ulcers in both patients and experimental animals 
(Chandra and Imam, 1973; Huang and Lin, 2004). With an increased focus on the gut-brain 
axis, several theories regarding the development and progression of neurodegenerative 
diseases have focused on whether these neurological disorders begin in the enteric nervous 
system (ENS) (Pellegrini et al., 2015). If this is indeed the case, then changes in GI 
physiology are likely to occur before any CNS-controlled symptoms occur.  
The ENS comprises of enteric neurons and glial cells present in two distinct layers in the GI 
tract and plays an important role governing nutrient absorption, peristalsis and maintaining 
bi-directional communication with peripheral immune cells and the CNS. Particularly, 
enteric glial cells (EGCs) are present not only in close contact with enteric neurons but are 
also present in the muscle layers and lamina propria (Gulbransen and Sharkey, 2012). EGCs 
play an important role in maintaining intestinal barrier and communicate with surveilling 
immune cells, smooth muscles cells as well as the epithelia lining the gut (Veiga-Fernandes 
and Pachnis, 2017; von Boyen and Steinkamp, 2010). The presence of EGCs in the lamina 
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propria indeed throughout the GI tract, leads to the assumption that these cells might play an 
important role not only in pathogen surveillance but also in sensing potential ingested toxins 
such as pesticides, heavy metals etc. 
With much research devoted to understanding the mechanisms behind Mn toxicity in the 
brain, scant attention has been paid to its toxic effects in the gut. To our knowledge, no 
published data exist exploring Mn’s potential toxic role in the ENS. Hence using both in vitro 
and in vivo models, we investigated the potential toxic effects of chronic Mn exposure in the 
ENS. Our results from these studies reveal that chronic Mn exposure affects the enteric 
neuronal and, in particular, the enteric glial functions and promotes an inflammatory 
response negatively affecting gastrointestinal transit. More importantly, with Mn found at 
higher than acceptable levels in a number of wells and underground water across USA 
(Ayotte et al., 2011), the effect of chronic exposure to this environmental neurotoxin on 
human health is of particular import. 
 
Materials and methods 
Chemicals and reagents 
Manganese (II) chloride tetrahydrate (MnCl2) and β-actin antibody were purchased from 
Sigma. Neurobasal medium and Dulbecco’s modified Eagle’s media (DMEM), B27 and N2 
supplements, fetal bovine serum (FBS), Trypsin-EDTA (TE), L-glutamine, penicillin, and 
streptomycin were purchased from Invitrogen. Antibodies for PGP9.5 (Cat # AB1761-I) and 
GFAP (Cat # MAB3402) were purchased from Millipore while iNOS (Cat # sc-651) and Bax 
(Cat # sc-493) antibodies were purchased from Santa Cruz.  Mouse recombinant GDNF (Cat 
# 450-44) and interferon-γ (Cat # 315-05) were purchased from Peprotech.  
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Cell cultures 
The rat enteric glial cell line (Cat # CRL-2690) was purchased from ATCC. Cells were 
grown in DMEM media supplemented with 10% FBS, 1% L-glutamine, penicillin (100 
units/mL) and streptomycin (100 units/mL), and maintained at 37°C in a humidified 
atmosphere of 5% CO2.  
 
To obtain a primary enteric mixed culture, intestines of E15; C57BL6 mice were obtained 
and minced in sterile ice-cold DMEM media containing antibiotics. The finely chopped 
pieces were enzymatically digested in serum-free media containing collagenase (0.2 mg/ml) 
and dispase (0.2 mg/ml) at 37°C for 30 minutes (min). The enzymatic digestion was stopped 
by adding 10% FBS and centrifuging the cells at 250 x g for 5 min. Supernatant was 
aspirated and the pellet was triturated in 10% DMEM/F-12 till a single cell suspension was 
obtained. Cells were filtered through a 40-µ cell strainer and plated on poly-D-lysine- (PDL-) 
and laminin pre-coated plates. After 24 h, media was changed to 1% DMEM/F-12 containing 
50 ng/ml GDNF, N2 and B27 supplements and cultured for 3 weeks at 37°C and 5% CO2. 
Half of the media was changed every 2 days. 
 
MTS assay 
Cell viability was measured by Cell Titer 96® aqueous non-radioactive cell proliferation 
assay (MTS assay, Promega) as previously described (Ay et al., 2015). MTS salt is reduced 
to purple-colored formazan in healthy cells so the amount of formazan produced is indicative 
of mitochondrial activity and in turn cell metabolic activity. Briefly, 25,000 enteric glial cells 
(EGCs) were seeded onto 96-well plates and treated with different doses of Mn (0-1000 µM) 
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for 24 h. Before completion of treatment, 20 µL of MTS solution was added to each well, and 
the plates were incubated at 37°C and 5% CO2 for 1.5 h. Measurements were made at 
490 nm and 670 nm (reference wavelength) using a fluorescence microplate reader 
(SpectraMax Gemini XS; Molecular Devices, Sunnyvale, CA, USA). 
 
SYTOX green assay 
Cell death was determined by the cell-impermeable dye SYTOX green (Song et al., 2010). 
EGCs were grown in 96-well plates and treated with different doses of Mn in 2% DMEM for 
24 h. After treatment, 1 µM SYTOX green was added to each well for 20 min. Cell death was 
quantitatively measured with an excitation wavelength of 485 nm and an emission 
wavelength of 525 nm using a fluorescence microplate reader (SpectraMax Gemini). Nuclei 
were stained with Hoechst 3342 (5 µg/ml) for 15 min to determine total cell number in each 
well. Resulting green fluorescence readings were normalized to cell number. 
Photomicrographs showing cell death and cell morphology were also taken using an EVOS 
Floid cell imager (Invitrogen). 
 
Caspase-3 activity 
Following 24-hour exposure to different doses of Mn, EGCs were collected in individual 
tubes and 230 µl lysis buffer (10% sucrose, 5 mM dithiothreitol, 100mM HEPES, 0.1% 
CHAPS and 20 mM EDTA in dH20, pH 7.4) was added to each sample and incubated for 20 
minutes at 37°C to lyse the cells. Thereafter, 190 µl of lysate was added to individual wells 
of a 96 well black, clear bottom plate (catalog # Greiner 655079) containing 10 µl caspase-3 
substrate (50 µM Ac-DEVD-AFC) at 37°C for 60 minutes. Formation of 7-amino-4-
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methylcoumarin (AFC) resulting from caspase-3 activity was measured at Ex. 460 and Em. 
510 nm using a fluorescence plate reader. The caspase-3 activity was normalized to protein 
concentration as determined by Bradford protein assay (Harischandra et al., 2015). 
 
Determination of mitochondrial morphology and mass 
40,000 EGCs were plated on PDL-coated coverslips and treated with different doses of Mn 
for 24 h. After treatment, cells were washed with HBSS containing Ca+2 and Mg+2 to remove 
any residual media. Next, 100 nM MitoTracker Red CMxRos probe (Invitrogen) was added 
to each well to stain the cells for 15 min. Cells were triple-washed with sterile HBSS to 
remove any dye and then fixed for 20 min in 4% paraformaldehyde (PFA). Alexa-488 
phalloidin (Invitrogen) was used at a 1:100 dilution for 30 min to stain F-actin while nuclei 
were stained using Hoechst 3342 at a final concentration of 0.2 µg/ml for 7 min. The wells 
were washed three times with distilled water and coverslips were mounted onto pre-cleaned 
glass slides using Fluoromount (Sigma). Images were obtained using an inverted 
fluorescence Leica DMIRE2 confocal microscope with 63X magnification and image 
analysis was performed using ImageJ. Quantification of mitochondrial length and degree of 
circularity was accomplished using a macro text file plug-in for ImageJ (Dagda et al., 2009). 
For analyzing the images, eight images per group were quantified and two separate 
experiments were performed.  
 
To determine mitochondrial mass, cells were stained with the MitoTracker Green FM probe. 
First, 25,000 EGCs were plated per well of a 96-well plate. Cells were treated with different 
doses of Mn (0-1000 µM) for 24 h. After treatment, the media was removed and 100 µl of 
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200 nM MitoTracker Green dye diluted in serum-free DMEM media was added to each well 
and incubated at 37 °C for 15 min. Following incubation, green fluorescence was measured 
at an excitation wavelength of 485 nm and an emission wavelength of 520 nm using a 
fluorescence microplate reader. Nuclei were stained with Hoechst (5 µg/ml) for 15 min to 
determine total cell number in each well. Resulting green fluorescence readings were 
normalized to cell number.  
 
Aconitase assay 
Mitochondrial aconitase (m-aconitase) levels in EGC’s were measured using a commercial 
aconitase assay kit (Abcam, Cat.# ab83459) as described before with minor modifications 
(Langley et al., 2017). Briefly, 1 × 106 EGC’s were grown in a T25 cell culture flask and 
exposed to 10 µM and 100 µM Mn for 24h. Cells were collected after treatment and 
resuspended in the supplied assay buffer on ice followed by centrifugation at 2000 × g for 
5 min at 4 °C. The resulting supernatant was collected and further centrifuged at 20,000 × g 
for 15 min to collect the mitochondrial fraction. The pellet was thoroughly mixed with 100 µl 
of assay buffer and sonicated for 25 s at 4 °C. Citrate was added as a substrate to each well. 
Aconitase converts citrate to isocitrate that is further processed leading to the formation of a 
colored end product. The plate was then read at 450 nm using a microplate reader. The OD 
values were normalized to the protein concentration of each sample and the results were 
expressed as percentage control. 
 
Mitochondrial oxygen consumption and extracellular flux analysis using Seahorse 
bioanalyzer 
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Mitochondrial oxygen consumption in EGCs treated with different doses of Mn was 
measured using the XFe-24 Seahorse bioanalyzer (Seahorse Bioscience) and company 
recommended Mito Stress kit (Seahorse bioscience). One day before measurements, EGCs 
were seeded at 30,000 cells/well. The next day, cells were treated with 0, 10 or 100 µM Mn 
for 24 hours. Mitochondrial oxygen consumption rate (OCR) and ATP production was 
measured using Mito Stress kit. The experiment was repeated two times (n = 2) in triplicate. 
No significant inter-assay differences were detected between the two repetitions regarding 
the appearance and viability of cells or the values of O2 consumption that were obtained. 
 
3[H] Glutamate uptake assay 
30,000 EGCs were plated per well of a 24-well plate. Cells were treated in triplicate with 0, 
10 or 100 µM Mn for 24 hours. After treatment, cells were washed in Krebs solution 
(containing in mM: 32 NaCl, 4 KCl, 1.2 Na2HPO4, 1.4 MgCl2, 6 glucose, 10 Hepes, 1 mM 
CaCl2, pH 7.4) to remove any media. Cells were incubated with 2 µCi L-[3,4 3H] glutamic 
acid for 15 minutes at 37°C. Media was removed and cells were washed twice with ice-cold 
Krebs solution to stop the uptake. Cells were lysed in 0.5 ml 1N NaOH and the total 
radiolabeled glutamate uptake were measured via liquid scintillation counting. Experiments 
were repeated thrice, each time in triplicates. 
 
Animal studies 
We purchased 8 to 10 week old male C57BL/6 mice from Charles River Laboratories for all 
animal experiments. Mice were housed on a 12-h light cycle with ad libitum access to food 
and water. After 2 weeks of acclimatization, mice received either 15-mg/kg-body weight/day 
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Mn (as MnCl2•2H2O) for 30 days or an equal volume of vehicle (water) via oral gavage. This 
dose regimen was chosen based on previous Mn neurotoxicity studies in humans and rodents 
(Crossgrove and Zheng, 2004; Li et al., 2006; Zheng et al., 2000). Animal care procedures 
strictly followed the NIH Guide for the Care and Use of Laboratory Animals and were 
approved by the Iowa State University IACUC. Body weight and whole gut transit time were 
measured every 10 days. At the end of the treatment regimen, animals were euthanized by 
CO2, and then 3-cm strips of the duodenum, ileum and colon were collected and emptied of 
their contents by rinsing thoroughly in ice-cold PBS. Tissues were further excised into 1-cm 
pieces for various biochemical tests and stored at -80°C till further processing. 
 
Behavioral analysis 
Behavioral impairments resulting from Mn toxicity were assayed using the Versamax 
activity monitor and the Rotarod test, as described previously (Ghosh et al., 2016a). Briefly, 
exploratory locomotor activity was measured using the Versamax open-field apparatus 
(Accuscan Instruments, Columbus, OH) and the following indices were monitored for 10 
min: rearing (labeled as vertical) activity and horizontal activity. Motor coordination was 
tested by measuring the latency to fall from a 3-cm diameter rod rotating at a constant 20-
rpm till the mice fell or for 20 min. (Rotarod, Accuscan Instruments). Each mouse was 
subjected to 5 trials separated by 5- to 7-min intervals to eliminate stress and fatigue.  
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Gastrointestinal function testing 
Whole gut transit time (WGTT) 
WGTT was measured by ingestion of carmine red, a red dye that cannot be absorbed by the 
GI tract. Briefly, WGTT was measured by intragastric gavage of each mouse with 0.3 ml of 
6% (w/v) carmine dye in 0.5% methylcellulose as previously described (Anderson et al., 
2007). The time taken from administration of the dye until first appearance of a red stool 
pellet was recorded. Animals whose stool had no dye even after a maximum observation time 
of 8 h were recorded as >8 h. 
Bead latency 
Distal colonic motility was measured by the bead expulsion test (Vilz et al., 2012). Mice 
were anesthetized with isoflurane (1–2min) and a 2 mm-diameter lubricated glass bead is 
introduced into the distal colon (2cm from the anus margin) using a fire-polished glass rod. 
After insertion of the bead, mice were isolated in a plastic cage for observation. The time 
required for expulsion of the glass bead was recorded (bead latency) which is typically less 
than 15 min.  
Fecal water content 
30 days post Mn exposure, mice were kept in clear plastic cages and fecal pellets from 
individual cages were collected over the course of 1 hour. Pellets were transferred in 1.5 ml 
centrifuge tubes, capped and weighed to collect the wet weight of the pellets. Thereafter, 
with the caps opened, the tubes were placed in a 55C incubator and dried for 24 hours to dry 
out the pellets. The tubes were recapped and weighed after drying to obtain the dry weight of 
the pellets. Water content was calculated by calculating the difference between wet and dry 
weights. 
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Social discrimination and novel scent tests 
To determine the olfactory function of control and Mn-exposed mice, we used a 
social discrimination test as previously described (Ngwa et al., 2014). However, this 
procedure was adapted to use AnyMaze tracking software (AMS, Stoelting Co., Wood Dale, 
IL ) to determine time spent sniffing based on the animals head being within a defined zone 
(1-cm perimeter around dish) surrounding the bedding. Total time spent sniffing the opposite 
sex’s bedding (from a group-housed cage) was recording during a 3-min trial. Similarly, 
AMS was used to determine time sniffing a novel scent. During a 3-min trial, time spent 
sniffing scented and non-scented zones was recorded using AMS. Vanilla was used as the 
novel scent whereas water served as the non-scent. 
 
Quantitative real-time PCR (qRT-PCR) 
Ten tissues of distal colon from control and Mn-treated groups were utilized for qRT-PCR. 
The samples were homogenized in a bullet blender (Next Advance) using DNAse- and 
RNAse-free stainless steel beads and RNA was extracted using RNeasy Plus Mini kit 
(Qiagen). 1 µg total RNA was converted to cDNA using the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems Inc.) following manufacturer's instructions. Real-time 
PCR was performed in an Mx3000P QPCR system (Stratagene) using the Brilliant SYBR 
Green QPCR Master Mix kit  (Stratagene), with cDNAs corresponding to 1 µg of total RNA, 
10 µl of 2 × master mix and 0.2 µM of each primer in a 20-µl final reaction volume. All 
reactions were performed in triplicate. Mouse 18S rRNA was used as an internal standard for 
normalization. Validated QuantiTect primer sets for mouse 18S rRNA (Cat# QT02448075), 
TNFα (QT00104006), IL-1β (QT01048355) and iNOS (QT00100275, Qiagen) were also 
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used. The PCR cycling conditions contained an initial denaturation at 95°C for 10 min, 
followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, and 
extension at 72°C for 30 sec. Fluorescence was detected during the annealing step of each 
cycle. Dissociation curves were run to verify the singularity of the PCR product. Data were 
analyzed using the comparative threshold cycle (Ct) method (Livak and Schmittgen, 2001).  
 
Western blots 
Whole cell lysates or tissue lysates were prepared using modified radio immune precipitation 
assay (RIPA) buffer containing 20 mM Tris–HCl, pH 8.0, 2 mM EDTA, 10 mM EGTA, 2 
mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 20mM sodium 
orthovanadate, 1 mM sodium fluoride and protease and phosphatase inhibitor cocktail 
(Thermo Scientific, Waltham, MA), as described previously (Harischandra et al., 2015; 
Harischandra et al., 2014). The supernatants were obtained after centrifuging the 
homogenates at 15,000 rpm for 60 min. Protein concentration was measured using Bradford 
dye (Bio-Rad). Lysates containing equal amounts of protein were separated on a 12 or 15% 
SDS-polyacrylamide gel. After separation, proteins were electro-blotted onto a nitrocellulose 
membrane, and nonspecific binding sites were blocked with LICOR blocking buffer. PGP9.5 
(1:1000), GFAP (1:1200), Bax (1:500), iNOS (1:500) and β-actin (1:10000) primary 
antibodies were used to blot the membranes for 16 h at 4°C. Thereafter, blots were washed in 
phosphate buffered saline (PBS) containing 0.01% Tween-20, incubated in respective 
secondary antibodies (Alexa Goat anti mouse 680 or Alexa Goat anti-rabbit 800) for 1 hour. 
Fluorescent bands corresponding to the protein of interest were observed by scanning 
membranes in a LICOR scanner. 
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Immunocytochemistry and Immunohistochemistry 
For immunocytochemistry, primary enteric cells were grown on 12-mm coverslips 
previously coated with 50 µg/ml PDL for 3 hours followed by 10 µg/ml laminin for 12 hours. 
Two weeks post-plating, cells were treated with 100 µM MnCl2 for 24 h. After treatment, 
cells were washed with PBS and incubated in 4% PFA for 30 min at RT. After fixing, cells 
were washed with PBS and incubated in blocking buffer (2% BSA, 0.05% Tween-20, and 
0.5% Triton X-100 in PBS) for 1 h. Cells were then incubated with antibodies against 
PGP9.5 (1:1000) or GFAP (1:1000) and iNOS (1:1000) overnight at 4°C. After primary 
incubation, cells were washed and incubated in the dark for 90 min with Alexa-488 and -555 
dye-conjugated secondary antibodies (Invitrogen, 1:1500). Nuclei were stained with 0.2 
µg/ml Hoechst and the coverslips were then mounted on glass slides (Superfrost, Invitrogen) 
and viewed with 63× and 43× oil objectives using a Leica DMIRE2 confocal microscope. 
 
For Immunohistochemistry, at the end of the treatment regime, animals were perfused first 
with PBS followed by 4% PFA. Guts were removed and post-fixed in 10% formalin for an 
additional 24 h. Tissues were embedded in paraffin and sectioned at 7 µm at Iowa State 
University’s veterinary pathology lab. Paraffin-embedded sections of mouse tissues were 
deparaffinized in decreasing alcohol grades. Heat-mediated antigen retrieval was performed 
using 10 mM citrate buffer (pH 6.0) for 30 min. Sections were then incubated with blocking 
reagent (5% normal goat serum, 2% BSA and 0.5% Triton X-100 in PBS) for 60 min before 
being incubated with iNOS, PGP9.5 or GFAP primary antibodies for 24 h. Sections were 
then washed many times in PBS and incubated in the dark for 90 min with Alexa-488 
and -555 dye-conjugated secondary antibodies (1:1500). Nuclei were stained with Hoechst 
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dye. Slides were viewed with 63× and 43× oil objectives using a Leica DMIRE2 confocal 
microscope. 
 
Inductively coupled plasma mass spectroscopy (ICP-MS)  
Colon samples were carefully excised and weighed prior to sample preparation. Samples 
were analyzed for Cd, Ca, Cr, Co, Cu, Fe, Mg, Mn, Mo, P, K, Se, Na, and Zn using 
Inductively coupled plasma mass spectrometry (ICP-MS, Analytik Jena Inc. Woburn, MA, 
USA) in CRI mode with hydrogen as the skimmer gas. Standards for elemental analyses 
were obtained from Inorganic Ventures (Christiansburg, VA) while digestion vessels; trace 
mineral grade nitric acid and hydrochloric acid were obtained from Fisher Scientific 
(Pittsburgh, PA). Briefly, samples were digested in 70 % nitric acid at 60˚C for ≥12 hours. 
Pre-weighed samples were transferred to 15mL tubes and 0.25 mL of 70% nitric acid was 
added.  All samples were digested overnight at 60˚C. After digestion, all samples were 
diluted to 5 mL using 1% nitric acid with 0.5% hydrochloric acid and then analyzed by ICP-
MS. For quality control, Bi, Sc, In, Li, Y, and Tb were used as internal standards for the ICP-
MS. 
Genomic DNA isolation 
Immediately following sacrifice, the colon was removed and fecal pellets promptly collected, 
stored in an Eppendorf tube, and transferred into a -80°C freezer for long-term storage until 
analysis. Genomic DNA isolation was performed using the PowerSoil DNA Isolation kit 
(MoBio, Carlsbad, CA) on samples from 10 mice per group for each time point. The purified 
genomic DNA extracts were quantified using a Qubit 2.0 Fluorometer (Life Technologies, 
Carlsbad, CA) and stored at -20°C in 10 mM Tris buffer. 
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DNA sequencing and Analysis 
PCR amplification of the V4 variable region of the 16S rRNA gene using V4 region-specific 
barcoded primers (515F-816R) and amplicon sequencing were performed by Institute for 
Genomics & Systems Biology at the Argonne National Laboratory (Argonne, IL) on the 
Illumina MiSeq Platform. The sequences were analyzed using QIIME (Quantitative Insights 
into Microbial Ecology) (Caporaso et al., 2010). Briefly, reads were first demultiplexed and 
quality filtered, then sequences with homopolymer runs or ambiguous bases greater than six, 
nonmatching barcodes, barcode errors, or quality scores less than 25 were removed. 
Operational taxonomic units (OTUs) were called using UCLUST and the closed reference 
OTU picking strategy in QIIME (Edgar, 2010). Sequences were aligned to the Greengenes 
(13_8) database using PyNAST at 97% similarity (DeSantis et al., 2006). Taxonomic 
assignments were made based on the Greengenes reference database using the RDP classifier 
2.2 in QIIME (Wang et al., 2007). Alpha diversity, beta diversity, principal coordinate plots 
(PCoA), Analysis of similarity (ANOSIM), and Adonis tests were also generated using 
QIIME. Wilcoxon Rank Sum tests were performed on taxonomic summaries, obtained from 
the QIIME pipeline, using a custom R script (R Project) obtained from the Institute for 
Genome Sciences at the University of Maryland School of Medicine.  
 
Gas chromatography and mass spectroscopy analysis (GC-MS)  
To isolate the metabolites for the GC-MS analysis, we followed the methods described by 
Noutsos et al (Noutsos et al., 2015). Identification of fecal metabolites was done by 
comparing the mass spectral to NIST08 Library and using Retention Indices and were 
quantitated relative to internal standards. Prior to metabolite extraction, ~20 - 30 mg of fecal 
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matter was weighed, spiked with internal standards (20 µg of ribitol and 20 µg of 
nonadecanoic acid), and homogenized with 0.35 mL of hot methanol (60°C). The mixture 
was immediately incubated for 10 min at 60°C and sonicated for 10 min. 0.3 mL of 
chloroform and water respectively were added to this mixture and vortexed for 3 min. After 
centrifugation to separate phases, 0.2 mL of the upper polar phase and 0.2 mL of the lower 
non-polar phase were removed and transferred into 2-mL glass vials. Both fractions were 
dried in a SpeedVac concentrator. The extracts were subjected to methoximation with 
methoxyamine hydrochloride at 30°C for 90 min. Samples were silylated with 
BSTFA/TCMS at 60°C for 30 min, and then subjected to gas chromatography–mass 
spectrometry (GC-MS, Agilent Technologies) on an 6890N gas chromatograph in tandem 
with a 5973MSD detector equipped with a gas ionization detector (gas flow: UHP Helium, 
1.0 ml/min.; ionization mode: El; polarity: positive; skimmer/focusing lens voltages: 70 eV). 
Samples were loaded onto the GC with a 7683B automatic liquid sampler. The mass range 
was set from 40–1000 m/z. The separation column was an HP5MSI (30 m long, 0.250 mm 
ID, 0.25 µm film thickness). The gas chromatography was operated by ChemStation 
software. 
 
Data analysis 
Data analysis was performed using Prism 4.0 Software (GraphPad Prism, San Diego, CA). 
Data were first analyzed using Student t-test or one-way ANOVA, and then Tukey’s post-hoc 
test to compare all treatment groups. Differences with p<0.05 were considered significant. 
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Results 
Manganese exposure induces mitochondrial stress in enteric glial cells 
To determine response of the EGC cell line to Mn, we performed dose-response cytotoxicity 
and mitochondrial viability assays. MTS, otherwise known as 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, is a compound that is reduced 
by viable cells with healthy and active mitochondria to a purple-colored formazan end 
product whose amount directly correlates with the metabolic capacity of the cells. When 
EGCs were treated with increasing doses of Mn (0 – 1000 µM) for 24 h, a dose-dependent 
decrease in formazan production was observed. The IC50 was calculated by a three-parameter 
non-linear regression curve and found to be about 5 µM (Fig. 1A). Since the metabolic 
activity assayed by MTS is in turn directly dependent on mitochondrial health, the results can 
be interpreted as a dose-dependent decrease in mitochondrial viability. Furthermore, EGCs 
treated with 0, 1, 3, 10 and 30 µM Mn for 24 h lost mitochondrial mass as evidenced by 
MitoTracker Green assay (Fig. 1B). Mitotracker Green FM is a dye that is fluorescent only 
upon accumulation in a mitochondrial lipid-rich environment (Agnello et al., 2008). Healthy 
mitochondria undergo multiplication by either the process of fission or fusion. If the 
mitochondria are stressed, they do not undergo further replication, consequently stressed 
cells could show less mitochondrial mass compared to untreated control cells. Corroborating 
with this point, the 3, 10 and 30 µM Mn doses decreased the mitochondrial mass by about 
30, 32 and 60%, respectively, compared to untreated controls. To further strengthen our 
theory of Mn-induced mitochondrial damage, we observed mitochondrial morphology of 
treated and untreated EGC’s using Mitotracker Red. As shown in Fig. 1C, untreated cells 
exhibited the characteristics of healthy mitochondria, such as long thread-like strands densely 
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surrounding the nucleus. However, when treated with Mn, these mitochondria become 
rounded and begin to disintegrate. Even at a low dose of 10 µM Mn, some mitochondria 
appeared rounded indicating their stressed status. At a high dose such as 100 µM Mn, 
mitochondria appeared to have coalesced into rounded structures surrounding the nucleus 
while at a very toxic dose of 1000 µM, fine punctate staining was observed indicating that 
the mitochondria have disintegrated. We quantified the degree of circularity (a measure of 
mitochondrial toxicity) using imageJ. The results show a 20 and 25% increase in circularity 
in cells treated with 10 and 100 µM Mn compared to untreated controls. As mentioned 
before, at 1000 µM, most of the mitochondria have disintegrated hence the degree of 
circularity could not be measured (Fig 1D). Similarly, mitochondrial aconitase (m-aconitase) 
activity was decreased in EGC’s treated with 100 µM Mn (Fig 1E). m-aconitase activity is 
mainly hampered by superoxide production (Fig 1F) and consequently mitochondrial 
toxicity. We hypothesized that Mn exposure could impair basal mitochondrial respiration as 
well as spare respiratory capacity. Hence we measured the oxygen consumption rate (OCR) 
of 100 µM and untreated EGCs as an indicator of mitochondrial respiration (Figure 1G). 
There was significant reduction in basal respiration and ATP production  (Figure 1H) in Mn 
treated EGCs compared to untreated controls indicating a decrease in mitochondrial 
respiration and hence mitochondrial (and cellular) stress following Mn exposure. These 
results convincingly prove that Mn causes mitochondrial damage in EGC’s in a dose-
dependent manner.  
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Cell death in enteric glia occurs only at higher concentrations of manganese 
Interestingly, when the same Mn treatment paradigm was used to measure cytotoxicity in 
EGCs, we found that only EGCs treated with higher Mn doses of ≥300 µM stained positively 
for SYTOX green, a dye that can enter only dead cells with a compromised cell membrane 
(Fig. 2A-B). We further validated this observation by assessing caspase-3 activity of EGCs 
treated 24 h with different Mn doses. As shown in figure 2C, significant caspase-3 activity 
was observed mainly in cells exposed to ≥300 µM Mn for 24 hours.  Would stressed enteric 
glia still manage to function as effectively as normal enteric glia? To answer this question, 
we analyzed glutamate uptake capacity of Mn exposed EGCs. Glutamate is one of the several 
neurotransmitters produced by the ENS and plays a role in the rhythmic intestinal 
contractions seen in the gut as well as in the bi-directional signaling of the gut-brain axis 
(Filpa et al., 2016). In the CNS, astrocytes play a major role in the glutamate uptake and 
regulating glutamatergic synapses. Since EGCs are similar to astrocytes (both share common 
surface markers GFAP and S100β) there is a strong possibility that these cells also regulate 
glutamate signaling in the gut much like astrocytes do in the brain. Hence we decided to 
assess glutamate uptake in these cells when treated with increasing concentrations of Mn. 
Cells treated with 5 or 10 µM Mn showed ~ 10% decreased uptake when compared to 
untreated cells. In comparison, EGCs treated with 100 µM Mn showed more than 50% 
decrease in glutamate uptake when compared to untreated controls (Fig 2D). As seen with 
our cytotoxicity assay and western blot, cells while stressed are not dead. Taken together, 
these results show that exposure to even small amounts of Mn can alter functioning of these 
cells, yet the actual dose required for cell death is quite high. 
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Manganese potentiates inflammation and cell death of neurons in a primary enteric 
culture 
While EGCs might be particularly sensitive to Mn when observed as a pure culture, the 
kinetics of Mn-induced mitochondrial dysfunction would differ in the intestine since it is a 
complex network of various cell types including the EGCs and neurons, smooth muscle cells, 
surveilling peripheral immune cells and epithelial cells. As expected, when the primary 
enteric mixed culture was treated with increasing doses of Mn (0 – 1000 µM) for 24 h, the 
IC50 was calculated to be about 100 µM (Fig. 3A). At this dose, Mn triggered inflammation 
as evidenced by an upregulation in mRNA transcripts of TNFα and iNOS (Fig. 3B). There 
was a slight reduction (n=6, p< 0.06) in GFAP expression as evidenced by Western blot (Fig. 
3C) indicating that 100 µM Mn was negatively affecting glial cell health. In the ENS, enteric 
glial cells are closely associated with the enteric neurons. Importantly, Western blot analysis 
showed that 100 µM Mn treatment decreased enteric neuronal PGP9.5 expression after 24 
hours (Fig. 3D). Interestingly, expression of ferroportin, which is a Mn-responsive protein 
that can transport Mn out of the cell- was decreased while protein levels of DMT1 – a 
transporter involved in the influx of divalent metals (including Mn) – showed no change in 
the cultures exposed to Mn compared to controls (Figure 3D). These findings indicate that 
Mn treatment induces inflammation and neuronal cell death in primary enteric mixed 
cultures.  
Our method of isolating and growing the mixed enteric culture is capable of generating 
spontaneous smooth-muscle contractions similar to the intestinal contractions seen in vivo. 
Primary enteric mixed cultures grown for approximately 3 weeks on PDL and laminin-coated 
plates show extensive neuronal networks (red arrows) growing over a bed of what appears to 
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be smooth muscle and epithelial cells (yellow arrow, S.figure 1A). Other cells types, possibly 
endothelial cells and fibroblasts are also present in the culture (S.figure 1B- 1C). At 3-4 
weeks post-plating, isolated contractions were seen in different parts of the culture (Figure 
3F). These spontaneous contractions gradually reduced in cultures treated with 100 µM Mn 
for 24 h (Figure 3G.). Western blot results and videographic evidence show loss of enteric 
neuronal cells. Since peristalsis occurs due to a concerted influence of the ENS, interstitial 
cells of Cajal and the smooth muscle cells, it is possible that the loss of enteric neurons 
disrupts this signaling thereby affecting muscle contraction (Huizinga, 1999).  
 
Low-dose, chronic Mn administration in mice does not induce motor impairment  
To assess gastro-intestinal changes following increased ingestion of Mn, mice were given a 
dose of 15 mg/kg/day for 30 days (Fig. 4A). While Mn-treated mice on an average, did not 
show any significant weight gain; the untreated group showed a trend of weight gain (Fig. 
4B). Similarly, Rotarod (Fig. 4C) and Versamax open-field tests (Fig. 4D-E) did not show 
any significant differences between the two groups. The open-field test evaluates general 
locomotor activity in mice while Rotarod test evaluates motor co-ordination. Together, these 
two tests are routinely used to assess movement-associated neurological dysfunction in mice. 
Published reports have described significant reduction in motor behavior in mice treated with 
either 59 mg/kg Mn for 10 days or 100 mg/kg Mn for 8 weeks (Liu et al., 2006; Vezer et al., 
2007). These mice also showed weight loss and other signs of sickness. However, as the aim 
of our study was to observe changes in gut physiology, the weight loss would be a 
compounding factor in any inference we derived from this study. Hence a non-toxic dose of 
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15 mg/kg/day for 30 days was chosen to observe any physiological changes in the gut 
intestinal physiology.  
One of the consequences of enteric inflammation or ENS abnormalities is a change in gut 
physiology, especially peristalsis (Lee et al., 2014). Interestingly, increased WGTT was 
observed in the Mn-treated mice indicating decreased peristalsis. This group showed a trend 
(p<0.06) of altered intestinal transit time from day 20 onwards when compared to the control 
group (Fig. 4F). From day 20, these mice took an average of 350±10 min to expel the 
carmine red meal fed to them compared to the 320±10 min it took for mice in the control 
group to expel the same meal. Despite the longer transit time in both small and large 
intestine, there was no change in the fecal water content between groups (S. Figure 4). With 
regards to CTT, Mn-treated mice took on an average 7 minutes to expel the glass bead as 
opposed to control mice who took ~ 5.7 minutes (Fig. 4G). Taken together, the results point 
towards the presence of intestinal dysmotility despite a low-dose exposure to Mn and this 
intestinal de-regulation is seen before CNS-related symptoms are observed. 
 
Low-dose, chronic Mn administration in mice causing enteric inflammation and 
increases gastrointestinal transit time 
Microscopic analysis of tissue architecture in Mn-treated ileum and colon by hematoxylin 
and eosin (H&E) staining showed no signs of cell necrosis and immune cell infiltration (Fig. 
5A). However, Alcian-blue-Periodic Acid Schiff (Ab-PAS) showed differential staining in 
the colons of control and treatment groups (Fig. 5B). Ab-PAS stains acidic and neutral 
mucopolysaccharides and glycoproteins, collectively known as mucins, that line the 
gastrointestinal tract (GIT) and protect the gut epithelium from mechanical shear stress as 
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well as from bacterial translocation into the deeper tissue of the intestine (Faure et al., 2003). 
These mucins are produced by goblet cells present in the villi. Mn-treated mice showed less 
intense staining as well as fewer goblet cells, indicating lower production of these 
mucopolysaccharides. An inadequate intestinal lining of mucin could slow the rate of 
movement of food. It might also affect the epithelial lining allowing for translocation of 
unwanted substances from the lumen to the sub-mucosa contributing to inflammation. 
Supporting this idea, we observed significant intestinal inflammation in the colon of Mn-
treated mice. As shown in Fig. 5C, quantitative RT-PCR analysis showed 2.5- and 3.5-fold 
higher mRNA transcripts of TNFα  and iNOS, respectively, in Mn-treated animals. 
Furthermore, Western blotting showed Mn increased the protein levels of iNOS (Fig. 5D). To 
ascertain if Mn-induced iNOS increase in part occurs in the ENS, whole mount sections 
containing the myenteric plexus were probed for GFAP and iNOS. Indeed, 
immunofluorescence images revealed more punctate presence of iNOS in the myenteric 
ganglia of Mn-treated animals (Fig. 5E). Protein analysis of full thickness colon (n=6) from 
both groups showed an increase in EGC marker GFAP as well as a decrease in mitochondrial 
protein DJ-1 (Fig. 5F). The receptor DMT1 is involved in the influx of divalent metal ions 
into cells while ferroportin (Fpn) removes iron and Mn from the cell. We found that while 
the protein levels of DMT1 remain unchanged, the levels of Fpn decreased in the Mn group 
suggesting a dysfunction in the export of metal from the cell. Indeed, as shown in figure 5G, 
q-RT-PCR analysis of common Mn transporters DMT1, Fpn and SLC30A10- a manganese 
efflux receptor- showed a decrease in SLC30A10 mRNA levels in the colon of Mn treated 
mice. Tissue levels of Mn were significantly increased (Figure 5H) in the colons of Mn-
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treated group compared to control thus substantiating western blot and q-RT PCR results. No 
significant changes in tissue levels of other metals were found between the groups (S.Fig. 3). 
 
Changes in taxonomic abundances between control and Mn-treated mice 
The presence of increased intestinal transit time as well as upregulated iNOS and TNFα in 
the ENS pointed to some degree of colon inflammation. Since it is well known that a 
majority of the gut microbiota resides in the colon, we decided to analyze any potential 
changes in the gut bacterial population between age-matched untreated and Mn-treated mice.  
A total of 7,152,846 reads passed quality filtering with an average of 89,410.58±21,937.2 
sequences per sample. DNA sequences representing fecal samples were submitted to 
comparisons at 97% similarity to the Greengenes database. Wilcoxon Rank Sum tests were 
used to compare taxonomic abundances from the control and Mn-treatment groups of the 
same day (i.e., day 0 control and day 0 Mn-treated groups). Figure 6A shows the taxonomic 
summary at the phylum level. For each group, Bacteroidetes, was the dominant phylum 
(control:63.75-73.83%, Mn:64.87-73.41%), followed by Firmicutes (control:24.42-34.41%; 
Mn:23.17-32.27%). Comparing taxonomic abundances at the phylum level, there were no 
significant differences between the control and Mn-treated groups at the same time point.  
 
At the class level (Figure 6b), Bacteroidia was the dominant organism in each group 
(control: 63.75-73.83%; Mn: 64.87-73.41%). Within the phylum Firmicutes, the dominant 
classes were Clostridia (control: 21.54-29.90%; Mn: 20.10-28.80%) and Bacilli (control: 
1.87-3.93%; Mn: 1.55-3.53%). While there were no significant changes in abundance 
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between the control and Mn-treated groups, on day 20 there appeared to be an enrichment of 
Gammaproteobacteria in the Mn treated mice (p=0.0819). 
 
At the genus level (Figure 6C), the dominant genera were Bacteroides, Parabacteroides, and 
an unknown genus in the family S24-7, an environmental organism in the phylum 
Bacteroidetes. The two most dominant genera in the phylum Firmicutes were Lactobacillus 
and unknown genus in the order Clostridiales. In both groups, S24-7 increases over the 30-
day period, while Bacteroides decreases. Statistical comparisons showed no differences 
between the control and Mn-treated mice at any time point. 
Alpha diversity metrics were used to compare within sample diversity. Non-parametric two 
sample t-tests using Monte Carlo permutations were used to compare the observed OTUs 
(Figure 6d) and Faith’s Phylogenetic Diversity (Figure 6e). Comparisons of alpha diversity 
values showed that control and Mn-treated mice did not differ significantly at any time point. 
Mn treatment had no effect on the diversity of the microbiota over the 30-day period. 
Inspection of the observed OTUs rarefaction plot showed the curves plateau, indicating the 
sequencing depth was sufficient as to exclude the discovery or new or rare OTUs.  
Weighted (Figure 5f) Unifrac PCoA plots were generated using QIIME Groupings was 
compared using adonis and analysis of similarity (ANOSIM) tests. There appeared to be no 
obvious clustering based on treatment and sample date. Statistical test indicate no differences 
in groups at any time point. Adonis tests resulted in a p-value of 0.06 and R2 value of 0.1293, 
meaning the clustering accounts for only 12.93% of the variation seen. ANOSIM tests 
resulted in a p-value of 0.19 and a test statistic of 0.0262, indicating weak grouping based on 
treatment and sample date. 
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Temporal and transient changes in fecal metabolites of mice treated with manganese 
Abnormal peristalsis and changes in the gut microbial composition can have downstream 
effects on the bacterial population as well as the host’s physiology. While there was no 
significant difference in the bacterial population changes in the host physiology, we wanted 
to confirm any changes in fecal metabolites that can indicate a change in the host physiology. 
We used GC-MS to screen fecal metabolites to determine any changes that might have 
occurred over the range of carbohydrates, amino acids, fatty acids etc. Log-scale 
transformation of data was used to provide better separation of samples and results are 
presented in a heat map with increasing color intensity corresponding to higher samples 
amount with respect to average control sample amounts (Figure 7A). A total of 1064 
metabolites were identified using the NIST08 library and metabolites fell in 22 categories. 
GC-MS analysis of fecal samples collected at days 0, 10, 20 and 30 showed some significant 
differences as early as day 10 between Mn-treated and untreated mice. Notably decreased 
alanine production (p<0.05), α-linolenic acid acid (p<0.03) and oleic acid (p<0.03) 
production and increased and palmitic acid (p<0.065) production was seen at day 10 in the 
feces of Mn-treated mice when compared to day 10 control mice (Figure 7B-7D).  α-
linolenic acid is an omega-3 fatty acid that has been shown to reduce inflammation with 
reduced levels seen in many chronic diseases such as arthritis and high blood pressure (de 
Lorgeril et al., 1994). There appears to be a bi-directional relation between probiotic bacteria 
and omega-3 fatty acids since atopic infants given bifidobacterium over 7 months showed 
increased plasma α-linolenic acid levels (Logan and Katzman, 2005). Palmitic acid is the 
most common saturated fatty acid found in the body Increased palmitic acid can reduce 
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insulin production in pancreatic β-cells thus leading to type-2 diabetes (Solinas et al., 2006). 
Thus decreased alanine along with increased palmitic and stearic acid points towards 
intestinal dysregulation as early as 10 days post Mn exposure whereas the sugar 
glucopyranose was found to be lower in the fecal samples of Mn-treated mice at day 20 (Fig. 
7E). The various classes of differentially expressed metabolites are summarized in figures 
7F-7G in the form of pie charts. The pie charts illustrate the range of metabolites altered 
following Mn exposure at days 20 and 30. Amino acids, sugars, fatty acids as well as 
glycolytic intermediates reflected the largest percentage of compounds affected following 
Mn exposure.  Thus transient changes in fecal metabolites, especially compounds that play a 
part in carbohydrate and fatty acid metabolism, are seen in the Mn treated mice. 
 
Discussion 
Since the discovery by Braak and colleagues that aggregated proteins - a hallmark of many 
neurodegenerative diseases including PD - are seen in the ENS of a number of early PD 
patients, scientific interest in the possibility of enteric dysfunction preceding CNS 
dysfunction has increased (Braak et al., 2006). Recent publications have shown a possible 
connection between ingestion/inhalation of environmental toxins and development of 
neurological disorders (Bhatt et al., 1999; Gomez-Mejiba et al., 2009). In the case of metal 
toxicity, Mn, aluminum, mercury and lead are known to be neurotoxic when present in high 
amounts in the body (Farina et al., 2013). While Mn toxicity in the brain has been studied 
extensively, scant attention has been paid to its possible toxic influence on enteric neurons 
despite cases of gastrointestinal disturbances having been reported following chronic Mn 
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exposure (Chandra and Imam, 1973; Huang and Lin, 2004). Hence we decided to investigate 
the possible toxic role of Mn exposure in the GI tract.  
The GI tract is a complex composition of various cell types including enteric neurons and 
glia as well as resident immune cells. As mentioned before, EGCs are known to project into 
the mucosal villi, playing a crucial role in maintaining the intestinal barrier as well as cross-
talking with immune cells and enteric neurons (Gulbransen and Sharkey, 2012; Neunlist et 
al., 2013; Savidge et al., 2007b). Recent evidence has suggested that a number of GI tract-
related disorders occur partly due to a dysregulation of EGCs (von Boyen and Steinkamp, 
2010; Yu and Li, 2014). Since EGCs can come into direct contact with Mn as it is absorbed 
via the enterocytes on the villi, we focused on the effect of Mn on EGCs. Similar to previous 
results showing astrocytes as being particularly sensitive to Mn toxicity (Wedler et al., 1982), 
EGCs are also affected by low doses of this metal. In particular, the mitochondria appear to 
be more sensitive as shown via various mitochondria-specific assays in this paper. Curiously 
enough, when exposed to similar doses of iron, copper and magnesium, the EGC’s were 
resistant to mitochondrial stress and damage as shown in S.Figure 1. This shows that Mn 
selectively exerts toxic effect on the EGC’s. While mitochondria show signs of damage 
induced by minute doses of Mn, the cells per se do not undergo apoptosis until the dose 
exceeds 300 µM for 24 h. This means that a window exists when cells, although stressed, do 
not die immediately (Fig. 2B-2C). However, stressed EGCs can increase iNOS production 
and release pro-inflammatory factors, which can affect surrounding non-glial cells, activating 
or suppressing immune cells or contributing to stressed enteric neurons (Bogdan, 2001; 
Capoccia et al., 2015). The ENS, in conjunction with different neuropeptides, Cajal cells and 
enteric smooth muscle cells, controls the peristaltic movement of ingested food through the 
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intestine. This is necessary for absorption of food and micronutrients (in the small intestine) 
as well as water and salt retention and fecal production (in the large intestine) (Huizinga, 
1999). However in the long-term, the abnormal peristalsis exhibited by Mn-treated mice may 
have unfavorable consequences on health.  
While enteric neurons are more resistant to Mn toxicity, they can be susceptible to stress 
induced by pro-inflammatory factors released by activated and stressed EGCs (Fig 3B) 
(Brown et al., 2016) that could potentiate enteric neuronal death (Fig 3D). Also, both primary 
enteric cultures and mice treated with a low dose of Mn for a prolonged period showed 
altered smooth muscle contractions. For instance, primary cultures treated with 100 µM Mn 
for 24 h showed decreased or no contractions along with apoptotic ganglia seen floating in 
the media (Figure 3F). Similarly, animals given 15 mg/kg/day Mn showed increased 
intestinal transit time compared to controls after day 20 (Figure 4F). These results have 
serious implications concerning the role of the ENS in regulating intestinal peristalsis and 
nutrient absorption. Slower peristalsis can result in small intestine bacterial overgrowth as 
well as constipation- two undesirable complications that can lead to poor digestion and 
nutrient imbalance thus affecting health in general. It is possible that interstitial cells of Cajal, 
called the pacemaker of the gut, might be sensitive to even small concentrations of Mn, 
similar to EGCs. These cells use changes in potassium and Ca+2 levels to communicate with 
smooth muscle cells and signal the timing and duration of each contraction (Parsons and 
Huizinga, 2010). Mn might compete with Ca+2 in entering the cell, limiting the generation of 
action potentials that cause surrounding smooth muscle cells to contract. However, more 
research is needed to understand this effect.  
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Following 30 days Mn exposure, mice had significantly more amount of Mn in the colon 
compared to vehicle (water) treated mice (Fig 5H). Indeed this impairment in Mn 
homeostasis was confirmed by probing for common Mn cellular transporters DMT1, 
ferroportin (Fpn) and SLC30A10. DMT1 is a receptor that transports most divalent ions- 
including Mn- inside a cell. DMT1 is expressed throughout the intestine especially on 
enterocytes present on intestinal villi and in the colon (Takeuchi et al., 2005). Similarly, Fpn 
and SLC30A10 are transporters present throughout the GI tract and are mainly involved in 
efflux of divalent metal ions. SLC30A10 is a Mn-specific efflux protein that removes Mn 
from the cell (Leyva-Illades et al., 2014). q-RT PCR analysis revealed decrease in 
SLC30A10 expression in the colon of Mn treated mice (Figure 5G) while Western blot 
analysis revealed decreased Fpn expression in the colon of Mn-exposed mice (Figure 5F). 
This could account for the increase in tissue Mn content in this group. Interestingly, no 
significant differences were observed between the groups with respect to other trace metals. 
Therefore, it is possible that presence of excess Mn in the intestinal tissue lead to oxidative 
stress and inflammation  
H&E staining of the colon tissue of Mn-treated animals did not show any overt signs of 
immune cell infiltration indicative of large-scale inflammation or tissue damage (Fig. 5A). 
However, goblet cell numbers and consequently mucin production decreased in the treatment 
group (Fig. 5B). This shows that although cell death and tissue damage have not occurred 
following chronic Mn exposure, the function of certain cell types such as goblet cells was 
affected causing mild yet significant changes in the GI tract. Western blot and q-RT PCR 
quantification showed increased iNOS production, while immunofluorescence images 
showed a similar increase in iNOS in the myenteric plexus of the colon of Mn-treated mice. 
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Also, mRNA levels of TNFα were upregulated by low-dose, chronic Mn exposure. 
Collectively, these results indicate Mn-induced inflammation in the colon. Repeated toxin 
exposure has been thought to generate oxidative stress, intestinal inflammation and 
subsequently potentiate protein aggregation (House and Tansey, 2017). Hence we decided to 
probe for oligomeric protein expression using the A11 antibody. Slot blot analysis of colon 
lysates from Mn-exposed and unexposed mice (n=5) showed a trend of increased oligomeric 
protein expression in the colons from Mn-exposed group compared to controls (S. Figure 5). 
In recent years, researchers have increasingly recognized the importance of gut microbiota in 
driving enteric inflammation as well as maintaining host health. In particular, there is 
considerable interest in the theory that the gut microbiome plays an important role in certain 
neurological disorders such as autism and PD (Ghaisas et al., 2016; Mulle et al., 2013; 
Scheperjans et al., 2015). While it is not known exactly how enteric microbiota initiate or 
aggravate neurological dysfunctions, it is thought that ingesting or inhaling environmental 
toxins affects the microbial population either by selectively enriching certain species of 
pathogenic bacteria or by reducing the number of beneficial bacteria, thus driving 
inflammation. Through the gut-brain axis, enteric inflammation is communicated to the CNS 
where neuroinflammation and later neurodegeneration progresses (Carabotti et al., 2015). 
The intestinal microbiota forms a regionally diverse and complex ecosystem, with a majority 
of the microorganisms residing in the large intestine (colon), while being sparsely present in 
the stomach and small intestine. Since we found inflammation in the colon, we characterized 
the gut bacteria of control and Mn-treated mice. Although we were unable to detect 
significant differences early during the treatment regime, a trend for increased 
Gammaproteobacteria was observed around 20 days post Mn exposure (Fig. 5B). 
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Interestingly, this class includes several pathogenic and opportunistic species (Li et al., 
2012). It is also worth noting that this change in bacterial population coincided with 
increased intestinal transit time. Longer exposure to Mn could result in statistically 
significant changes in the composition of the gut microbiota. 
Changes in fecal metabolite composition indicate either altered bacteria to host signaling or 
vice versa. Alanine, an amino acid that plays an important role in the biochemistry of a 
number of essential biological compounds was decreased within 10 days of Mn treatment. 
On the other hand, saturated fatty acids such as palmitic acid and stearic acid were present in 
significantly higher amounts in the treatment group compared to the control group. However, 
these changes were transient between the two groups as there were no significant differences 
by the end of the 30-day treatment. What is interesting though is the timeline of events that 
occur. 10 days post Mn treatment; changes in saturated fatty acid composition were 
observed. This was followed by an increase in Gammproteobacteria and in parallel, 
increased intestinal transit time.  
To conclude, Mn overexposure affects the ENS even at low doses, impacting mainly the 
EGCs by causing mitochondrial damage. It also causes inflammation in the gut leading to 
decreased mucin production and slower peristalsis. These effects are observed despite 
exposure to non-toxic amounts of Mn, adding credence to the theory that environmental 
toxins influence ENS dysregulation and subsequently gastrointestinal dysfunction. Owing to 
the communication between the ENS and CNS via the gut-brain axis, this ENS dysregulation 
might ultimately contribute to irregularities in CNS functioning that precedes many 
neurological disorders.  
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Figure legends 
 
Figure 1. EGCs are highly sensitive to Mn. (A) EGCs were treated with increasing 
concentrations of Mn for 24 h. Cell viability was measured by MTS assay. Values are 
normalized to control and expressed as percent control. (B) EGCs treated with 1-30 µM Mn 
for 24 h were stained with 100 nM MitoTracker Green FM for 20 min. When this green 
fluorescence intensity is normalized to cell number (counted by Hoechst staining), it is 
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directly proportional to mitochondrial mass in each well. (C) Mitochondrial morphology was 
visualized by staining control and Mn-treated cells with 200 nM MitoTracker Red for 10 
min. Scale bar = 10 µm. (D) Mitochondrial circularity expressed as percent control was 
determined by ImageJ analysis of mitochondria from seven different images/group. (E) 
EGC’s were treated with 10 or 1000 µM Mn for 24 h then mitochondrial-aconitase activity 
was measured using a commercial kit as per manufacturer’s instructions. (F) Dose dependent 
increase in mitochondrial superoxide upon Mn treatment was measured by MitoSox dye 
fluorescence. (G) Tracing showing oxygen consumption rate (OCR) of EGCs treated with 0, 
5, 10 or 100 µM Mn for 24 h as measured by Seahorse XF24e. (H) Dose dependent decrease 
in ATP production in EGCs treated with increasing concentration of Mn. (G) ATP 
production of untreated and Mn-treated EGCs after 24 hour exposure. Data represented as 
mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, ns = non-significant) of four to six replicates. 
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Figure 2. Enteric glial cytotoxicity occurs at higher concentrations of Mn. (A-B) Phase 
contrast and green fluorescence super-imposed images of EGCs treated with different doses 
of Mn (1-1000 µM) for 24 h. Cell death, which is expressed as % control and is directly 
proportional to green fluorescence intensity, was visible only at doses of 300 µM Mn and 
above. (C) Caspase-3 activity in EGCs treated with increasing dose of Mn for 24 hours. 
Significant caspase-3 activity was seen in 300 µM and 1000 µM Mn treatments. (D) 
Decreased ability of Mn treated EGCs to re-uptake L-[3,4 3H] glutamic acid. Data 
represented as the group mean ± SEM from at least 3 experiments. Asterisks (***p<0.001, 
**p<0.01 and *p<0.05) indicate significant differences between Mn-treated groups and 
control.  
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Figure 3. Mn treatment induces inflammation and enteric neuronal death in a primary 
enteric mixed culture. (A) Cell viability of the primary enteric mixed culture treated with 
increasing doses of Mn was measured by MTS assay, with values normalized to control and 
expressed as percent control (n=6). (B) qRT-PCR analysis of TNFα, IL-1β and iNOS mRNA 
transcripts, normalized to 18S rRNA expression. (C) Representative Western blot image 
showing decreased GFAP expression following 100 µM Mn exposure. (D) Western blot 
analysis of enteric neuron marker PGP9.5 and Mn transporters DMT1 and ferroportin 
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expression in untreated and 100 µM Mn-treated primary enteric mixed cultures (n=6). 
Quantification of bands revealed reduced PGP9.5 and ferroportin expression in Mn-treated 
samples. Expression of β−actin was used as a loading control. (E) Video showing 
spontaneous contractions in a 3-week old primary enteric culture. (F) Loss of spontaneous 
contractions in 3-week old primary enteric culture following 24 h treatment with 100 µM 
Mn. Data represented as the group mean ± SEM from at least 3 experiments. Asterisks 
(***p<0.001 and **p<0.01) indicate significant differences between Mn-treated groups and 
control.  
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Figure 1 continued  
Figure 4. Altered gastrointestinal motility but no behavioral changes in mice treated 
with a low dose of Mn. (A) Schematic representation of the Mn treatment paradigm in C57 
mice. (B) Mouse body weight development over the course of Mn study. (C) Rotarod test 
showing no statistical difference between control and Mn-treated mice with regards to 
balance and co-ordination. (D) Open-field test showing no difference in horizontal activity 
between the two groups. (E) No difference in vertical activity between the two groups as 
measured by open-field test. (F) Whole gut transit time (WGTT) as measured by carmine red 
meal over the course of the study. Increased WGTT was observed in the treatment group 
from day 20 onwards when compared to age-matched controls (n=13). (G) Bead latency test 
to determine distal colon transit time. No significant difference was observed between 
groups. Data represented as the group mean ± SEM from n=10 or n=13. Asterisks 
(***p<0.001 and **p<0.01) indicate significant differences between Mn-treated group and 
control. 
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Figure 5 continued  
 
Figure 5. Evidence of colonic inflammation in mice treated with a low dose of Mn. (A) 
Representative 20x images of H&E-stained colon sections from untreated and Mn-treated 
groups (n=3). Scale bar = 100 µm. (B) Representative 20x images of Ab-PAS-stained colon 
sections. Mn-treated mice had fewer goblet cells and consequently less mucin production 
relative to controls as evidenced by decreased mucin staining in the colon sections of the 
treatment group. Scale bar = 100 µm. (C) qRT-PCR analysis of TNFα, IL-1β and iNOS 
mRNA transcripts, normalized to 18S rRNA expression (n=6). (D) Western blot analysis of 
iNOS production in colon samples from untreated and Mn-treated mice. (E) Representative 
40x immunofluorescence images showing increased iNOS production in the myenteric 
plexus of Mn-treated mouse when compared to control. Scale bar = 100 µm. Arrows indicate 
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presence of punctate iNOS staining. (F) Western blot showing larger presence of EGCs, 
decreased mitochondrial protein DJ-1 expression along with decreased expression of 
ferroportin receptor indicates intestinal dysregulation in Mn treated mice. (G) Lower 
SLC30A10 transcripts in Mn-treated mice compared to control mice indicating dysreglation 
in Mn homeostasis in colon tissue. (H) ICP-MS data showing higher Mn+2 content in colon 
tissue. Asterisks (*p<0.05 and **p<0.01) indicate significant differences between Mn-treated 
group and control. 
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Figure 6 continued 
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Figure 6. Changes in the gastrointestinal microbiota following manganese treatment. 
Taxonomic summaries at the phylum (A), class (B), and genus (C) levels. Rarefaction plots 
of observed species richness (D) and Faith’s Phylogenetic Diveristy (E). Weighted Unifrac 
PCoA plots (F) where each point is a single sample and each color represents a group.  
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Figure 7 continued 
 
Figure 7: Changes in fecal metabolites following chronic manganese exposure. (A) Heat-
map showing log-transformed GC-MS data (n=4-6). Color bar values correspond to log 
abundance of metabolites in individual samples measured in metabolomic analysis. (B) 
Alanine in pmoles per mg fecal sample in control and Mn-treated groups at day 10 (n=3-4). 
(C) Oleic acid in pmoles per mg fecal sample in control and Mn-treated groups at day 10 
(n=3-4). (D) α-linolenic acid in pmoles per mg fecal sample in control and Mn-treated 
groups at day 10 (n=3-4). (E) Pie-chart denoting global changes in different classes of fecal 
metabolites in control samples at day 30. (F) Pie-chart denoting global changes in different 
classes of fecal metabolites in Mn exposed samples at day 30. 
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Supplementary Figure 1: Enteric glial cells are most susceptible to Mn-induced 
mitochondrial stress. (A) MTS assay of EGC’s (n=6) treated with increasing doses of 
Copper (Cu), Iron (Fe), Magnesium (Mg) and Manganese (Mn). A potent decrease in 
metabolic activity was observed in cells treated with Mn compared to other metals. Values 
are normalized to control and expressed as percent control. (B) MitoSox assay showing 
significant increase in mitochondrial superoxide production mainly in EGC;s treated with Mn 
compared to other metals. Asterisks (*p<0.05 and **p<0.01) indicate significant differences 
between different treatments and control. 
 
Supplementary Figure 2: Heterogeneous cell population in primary enteric mixed 
culture. (A) 40x image showing neurospheres (red arrow) as well as differentiated neurons 
growing in the culture after 14 days in vitro. (B-C). Fibroblasts (purple arrow) and 
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endothelial cells (green arrow) growing in confluent layers on the cell culture plate 10 days 
in vitro.  
Supplementary Figure 3: Trend of increase bile salt secretion in Mn-treated mice. 
Clinical pathology results of plasma samples showing mildly elevated bilirubin and blood 
urea nitrogen (BUN) levels in Mn treated mice compared to control mice (p<0.07). 
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Supplementary Figure 4: ICP-MS data for trace metals. With the exception of Na+2, no 
significant differences were seen between the two groups for the common tested trace metal 
as shown in the table. 
 
 
Supplementary Figure 5: Fecal water content. No change in fecal water content between 
control and Mn-exposed mice.  
 
 
Supplementary Figure 5: No change in oligomeric protein expression between control 
and Mn-exposed mice. Dot Blot analysis of oligomeric protein in colon lysates from control 
and Mn-treated mice (n=5) 
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Supplementary Figure 6: Olfaction test. (A) Mn-treated mice showed lower ability to 
detect pheromones released from opposite sex bedding (OST). (B) Mn-treated mice showed 
lower ability to detect vanilla scent from non-scented (water) area (NST). Asterisks 
(*p<0.05) indicate significant differences between Mn-treated group and control. 
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Abstract 
Gastrointestinal (GI) disturbances are one of the earliest symptoms affecting most patients 
with Parkinson’s disease (PD). In many cases these symptoms are observed years before 
motor impairments become apparent. Hence there is an increasing interest in understanding 
the molecular and cellular mechanisms that potentiate this early GI dysfunction. The 
MitoPark model is a chronic, progressive mouse model recapitulating several key 
pathophysiological aspects of PD. However GI dysfunction has not been categorized in this 
model. Here we show that GI motility was one of the first non-motor symptoms to develop, 
seen as early as 8 weeks with significantly different transit times from 12 weeks onwards. 
These symptoms are observed well before motor symptoms develop paralleling PD 
progression in humans. We also observed increased colon transit time and reduced fecal 
water content indicating constipation at 24 weeks of age compared to age matched littermate 
controls. Intestinal inflammation was observed with increased expression of iNOS and TNFα 
in the small and large intestine. Specifically, iNOS was observed mainly in the enteric plexi 
indicating enteric glial cell activation. At 24 weeks, there was pronounced loss of tyrosine 
hydroxylase positive neurons both in the mid-brain region as well as the gut leading to a 
corresponding decrease in dopamine production. However, despite loss of dopaminergic 
neurons, the total number of neurons did not significantly differ between the two groups. We 
also observed decreased DARPP-32 expression in the colon validating the loss of 
dopaminergic neurons in the gut. These mice also develop misfolded proteins as evidenced 
by positive oligomeric protein expression. Notably, exposure of young mice to an 
environmental toxin Mn, at a low dose of 10mg/ Kg body weight for 4 weeks lead to a 
dramatic increase in misfolded proteins when compared to unexposed MitoPark mice. 
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Together, the data sheds more light on the role of dopamine in maintaining intestinal health. 
Importantly, this model recapitulates the chronology and development of GI dysfunction 
along with other non-motor symptoms and can become an attractive model for pre-clinical 
assessment of the efficacy of new anti-parkinsonian drugs. 
 
Introduction 
Parkinson’s disease (PD) is a chronic and progressive neurological disorder caused by loss of 
dopaminergic neurons present in the substantia nigra region of the brain. This disorder 
displays an array of symptoms, the most prominent being a sustained loss of motor control 
leading to bradykinesia, muscle rigidity, postural instability and poor coordination. Since 
publication of the medical essay “The Shaking Palsy” by Dr. James Parkinson, it has been 
known that PD is a multicentric disease affecting even the autonomic nerves and the enteric 
nervous system (ENS). Today, a number of retrospective studies and clinical observations of 
PD patients have shown the presence of many non-motor symptoms that may precede the 
disorder often decades before motor symptoms are diagnosed. The common non-motor 
symptoms include, dysphagia, constipation, hyposmia and sleep disturbances (Chen et al., 
2013). An increasing number of studies have reported gastrointestinal problems especially 
constipation in 25-80% PD patients. Aside from constipation, PD patients also experience, 
dysphagia, excessive drooling, nausea and dyspepsia (Cersosimo and Benarroch, 2012; 
Pfeiffer, 2003).  
Gastrointestinal motility is controlled by neural and hormonal signals arising from central 
and peripheral nervous systems. Notably, the enteric nervous system (ENS) plays an 
important role in maintaining a healthy gastrointestinal (GI) physiology by influencing 
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smooth muscle contraction and relaxation, absorption of nutrients and cross-talk with the 
immune cells patrolling the GI tract (Hansen, 2003). Of the many neurotransmitters that are 
produced in the GI tract, dopamine and serotonin are two important neurotransmitters 
involved in GI motility. Depending on the receptor subtype and location, both 
neurotransmitters modulate excitatory and inhibitory signals leading to location-specific 
contraction or relaxation of the GI tract. This complex signaling process results in 
coordinated peristalsis of the gut thus enabling nutrient absorption and proper waste removal. 
In the case of PD, an imbalance in dopamine secretion and/or reuptake has been speculated to 
induce irregular peristalsis (Greene et al., 2009; Zhang et al., 2007). This irregular peristalsis 
can lead to overgrowth of bacteria in the small bowel, sub optimal nutrient absorption and 
inadequate defecation. This irregularity in intestinal transit and hence absorption may also be 
an important reason why levodopa - despite being the therapeutic agent of choice given to 
PD patients- still shows inconsistent success in alleviating motor symptoms.  Till date, 
several ex vivo studies on intestinal smooth muscles have been carried out, however the 
results differ from one another due to inconsistent sample preparation as well as the use of 
non-selective agonists or antagonists (Walker et al., 2000). Similarly, toxin-based rodent 
models of PD have also shown inconsistent results with regards to small and large intestinal 
motility(Anderson et al., 2007; Greene et al., 2009; Pellegrini et al., 2016). Hence there is a 
need to develop an in vivo model of PD that faithfully reproduces most of the GI symptoms 
seen in PD. 
The MitoPark mouse model is generated by the cre/lox system wherein the mitochondrial 
transcription factor A (Tfam) is selectively removed from dopaminergic (DAT positive) 
neurons. This results in a progressive development of motor symptoms, notably loss of 
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coordination and muscle rigidity. Previously, other groups have shown development of non-
motor symptoms in the MitoPark mouse model (Ekstrand et al., 2007; Galter et al., 2010). 
However, despite being an important non-motor symptom, GI disturbances in this model 
have not been described. Hence the aim of this study was to characterize GI motility and 
intestinal inflammation using a combination of motility and neurochemical tests.  
 
Materials and Methods 
Chemicals 
Manganese (II) chloride tetrahydrate (MnCl2) and β-actin antibody were purchased from 
Sigma. Antibodies for PGP9.5 (Cat # AB1761-I) and GFAP (Cat # MAB3402) and Tyrosine 
hydroxylase (TH, Cat. # MAB318) were purchased from Millipore while iNOS (Cat # sc-
651) and Bax (Cat # sc-493) antibodies were purchased from Santa Cruz. Hoechst 33342 
nuclear stain was purchased from Invitrogen (H3570). 
 
Experimental design 
MitoPark mice were kindly provided by Dr. Nils-Goran Larson at the Karolinska Institue, 
Stockholm (Ekstrand et al., 2007). MitoPark mice (DAT +/Cre: Tfam LoxP/LoxP) and their 
littermate controls (DAT+/+: Tfam +/LoxP) were fed ad libitum and maintained at 22°C under a 
12h light/dark cycle in standard conditions approved and supervised by the Institutional 
Animal Care and Use Committee (IACUC) at Iowa State University.  Mice were weighed 
and subjected to behavioral tests every four weeks. At the age of 24-weeks, mice were 
euthanized via cervical dislocation and gastrointestinal tissue (colon, ileum and duodenum) 
as well as various microdissected brain tissues were collected and stored at -80°C until 
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further analysis. Neurochemical, biochemical, and histological studies were performed 
following sacrifice at age 24 wks. 
 
In vivo GI motility assessment 
Gastric emptying 
Gastric emptying was performed on 24 week MitoPark and littermate controls. Prior to the 
experiment, mice were fasted for 12 hours with free access to water. At the time of the 
experiment, these mice were given access to standard laboratory diet for 1h. The amount of 
food consumed was calculated based on food weight before and after access. Two hours 
following food consumption, animals were sacrificed and the stomach was removed. Gastric 
emptying was calculated according to the following formula: gastric emptying (%) = [1 - 
(weight of food remaining in the stomach/weight of food intake)] * 100 (Tasselli et al., 
2013).  
Whole gut transit time (WGTT) 
Carmine red is a red dye that is not absorbed by the gut during digestion but excreted with 
other waste products. Hence a solution of this dye was used to determine total 
gastrointestinal transit time in MitoPark and littermate control mice from 8 to 24 weeks of 
age. A solution of carmine red (60 mg/ml) in 0.5% (vol/vol) Carboxymethyl cellulose was 
administered by oral gavage using a 24 gauge round-tip feeding needle (Tasselli et al., 2013). 
The volume of carmine red solution used for each animal was calculated based on animal 
weight (0.3mg/g body weight). Based on pilot studies, we found that following gavage; 
animals did not show presence of red fecal pellets for one hour. Hence animals were 
monitored at 15 min intervals for the presence of carmine red one hour following oral 
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gavage. Again, prior pilot studies indicated that majority of the mice showed red fecal pellets 
by 8 hours and hence the experiment was terminated after 8 hours. Total gastrointestinal (GI) 
transit time is considered as the interval between the initiation of gavage and the time of first 
observance of carmine red in stool. Animals whose stool had no dye even after a maximum 
observation time of 8 h were recorded as >8 hours.  
Bead latency 
Distal colonic motility was measured by the bead latency test. Mice were anesthetized with 
isoflurane and a lubricated, 2 mm-diameter glass bead was introduced into the distal colon to 
a total depth of 2 cm from the anus margin using a fire-polished glass rod. After insertion of 
the bead, mice were isolated in clear plastic cages without food and water. The time required 
for expulsion of the glass bead was recorded which is typically less than 15 min.  
One-hour stool collection 
Each mouse will be placed in a separate clean cage without food and water and fecal pellets 
were collected over the course of one hour. The pellets were collected immediately after 
expulsion and placed in 1.5 ml microcentrifuge tubes to avoid drying. Tubes with the fresh 
pellets were weighed to obtain the wet weight of the stool. Following overnight drying at 
65°C, the tubes were reweighed to obtain the dry weight. Total dry and wet stool weights as 
well as stool water content [(Wet weight – dry weight)/wet weight] *100 was calculated. 
Additionally, total number of fecal pellets and stool frequency was observed and recorded.  
 
Western blot 
Six tissues of colon from MitoPark and littermate control groups were e homogenized in a 
bullet blender (Next Advance) using 2mm diameter stainless steel beads. Tissue lysates were 
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prepared using modified radio immune precipitation assay (RIPA) buffer containing 20 mM 
Tris–HCl, pH 8.0, 2 mM EDTA, 10 mM EGTA, 2 mM dithiothreitol (DTT), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 20mM sodium orthovanadate, 1 mM sodium fluoride 
and protease and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA), as 
described previously [30, 31]. The supernatants were obtained after centrifuging the 
homogenates at 15,000 rpm for 60 min. Protein concentration was measured using Bradford 
dye (Bio-Rad). Lysates containing equal amounts of protein were separated on a 12 or 15% 
SDS-polyacrylamide gel. After separation, proteins were electro- blotted onto a nitrocellulose 
membrane, and nonspecific binding sites were blocked with LICOR blocking buffer. TNFα 
(1:1000), iNOS (1:500) and β-actin (1:10000) primary antibodies were used to blot the 
membranes for 16 h at 4°C. Thereafter, blots were washed in phosphate buffered saline 
(PBS) containing 0.01% Tween-20, incubated in respective secondary antibodies (Alexa 
Goat anti mouse 680 or Alexa Goat anti-rabbit 790) for 1 hour. Fluorescent bands 
corresponding to the protein of interest were observed by scanning membranes in a LiCor 
scanner. 
 
Quantitative real-time PCR (qRT-PCR) 
Colons from MitoPark and littermate control groups were utilized for qRT-PCR (n=6). The 
samples were homogenized in a bullet blender (Next Advance) using DNAse- and RNAse-
free stainless steel beads and RNA was extracted using RNeasy Plus Mini kit (Qiagen). 1 µg 
total RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems Inc.) following manufacturer’s instructions. Real-time PCR was 
performed in an Mx3000P QPCR system (Stratagene) using the Brilliant SYBR Green QPCR 
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Master Mix kit (Stratagene), with cDNAs corresponding to 1 µg of total RNA, 10 µl of 2 × 
master mix and 0.2 µM of each primer in a 20-µl final reaction volume. All reactions were 
performed in triplicate. Mouse 18S rRNA was used as an internal standard for normalization. 
Primers specific for NpY (NM_023456) were synthesized at the Iowa state University DNA 
facility while 18S rRNA (Cat# QT02448075) was obtained from Quantitect. The PCR 
cycling conditions contained an initial denaturation at 95°C for 10 min, followed by 40 
cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C 
for 30 sec. Fluorescence was detected during the annealing step of each cycle. Dissociation 
curves were run to verify the singularity of the PCR product. Data were analyzed using the 
comparative threshold cycle (Ct) method. 
 
Immunohistochemistry 
For immunohistochemistry, at the end of the treatment, animals were perfused first with PBS 
followed by 4% PFA. Guts were removed and post-fixed in 10% formalin for an additional 
24 h. Tissues were embedded in paraffin and sectioned at 7 µm at Iowa State University’s 
veterinary pathology lab. Paraffin-embedded sections of mouse tissues were deparaffinized 
in decreasing alcohol grades. Heat-mediated antigen retrieval was performed using 10 mM 
citrate buffer (pH 6.0) for 30 min. Sections were then incubated with blocking reagent (5% 
normal goat serum, 2% BSA and 0.5% Triton X-100 in PBS) for 60 min before being 
incubated with TUJ (1:500), iNOS (1:500) or GFAP (1:300) primary antibodies for 24 h. 
Sections were then washed many times in PBS and incubated in the dark for 90 min with 
Alexa-488 and 555 dye-conjugated secondary antibodies (1:1500). Nuclei were stained with 
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Hoechst dye. Slides were viewed with 63× and 43× oil objectives using a Leica DMIRE2 
confocal microscope. 
 
Monoamine assessment via High performance liquid chromatography 
Dissected colon and ileal segments were placed in buffer comprising 0.2 M perchloric acid, 
0.05% Na2EDTA, 0.1% Na2S2O5 and isoproterenol (internal standard) and stored at -80°C 
until lysate preparation. To extract monoamine neurotransmitters, the samples were 
homogenized using bullet blender and 0.2 mm diameter stainless steel beads. Lysates were 
centrifuged and 300 µl of lysate was added to 30 mg alumina. The pH of the solution was 
quickly increased to 8.6 using 1M Tris buffer. The tubes were now rotated in a rotating 
shaker at 4°C for 15 minutes and then centrifuged at 10,000 rpm. The supernatant was 
aspirated and the monoamine neurotransmitters were eluted form the alumina with 0.2 M 
perchloric acid.  Monoamine lysates were placed in a refrigerated automatic sampler (model 
WPS-3000TSL) until being separated isocratically by a reversed-phase C18 column with a 
flow rate of 0.6 ml/ min using a Dionex Ultimate 3000 HPLC system (pump ISO-3100SD, 
Thermo Scientific, Bannockburn, IL). Electrochemical detection was achieved using a 
CoulArray model 5600A coupled with an analytical cell (microdialysis cell 5014B) and a 
guard cell (model 5020) with cell potentials set at -350, 0, 150, and 220 mV. Data acquisition 
and analysis were performed using Chromeleon 7 and ESA CoulArray 3.10 HPLC Software 
and quantified data were normalized to wet tissue weight.  
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Statistical evaluation 
Data are expressed as the mean ± SEM. Unpaired t-test or two-way ANOVA followed by 
post hoc analysis using the Bonferroni method were performed using GraphPad Prism 6 
(GraphPad Software Company). Results were considered statistically significant at P < 0.05.  
 
Results 
MitoPark mice demonstrate age-dependent decrease in body weight but normal food 
intake compared to age-matched littermate controls 
For this study, mice were weighed once a month for 6 months to determine change in body 
weights (Figure 1A). Compared to age-matched littermate controls (LCs), MitoPark mice 
begin to display significantly lower body weights from 20 weeks of age (Figure 1B). There 
onwards, these mice steadily loose weight with the average weight of the LCs being 37 
grams compared to the MitoPark group with an average body weight of 24 grams just before 
conclusion of the study.   
To account for the weight loss and any intestinal dysmotility, we also measured food intake 
of both groups prior to conclusion of the study. Intriguingly, we found no difference in food 
intake between MitoPark and LCs even at 24 weeks of age when the MitoPark mice showed 
extensive weight loss  (Figure 1C).  
 
Spatial differences in gastrointestinal motility in MitoPark mice compared to age-
matched controls 
In the MitoPark mouse model, these mice gradually loose dopaminergic neurons and show 
age-dependent progression of motor and non-motor symptoms when compared to age-
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matched healthy mice (Galter et al., 2010; Li et al., 2013). Till date, various groups have 
studied the motor deficits in this model that mirror the adult-onset and age-dependent 
progressive motor symptoms seen in patients with PD. However, an important non-motor 
symptom – gastrointestinal dysfunction- that is seen in almost 80% PD patients has not been 
characterized in this model.  
Curiously, from 8 weeks of age MitoPark mice showed lower Whole gut transit time 
(WGTT) indicating more GI motility in these mice compared to LCs (Figure 2A). WGTT as 
the name suggests, measures GI motility from the time food enters the stomach till it is 
removed from the body as waste matter. With different regions of the GI tract uniquely 
involved in processes of digestion, absorption and waste production it is necessary to 
understand precisely which part of the gut is affected. Hence we evaluated regional motility 
by measuring gastric emptying and colon transit time. As gastric emptying involves 
euthanizing the mice, collecting and weighing stomach contents, this study was carried out 
only once at the culmination of the study.  
At 24 weeks of age, there was no difference in the gastric emptying between both groups 
(Figure 2B). However the MitoPark mice had increased colon transit time (CTT) compared 
to age-matched LCs (Figure 2C).  On an average, MitoPark mice took about 20 minutes to 
expel the glass bead inserted in the distal colon compared to LC mice that took about 4 
minutes to expel a similar bead. To determine the rate of bead propulsion (an indirect 
measurement of propulsive action of the colon) we divided the time required for bead 
expulsion with the colon length. The rate of bead movement in the distal colon was 
significantly decreased in the MitoPark group compared to the LC group (Figure 2D). 
Similarly MitoPark mice showed reduced fecal pellet output at 24 weeks of age further 
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suggesting loss of colonic motility in these mice when equated with LCs (Figure 2E). A trend 
of lower fecal water content was observed from 16 weeks in MitoPark mice when compared 
to age-matched LCs (Figure 2F). By 24-weeks of age, these mice now have significantly 
lower amount of fecal water content compared to age-matched LCs. Unusually, colon lengths 
in these mice were smaller when compared to that of the LCs despite no gross observation of 
inflammation (Figure 2G). 
 
Altered gastrointestinal monoamine neurotransmitter levels but no changes in 
dopamine receptor expression in the MitoPark mice 
Since dopamine plays an important role in modulating GI motility, we decided to assess 
intestinal dopamine content via HPLC.  
Following 12 weeks of age, MitoPark mice begin to show a reduction in striatal dopamine 
with significantly increased dopamine turnover from 12 week onwards (Galter et al., 2010). 
We observed reduced dopamine levels in 24-week old MitoPark mice compared to age 
matched LCs (Figure 3A). Curiously, the levels of 3,4-Dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) were unchanged in these mice compared to LCs 
(Figure 3A). We also measured the mRNA levels of prominent dopamine receptors present in 
the colon. We found no significant differences in D1R and D2R transcript levels between 
groups (Figure 3B). 
 
24 week-old MitoPark mice show low-grade intestinal inflammation 
Intestinal or systemic inflammation can cause alterations in GI motility. Given the perplexing 
spatial differences in motility in this transgenic model, we investigated the presence or 
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absence of inflammation in the GI tract. In the ileum, a trend of increased expression of 
tumor necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS) were 
observed in the MitoPark mice compared to age-matched LCs (Figure 4A). Enteric glial cells 
(EGCs) along with neurons form the enteric nervous system (ENS). EGCs are required for 
maintaining optimum gut epithelial barrier thus preventing translocation of intestinal bacteria 
and other harmful compounds from entering into the deeper layers of the GI tissue (Yu and 
Li, 2014). EGCs can also sense pathogenic and commensal or probiotic bacteria and hence 
are important in maintaining intestinal health (Turco et al., 2014). Various studies 
investigating the role of EGCs in diverse diseases have shown that EGCs increase in numbers 
in response to inflammation yet ablation or cell death of EGCs in healthy mice results in 
development of intestinal inflammation (Sharkey, 2015). At the age of 24 weeks, MitoPark 
mice showed increased glial fibrillary acidic protein (GFAP)- a marker of EGCs – by western 
blot analysis of full thickness colon samples (Figure 5A). However, EGCs are present not 
only in association with the neurons in the myenteric and submucosal plexus but are also 
present in the muscle layers and extend into the mucosal villi (S.Figure 1) Surprisingly, 
immunohistochemical analysis of GFAP expression presented significantly lower numbers of 
EGCs in the villi (Figure 4B) while higher expression of GFAP was observed in the 
myenteric plexus (Figure 4C).   
In the colon we observed significantly higher expression of TNFα and a trend of increased 
iNOS was observed (Figure 5A). Specifically, we found increased iNOS expression in the 
myenteric (LMMP) and sub-mucosal plexi (SMP) in the colon of MitoPark mice over LC 
colon (Figure 5E). Together the data points towards increased intestinal inflammation in 
these mice compared to age-matched LCs. In a rat model of PD, the toxin 6-hydroxy 
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dopamine (6-OHDA) caused a decrease in DARPP-32+ (Dopamine and cAMP regulated 
phosphoprotein-32) neurons in the substantia nigra. The consequence of reduced DARPP-32 
was reflected in muscle rigidity in these rats similar to that seen in PD patients. DARPP-32 is 
regulated in part by dopamine. Indeed 24-week MitoPark mice colon showed significantly 
lower expression of DARPP-32. Together the results suggest that at 24 weeks of age 
MitoPark mice have low-grade intestinal inflammation We also found higher expression of 
oligomeric proteins were observed in the 24 week MitoPark colon samples compared to LCs 
suggesting increased aggregated protein in the MitoPark gut (Figure 5B). However, based on 
published literature regarding this model, we speculate that the components of the aggregates 
may primarily be mitochondrial proteins rather than α-synuclein as no significant changes in 
aggregated α-synuclein levels were observed between groups (Figure 5C). 
 
Reduced number of dopaminergic neurons but no significant changes in total number 
of enteric neurons in the GI tract.  
Since the MitoPark mouse model utilizes the cre/lox system to specifically induce 
dopaminergic neuronal loss in the transgenic mice, this means that there is a progressive 
reduction in the number of dopaminergic neurons both in the mid-brain as well as the gut (S. 
Figure 2 and Figure 6A). As shown in Figure 5B, whole-mounts of the myenteric plexus 
present on longitudinal muscle shows reduction in tyrosine hydroxylase positive (TH+) 
dopaminergic neurons in the colon compared to age-matched LCs.  
However, colon and ileum sections stained for pan enteric neuronal marker - protein gene 
product 9.5 (PGP9.5) showed no significant differences between 24-week old MitoPark mice 
compared to LCs (Figure 6B).  
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Environmental toxin manganese exacerbates intestinal inflammation and oligomeric 
protein formation in the MitoPark colon 
Chronic exposure to manganese (Mn) is a known occupational and environmental hazard 
leading to neurological symptoms similar to PD (Rokad et al., 2016). Various labs including 
ours have investigated the role of Mn in the development of neuromotor and neurocognitive 
deficits (Afeseh Ngwa et al., 2011; Bouchard et al., 2007; Latchoumycandane et al., 2005). 
However, the effect of this toxin on the GI system in the context of PD has not been 
explored.  
8-week old MitoPark mice were given 10mg Mn/Kg body weight for 4 weeks via intragastric 
gavage while animals in the control group received vehicle (water) during this time period. 
After 4 weeks of Mn exposure, mice showed increased Bax expression in the colon 
compared to vehicle-treated controls (Figure 7A). Bax is a pro-apoptotic protein and its 
expression indicates increased cellular apoptosis when compared to control colon samples. 
Interestingly, a mere 4 weeks of low-dose Mn lead to a trend of increased oligomeric protein 
expression in the colon compared to the unexposed group (Figure 7B). Mn exposure also 
exacerbates motor dysfunction; for instance, between the ages 8-12 weeks movement 
coordination is similar between LCs and MitoPark mice, yet Mn exposed mice of the same 
age have coordination and motor deficits following exposure to Mn. Together the results – 
while preliminary- suggest that even a sub-acute exposure to Mn for 4 weeks can exacerbate 
protein aggregation in a living system with genetically disrupted protein quality control.  
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Discussion 
GI problems have been known to develop in PD patients sometimes decades before clinical 
diagnosis of the disease (Mukherjee et al., 2016). More importantly, the continued presence 
of altered intestinal transit can hamper optimal absorption of anti-parkinsonian medications 
thus decreasing the efficacy of these drugs (Bestetti et al., 2017; Mukherjee et al., 2016). 
Hence it is necessary to understand the role of dopaminergic neurons in gastrointestinal 
motility. The MitoPark transgenic mouse model recapitulates many characteristic symptoms 
of PD including a progressive loss of dopaminergic neurons as well as associated behavioral 
and motor deficits (Galter et al., 2010). Previously, we have observed the development of 
non-motor symptoms of reduced spatial memory retention as well anosmia early on in these 
mice compared to age-matched LCs (data not shown). In the present study, we show that GI 
dysfunction is one of the earliest non-motor symptoms observed in this model, a trait 
similarly seen in PD patients.  
 From 20 weeks of age, MitoPark mice begin to show weight loss compared to age-matched 
LCs (figure 1B). This weight loss occurred despite the fact that animals from both groups ate 
similar amounts of food (Figure 1C). Knowing that the gut-brain axis modulates appetite and 
hence feeding behavior, we decided to probe the hypothalamus of 24 week MitoPark and LC 
for the known appetite modulator- neuropeptide Y (NpY). In the hypothalamus, NpY is 
increased following fasting/food deprivation with the levels falling following food 
consumption (Hanson and Dallman, 1995; Schwartz et al., 1998). We observed increased 
mRNA expression of NpY in the hypothalamus of 24-week MitoPark mice when compared 
to LCs (S. Figure 2). This increased NpY is possibly in response to poor nutrient absorption 
and subsequent weight loss in these mice.  
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Since 8 weeks of age, MitoPark mice take less time to remove waste matter following 
intragastric gavage of a known volume of meal (Figure 2A). The GI tract includes the, 
stomach, the small intestine that is further divided into duodenum, jejunum and ileum, the 
large intestine or colon, appendix/cecum and the rectum. Each part of this GI tract play an 
important role in food breakdown, nutrient or electrolyte absorption and finally waste 
formation and removal. As a result, the motility pattern varies from one intestinal segment to 
another. Since WGTT measures the time required for the carmine red dye to pass through the 
entire tract, despite an altered motility time when compared to controls, it cannot confirm the 
exact region of dysfunction. Hence a combination of tests was performed to solve this 
problem. Subsequently, it was revealed that in MitoPark mice a normal gastric emptying rate 
(Figure 2B) but lower colon motility (Figure 2D-2E). Together, these results pointed towards 
increased peristalsis (constriction and relaxation of intestinal smooth muscles) in the small 
intestine but reduced peristalsis in the colon. Increased colon transit time has also been 
demonstrated in GI studies on PD cohorts. However, reports on gastric emptying and small 
intestinal transit time are conflicting with some studies reporting increased gastric emptying 
and small intestinal transit while others report no significant differences between younger PD 
(≤ 65 years) and healthy volunteers (Goetze et al., 2006; Hardoff et al., 2001; Heetun and 
Quigley, 2012). In most of the studies conducted, patients were already on l-DOPA 
replacement therapies. Long-term l-DOPA medication has been proven to increase intestinal 
transit time (Pfeiffer et al., 2012). Therefore such a major confounding factor must be taken 
into account when reporting intestinal dysmotility in patients with PD.  
In the GI tract and CNS, various dopamine receptors (D1R-D5R) are present and fall in two 
classes. D1 and D5 receptors fall in the D1R category that are mainly post-synaptic receptors 
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present on intestinal smooth muscle cells and blood vessels where as D2, D3 and D4 (D2R 
family of receptors) are present on enteric neurons. Dopamine plays a dual role in the GI 
tract based on the target receptors and cell type. For instance, dopamine can act on DA1 
receptors on smooth muscles and cause muscle relaxation while the same neurotransmitter on 
DA2 receptors present on post-ganglionic sympathetic nerves counteracts the effect of 
norepinephrine induced muscle relaxation thus inducing contraction (Kirschstein et al., 2009; 
Zizzo et al., 2010). Since our data shows spatial differences in GI motility, differential 
expression of these DA receptor subtypes might be the key to understanding this peculiar 
phenomenon. While there was a trend of increased D2 and D1 receptor transcript levels in 
the colon of MitoPark mice, these values were not significantly different from LCs. More 
studies need to be conducted to understand how loss of dopamine amounts to opposing 
motility behavior in the small and large intestine.  
Since this transgenic mouse model is based on progressive dopaminergic neuronal loss, as 
expected, we observed lower levels of dopamine (Figure 2A) and very few TH+ neurons 
(Figures 6A and 6B) in the GI tract compared to LCs. However no significant differences 
were observed in total neuronal population as stained by the pan enteric neuronal marker 
PGP9.5 (Figure 6C).  
Interestingly, Kirschstein et al showed that the dopamine exerts differential effects on 
intestinal smooth muscle contraction, showing increased contraction in the proximal but 
gradually relaxation in the distal parts of the gut (Kirschstein et al., 2009). This observation 
holds true for the MitoPark mouse model too. 
Another cause for disruption in normal GI motility is the presence of intestinal inflammation. 
Increased pro-inflammatory factors can disrupt normal cellular signaling leading to altered 
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intestinal transit times. When we probed ileum and colon samples for TNFα and iNOS, we 
observed increased protein expression of these pro-inflammatory factors especially in the 
colon (Figures 4A, 5A and 5D). Curiously, while western blot showed a mildly elevated 
expression of the enteric glial cell marker GFAP in the ileum, we observed reduced GFAP 
expression in the villi in this region compared to LCs. Despite expressing the same cell 
markers, nonetheless enteric glia differ in morphology and possibly cellular communication 
based on their location in the different layers of the gut (Boesmans et al., 2015; Rao et al., 
2015). It is possible that the loss of dopamine might have an effect on glial health and the 
presence of inflammation leading to a reduced glial cell expression in the villi and an 
increased presence of enteric glial cells to protect neurons from cell death. Future studies 
should focus on understanding the effect of dopamine on enteric glial cell health and 
functioning. 
Previous publications have reported presence of cytoplasmic inclusions constituting cellular 
fragments and aggregate proteins in the dopaminergic neurons of MitoPark mice (Ekstrand et 
al., 2007). Similarly, we have observed higher oligomeric protein expression in the colon of 
24-week old MitoPark mice compared to age-matched LCs (Figure 5B). Interestingly in the 
presence of an environmental toxicant such as Mn, these mice show higher incidence of 
protein aggregation as seen in Figure 7B. Notably, despite a low-dose Mn exposure regime, 
these mice had increased Bax expression in the colon (Figure 7A). Bax is a pro-apoptotic 
protein therefore increased Bax protein levels correspond to higher cell apoptotic incidences. 
Since the gut is made up of various cell types arranged in specific layers, the cell type 
particularly affected by Mn exposure would need to be determined. Still, increased Bax and 
protein aggregation upon low-dose Mn exposure demonstrates that a complex interaction 
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between genetic predisposition and environmental toxin exposure is what leads to protein 
aggregation and neurological dysfunctioning in most cases.  
To conclude, we have characterized GI dysfunction in the MitoPark mouse model of PD. 
Specifically, we show a progressive loss of normal GI motility with increased transit time in 
the colon and reduced transit time in the small intestine. At 24-weeks, MitoPark mice also 
developed mild intestinal inflammation and protein aggregation presumably due to loss of 
dopamine and deregulation in enteric glial cell numbers. Thus we demonstrate that the 
MitoPark mouse model recapitulates early GI dysfunction and constipation similar to PD 
patients and is an ideal pre-clinical candidate to determine the efficacy and action of new 
anti-parkisonian drugs.   
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Figures 
 
Figure 1: Weight loss observed in MitoPark mice despite regular food intake 
(A) Treatment paradigm. (B) Body weights measured over the duartion of the study showing 
progressive weight loss in MitoPark mice. (C) Food intake of both groups at 24 weeks of age. 
Food intake was measured by weighing food pellets before and after a 1 hour feeding time. 
The difference in pellet weight in miligrams was accounted as food consumed in that 1 hour. 
No difference was observed between groups. Data represented as the group mean ± SEM 
from n=10. Asterisks (**p<0.01 and ***p<0.001) indicate significant differences between 
MitoPark and LC. n.s = no statistical significance. 
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Figure 2: Gastrointestinal motility assessment showing faster small intestinal motility 
and slower large intestinal motility in MitoPark mice. 
(A) Whole gut transit time. Significant time difference was observed from 12 weeks of age 
onwards with MitoPark mice taking significantly lesser time to expel carmine red that was 
administered via intragastric gavage. (B) Gastric emptying. 24-week old  MitoPark and LC 
mice took similar times for ingested food to leave the stomach into the small intestine. (C) 
Colon transit time. 24-week old MitoPark mice took significantly more time in expeling the 
glass bead inserted 2 cm into the distal colon. (D) Rate of colonic motility- time required for 
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the glass bead to traverse the 2 cm distance  before being expelled by the animal. 24-week 
old MitoPark mice lower rate of motility compared to age matched LCs displaying a 
constipated behavior. (E) Stool frequency. 24-week old MitoPark mice expelled significantly 
fewer fecal pellets compared to LCs. (F) Fecal water content. MitoPark mice progressively 
show lower water content in their fecal pellets indicating constipation. (G) Colon length in 
centimeters. Representative photographs showing smaller colon length in 24-week old 
MitoPark mice compared to LCs. Data represented as the group mean ± SEM from n=10. 
Asterisks (*p<0.05, **p<0.01 and ***p<0.001) indicate significant differences between 
MitoPark and LC.  
 
Figure 3: Lower dopamine levels in the colon of 24 week old MitoPark mice compared 
to age-matched LCs. 
(A) HPLC analysis of manoamine neurotransmitter levels in the colon in nanograms per 
miligram tissue. Dopamine levels were decreased in the colon of 24-week old MitoPark mice 
compared to LCs. (B) Dopamine receptor mRNA transcript levels. No significant difference 
between D1R and D2R levels in the colon between groups. Data represented as the group 
mean ± SEM from n=10 or n=6. Asterisks (*p<0.05) indicate significant differences between 
MitoPark and LC. 
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Figure 4: Mild ileitis in older MitoPark mice compared to age-matched LCs. 
(A) Western blot of ileum samples (n=6) showing a trend of higher iNOS and TNFα 
expression in MitoPark mice compared to LCs. Blot intensities normalized to β-actin and 
expressed as arbitary units. (B) Representative 60x images of ileum sections stained with 
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GFAP showing decreased enteric glial numbers in the villi. Scale bar  = 11 µm Data 
represented as the group mean ± SEM from n=10 or n=6.  
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Figure 5 continued 
 
Figure 5: Colonic inflammation observed in 24-week MitoPark mice  (A) Western blot of 
colon samples (n=6) showing increased GFAP and TNFα and a decrease in DARPP-32 
expression in 24-week MitoPark mice compared to LCs. No significant differences in iNOS 
expressed was observed between groups. (B) Oligomeric protein detection. Dot blot analysis 
of oligomeric protein content in the colon of 24-week MitoPark and LCs. A trend though not 
significant increase in oligomeric protein expression was observed. (C) Dot blot analysis of 
aggregated α-synuclein expression in the colon showed no significant difference between 
groups. (D) Representative 60x image showing increased expression of iNOS in the 
myenteric (LMMP) and submucosal plexus (SMP) in 24-week MitoPark mice compared to 
LC. Data represented as the group mean ± SEM from n=6. Asterisks (*p<0.05, **p<0.01 and 
***p<0.001) indicate significant differences between MitoPark and LC.  
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 Figure 6: Decreased expression of dopaminergic neurons but no significant difference 
in total neuronal population between MitoPark and LCs: (A) Representative 60x image 
showing decreaed number of tyrosine hydroxylae (TH) positive neurons in the myenteric 
plexus of the colon in MitoPark mice. Scale bar = 7 µm (B) qRT-PCR analysis of TH mRNA 
transcript, normalized to 18S rRNA expression (n=6). (C) Representative 40x images of 
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PGP9.5 positive enteric neurons in the colon of LC and MitoPark mice. No significant 
differences were observed between groups. Scale bar = 35 µm. Data represented as the group 
mean ± SEM from n=6. Asterisks (*p<0.05) indicate significant differences between 
MitoPark and LC.  
 
 
Figure 7: Exposure to environmental manganese potentiates cell death in the colon of 
MitoPark mice. (A) Western blot of colon lysates showing increased bax protein expression 
in MitoPark mice given Mn compared to untreated transgenic mice. (B) Dot blot analysis 
showing increased oligomeric protein expression in the colon of MitoPark mice exposed to 
Mn compared to unexposed mice.  Data represented as the group mean ± SEM from n=3. 
Asterisks (*p<0.05) indicate significant differences between MitoPark and LC 
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Supplemental Figures 
 
S. Figure 1: 24-week MitoPark mice have significantly fewer number of dopaminergic 
neurons compared to age-matched LCs. DAB staining showing reduced TH positive 
dopaminergic neurons in the striatum and substantia nigra of MitoPark mice (left panels) 
compared to LCs (right panels).  
 
S. Figure 2: Increased neuropeptide Y expression in the hypothalamus of MitoPark 
mice. qRT-PCR analysis of NpY mRNA transcript, normalized to 18S rRNA expression 
(n=6). Data represented as the group mean ± SEM from n=3. Asterisks (*p<0.05) indicate 
significant differences between MitoPark and LC 
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CHAPTER III 
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Abstract 
Recent post-mortem studies on patients with Parkinson’s disease or autism spectrum 
disorders have found increased peripheral or intestinal inflammation. On the other hand, 
patients with chronic intestinal inflammation such as Crohn’s disease or ulcerative colitis are 
more susceptible to neurological complications as the disease chronicity increases. To 
determine the possibility that intestinal inflammation can potentiate neuroinflammation in the 
central nervous system (CNS), we assessed presence of pro-inflammatory cytokine 
expression and microglial activation in the CNS of mice given acute colitis. DSS induced 
acute colitis resulted in expected colonic inflammation and damage to the mucosa and sub-
mucosa. We observed immune cell influx at the sight of these lesions with increased iNOS 
production. The inflamed colons had lower levels of the neurotransmitter serotonin with 
increased metabolite turnover possibly due to decreased expression of 5-HT4 receptors. DSS-
treated animals also expressed high levels of prokineticin-2 in the distal colon to possibly 
counteract the loss of contractility due to lower serotonin and 5-HT4 levels. Interestingly, we 
also observed increased pro-inflammatory transcripts of TNFα, IL-1β and iNOS in the 
lumbosacral region of the spinal cord and in the substantia nigra with a slightly elevated 
microglial density in the ventromedial hypothalamus. Together, the data points to priming of 
the mid-brain region towards neuroinflammation following intestinal inflammation.  
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Introduction 
Ulcerative colitis (UC) is a chronic condition of intestinal inflammation of the colon. Along 
with Crohn’s disease, UC falls under the umbrella of inflammatory bowel diseases (IBD) and 
affects 1-1.3 million people in the United States and 2.5 million in Europe (Kaplan, 2015).  A 
rapidly emerging disease in developed countries, it constitutes about 0.5% of the diseases 
commonly seen in the general population (Molodecky et al., 2012). The disease is 
characterized by continued irregular recurrence of inflammation in the colon and especially 
the rectum. Unlike Crohn’s disease where inflammation can occur throughout the 
gastrointestinal (GI) tract, UC is mainly restricted to the mucosa and submucosa of the 
affected region. Histologically, severe crypt architecture distortion, decreased crypt density, 
reduced mucous production and massive immune cell infiltration (basal plasmacytosis) along 
with erythema and edema (DeRoche et al., 2014). The precise etiology of the disease is 
unknown hence there is no cure for colitis; the disease recurrences are managed by a 
combination of anti-inflammatory or immunosuppressive drugs, steroids, analgesics and 
modifications in personal diet. 
Understanding extraintestinal manifestations of IBD has steadily gained more importance 
due to new theories hypothesizing intestinal or peripheral inflammation as a trigger for 
neuroinflammation in the central nervous system (CNS) (Bonaz, 2013; Ghaisas et al., 2016). 
The idea that the GI and olfactory tract are (other than our skin) constantly exposed to 
pollutants, xenobiotics and potential toxic substances thus acting as a passageway for 
developing oxidative stress in the body has steadily gained credence following reports of 
intestinal inflammation or GI associated problems occurring in patients with Parkinson’s 
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disease and autism spectrum disorders (ASD) (Lin et al., 2016; Walker et al., 2013; Welch et 
al., 2005).  
The gut-brain axis is now recognized as an important conduit linking CNS signaling with GI 
functioning and vice versa. The autonomic nervous system including the sympathetic 
(visceral efferent neurons) and parasympathetic (including the splanchic and vagus nerves) 
nerves conveys signals bidirectionally thus integrating the functioning of the CNS and the GI 
tract. Following induction of UC or Crohn’s disease, patients report increased visceral pain 
indicating heightened pain perception (Taylor and Keely, 2007). Interestingly, nerve 
hyperplasia and an increase in neuronal cell number in the myenteric plexus have been noted 
in a number of reports (Dvorak and Silen, 1985; Steinhoff et al., 1988). Vagal and spinal 
sensory neurons arise from different regions in the brain stem and terminate along the gut 
wall either in the large or small intestine and stomach. Due to nerve hyperplasia following 
intestinal inflammation, there is altered neuronal signaling in the hypothalamus-pituitary axis 
(HPA) (Bonaz and Bernstein, 2013). Interestingly, the substantia nigra (SN) region is 
presented immediately caudal to the hypothalamus. Dopaminergic neurons are present in the 
SN and these neurons pass through the hypothalamus as they extend rostral, to the striatum. 
The SN region plays an important role in reward and movement and loss of dopaminergic 
neurons in the substantia nigra pars compacta results in development of Parkinson’s disease 
(PD). Notably, about 25-80% PD patients suffer from chronic GI problems including 
dyspepsia, dysphagia, excessive drooling or constipation and are thought to suffer from 
chronic intestinal inflammation compared to healthy individuals (Mishima et al., 2017; 
Shannon et al., 2012). Taking these facts into consideration, we hypothesize that peripheral 
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inflammation resulting from UC could be the trigger to develop neuroinflammation in the 
SN.   
 
Materials and Methods 
Chemicals 
Dextran sodium sulfate (DSS) was obtained from MP Biomedicals (Cat. # 02160110). 
Antibodies CD68 (Cat. # MABF216) and glial fibrillary acidic protein (GFAP, Cat. # 
MAB360) were obtained from Millipore. Tumor necrosis factor- alpha antibody (TNFα, Cat. 
# AF-410-NA) was purchased from R&D signaling while inducible nitric oxide synthase 
(iNOS, Cat. #D6B6S) was bought from cell signaling technologies and prokineticin-2 (PK-2, 
Cat. #sc-67176) was obtained from Santa Cruz. β-actin was purchased from Sigma (Cat. # 
A2228). Hoechst 33342 nuclear stain was purchased from Invitrogen (H3570).  
 
Animal studies 
We purchased 10-12 week old C3H mice from Harlan laboratory for all animal experiments. 
Mice were housed on a 12-h light cycle with ad libitum access to food and water. After 3 
days of acclimatization, mice received 3% DSS in drinking water for 7 days followed by 
regular tap water for 3 days or tap water for the entire duration of the study. This dose 
regimen was chosen based on previous rodent studies (Chaluvadi et al., 2009; Lange et al., 
1996; Sanders et al., 2006).  Animal care procedures strictly followed the NIH Guide for the 
Care and Use of Laboratory Animals and were approved by the Iowa State University 
IACUC. Body weight and whole gut transit time were measured every 10 days. At the end of 
the treatment regimen, animals were euthanized by CO2, and then 3-cm strips of the colon 
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were collected and emptied of their contents by rinsing thoroughly in ice-cold PBS. Tissues 
were further excised into 1-cm pieces for various biochemical tests and stored at -80°C till 
further processing. 
 
Tissue collection 
Following euthanasia, the colon and cecum were removed and washed in phosphate-buffered 
saline (PBS). Colons were placed on filter papers to measure colonic lengths, score 
macroscopic cecal lesions, and obtain photographs of each tissue. Gross cecal lesions were 
scored using published criteria (Ye et al., 2009). Macroscopic cecal lesions were scored 0–4 
as follows: no gross lesions (grade 0, normal); evidence of atrophy (grade 1, mild); excess 
intraluminal mucus with atrophy localized to the cecal apex (grade 2, moderate); generalized 
cecal atrophy with increased intraluminal mucus and no cecal contents (grade 3, severe); and 
score 3 plus bloody cecal content (grade 4, most severe. 
 
Multiplex cytokine Luminex immunoassays 
Blood was collected following terminal cardiac puncture and placed in serum collection 
tubes and frozen at −80°C. The levels of cytokines and chemokines in the supernatants were 
determined using the Luminex bead-based immunoassay platform (Panicker et al., 2015; 
Vignali, 2000) and prevalidated multiplex kits (Milliplex mouse cytokine panel, Millipore) 
according to the manufacturer's instructions. 
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Quantitative real-time PCR (qRT-PCR) 
Ten tissues of distal colon from control and DSS-treated groups were utilized for qRT-PCR. 
The samples were homogenized in a bullet blender (Next Advance) using DNAse- and 
RNAse-free stainless steel beads and RNA was extracted using RNeasy Plus Mini kit 
(Qiagen). 1 µg total RNA was converted to cDNA using the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems Inc.) following manufacturer's instructions. Real-time 
PCR was performed in an Mx3000P QPCR system (Stratagene) using the Brilliant SYBR 
Green QPCR Master Mix kit  (Stratagene), with cDNAs corresponding to 0.5 µg of total 
RNA, 10 µl of 2 × master mix and 0.2 µM of each primer in a 20-µl final reaction volume. 
All reactions were performed in triplicate. Mouse 18S rRNA was used as an internal standard 
for normalization. Validated QuantiTect primer sets for mouse 18S rRNA (Cat# 
QT02448075), TNFα (QT00104006), IL-1β (QT01048355) and iNOS (QT00100275, 
Qiagen) were also used. The PCR cycling conditions contained an initial denaturation at 
95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 60°C 
for 30 sec, and extension at 72°C for 30 sec. Fluorescence was detected during the annealing 
step of each cycle. Dissociation curves were run to verify the singularity of the PCR product. 
Data were analyzed using the comparative threshold cycle (Ct) method (Schmittgen and 
Livak, 2008).  
 
Western blots 
Whole cell lysates or tissue lysates were prepared using modified radio immune precipitation 
assay (RIPA) buffer containing 20 mM Tris–HCl, pH 8.0, 2 mM EDTA, 10 mM EGTA, 2 
mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 20mM sodium 
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orthovanadate, 1 mM sodium fluoride and protease and phosphatase inhibitor cocktail 
(Thermo Scientific, Waltham, MA), as described previously (Harischandra, Kondru et al. 
2014, Harischandra, Jin et al. 2015). The supernatants were obtained after centrifuging the 
homogenates at 15,000 rpm for 60 min. Protein concentration was measured using Bradford 
dye (Bio-Rad). Lysates containing equal amounts of protein were separated on a 12 or 15% 
SDS-polyacrylamide gel. After separation, proteins were electro-blotted onto a nitrocellulose 
membrane, and nonspecific binding sites were blocked with LICOR blocking buffer. PGP9.5 
(1:1000), GFAP (1:1200), Bax (1:500), iNOS (1:500) and β-actin (1:10000) primary 
antibodies were used to blot the membranes for 16 h at 4°C. Thereafter, blots were washed in 
phosphate buffered saline (PBS) containing 0.01% Tween-20, incubated in respective 
secondary antibodies (Alexa Goat anti mouse 680 or Alexa Goat anti-rabbit 800) for 1 hour. 
Fluorescent bands corresponding to the protein of interest were observed by scanning 
membranes in a LICOR scanner. 
 
Monoamine assessment via High performance liquid chromatography 
Dissected colon segments were placed in buffer comprising 0.2 M perchloric acid, 0.05% 
Na2EDTA, 0.1% Na2S2O5 and isoproterenol (internal standard) and stored at -80°C until 
lysate preparation. To extract monoamine neurotransmitters, the samples were homogenized 
using bullet blender and 0.2 mm diameter stainless steel beads. Lysates were centrifuged and 
300 µl of lysate was added to 30 mg alumina. The pH of the solution was quickly increased 
to 8.6 using 1M Tris buffer. The tubes were now rotated in a rotating shaker at 4°C for 15 
minutes and then centrifuged at 10,000 rpm. The supernatant was aspirated and the 
monoamine neurotransmitters were eluted form the alumina with 0.2 M perchloric acid.  
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Monoamine lysates were placed in a refrigerated automatic sampler (model WPS-3000TSL) 
until being separated isocratically by a reversed-phase C18 column with a flow rate of 
0.6 ml/ min using a Dionex Ultimate 3000 HPLC system (pump ISO-3100SD, Thermo 
Scientific, Bannockburn, IL). Electrochemical detection was achieved using a CoulArray 
model 5600A coupled with an analytical cell (microdialysis cell 5014B) and a guard cell 
(model 5020) with cell potentials set at -350, 0, 150, and 220 mV. Data acquisition and 
analysis were performed using Chromeleon 7 and ESA CoulArray 3.10 HPLC Software and 
quantified data were normalized to wet tissue weight.  
 
Immunocytochemistry and Immunohistochemistry 
For Immunohistochemistry, at the end of the treatment regime, animals were perfused first 
with PBS followed by 4% PFA. Guts were removed and post-fixed in 10% formalin for an 
additional 24 h. Tissues were embedded in paraffin and sectioned at 7 µm at Iowa State 
University’s veterinary pathology lab. Paraffin-embedded sections of mouse tissues were 
deparaffinized in decreasing alcohol grades. Heat-mediated antigen retrieval was performed 
using 10 mM citrate buffer (pH 6.0) for 30 min. Sections were then incubated with blocking 
reagent (5% normal goat serum, 2% BSA and 0.5% Triton X-100 in PBS) for 60 min before 
being incubated with iNOS, CD68, PGP9.5 or GFAP primary antibodies for 24 h at 4°C. 
Sections were then washed many times in PBS and incubated in the dark for 90 min with 
Alexa-488 and 555 dye-conjugated secondary antibodies (1:1500). Nuclei were stained with 
Hoechst dye (1:5000) for 10 minutes at room temperature. Slides were viewed with 63× and 
43× oil objectives using a Leica DMIRE2 confocal microscope. 
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Following perfusion, the rodent brains were removed and post fixed in 4% PFA for an 
additional 24 hours. To ensure cryopreservation of tissue architecture, the fixed brains were 
suspended in 30% sucrose for 3 days. The fixed brains were then embedded in OCT blocks 
and cryosectioned at 30 µm to obtain free-floating sections. The sections were washed in 1X 
PBS followed by heat mediated antigen retrieval using citrate buffer (pH 8.0) for 30 minutes. 
After blocking for 1 hour (5% normal goat serum, 2% BSA and 0.5% Triton X-100 in PBS) 
the sections were incubated in primary antibodies CD68 (mouse monoclonal, 1:300) and 
iNOS (rabbit monoclonal, 1:350) for 14 hours at 4°C followed by washing and secondary 
antibody application as mentioned above. Nuclei were stained with Hoechst dye (1:5000) for 
10 minutes at room temperature. Slides were viewed with 63× and 43× oil objectives using a 
Leica DMIRE2 confocal microscope 
 
Statistical analysis 
All data are means ± standard error (SE). Unpaired t-test was used for statistical analysis 
using Graphpad Prism v.6.01. P-values less than 0.05 were considered to indicate statistical 
significance. 
 
Results 
Acute DSS-induced ulcerative colitis results in intestinal mucosal and sub-mucosal 
damage as well as systemic inflammation 
We have used a known and validated DSS regime to induce acute colitis in these mice 
(Figure 1A). Thus mice given 3% DSS in drinking water for 7 days begin to show a steady 
decline in body weight (Figure 1B), movement and food consumption with some rectal 
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bleeding. Even after the mice receive regular drinking water without DSS, they do not regain 
their body weight by the end of the study. Following completion of the study, the colon was 
excised and gross observations were made. DSS treated (n=11) mice had shortened colons 
having cecal atrophy, enlarged cecal tonsil with thickening of the cecal and colon muscle 
wall (S. Table 1). A few mice (~50%) showed absence of formed fecal pellets indicating loss 
of colonic contractility in these mice. Such observation was not seen in any colon from the 
control group (n=10). There was considerable shortening of the colon with the average length 
in the DSS group being 6.9 cm compared to 9.3 cm seen in the control group (Figure 1C). 
Importantly, based on the high scores obtained by our scoring system (Figure 1E) as well as 
photographic evidence (Figure 1D), DSS treated mice showed much tissue damage compared 
to the control group. With pronounced weight loss and sickness behavior observed, we also 
assessed cytokine levels in the serum from both groups. As expected, DSS treated mice 
showed higher levels of IL-6 and IL-12 (Figure 1F) compared to control animals indicating 
peripheral inflammation following induction of UC.   
 
Intestinal inflammation induces enteric neuronal and glial cell expression affecting 
monoamine neurotransmitter signaling.  
Histological observation of hematoxylin and eosin stained sections showed alteration of the 
epithelia, massive immune cell infiltration in the mucosa and sub-mucosa and loss of crypts 
(Figure 2A). Distal colons from the DSS group had pronounced increase in pro-inflammatory 
factors such as TNFα, IL-1β and iNOS compared to the untreated group (Figure 2B). Loss of 
colonic epithelia leads to increased translocation of intestinal bacteria into the mucosa and 
deeper muscle layers exacerbating inflammation. The resulting intestinal damage and 
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inflammation results in pronounced immune cell migration with lymphocytes and neutrophils 
prominently seen at the sight of lesion (Campaniello et al., 2017). Indeed, colon sections 
from DSS treated mice showed increased iNOS and CD68+ immune cell influx at the sight of 
lesion compared to the few patrolling cells usually observed in healthy GI tissue (Figure 2C).   
 
Interestingly, we observed a decrease in dopamine (DA) and serotonin (5-HT) levels with no 
significant differences in their metabolites DOPAC and 5-HIAA respectively (Figure 3A). 
We also observed an increase in metabolite turnover (Figure 3B) indicating either a reduction 
in DA and 5-HT synthesis or reduced re-uptake by corresponding receptors. We then 
analyzed common DA and 5-HT receptor levels in the colon and found that the receptor 5-
HT4 had lower mRNA transcripts in the inflamed colon in comparison to the control group 
(Figure 3C). 5-HT4 is mainly expressed in the colonic epithelium and mediates mucus 
secretion from and degranulation of goblet cells, chloride secretion from enterocytes and 5-
HT production from enterochromaffin cells (Hoffman et al., 2012).  Importantly, agonists of 
this receptor promote GI motility and reduce visceral pain (Kim, 2009; Sengupta et al., 
2014). Thus reduced expression of this receptor can be linked to the sickness behavior and 
loose feces observed in the DSS treated mice. Acute DSS treatment increased the 
transcription of prokineticin-2 (PK-2, Figure 3D), a secreted protein that can potently induce 
GI contractions (Li et al., 2001). Immune cells also mainly secrete it during intestinal tissue 
damage. The presence of increased iNOS and PK-2 proteins were also quantified by Western 
blot. A 3-fold increase in iNOS and 3.5-fold increase in PK-2 was observed in DSS exposed 
colons compared to colons from untreated group (n=3-4, Figure 3F) Increased inflammation 
and corresponding intestinal damage has been linked to increased neurogenesis in the gut to 
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counteract the loss of enteric neurons and glial cells from the mucosal and sub-mucosal 
regions that are primarily affected in UC (Belkind-Gerson et al., 2015). Surprisingly, in this 
model of acute colitis we did not see increased expression of neurons (PGP9.5) or enteric glia 
(GFAP, Figure 3F) Rather, there was a decrease in glial derived neurotrophic factor (GDNF, 
Figure 3E), a protein involved in neurogenesis. Together, the data points towards acute colitis 
altering monoamine neurotransmitter production and signaling by downregulating their 
specific receptors. The immune influx and intestinal damage leads to high production of 
inflammatory factors that further exacerbate the inflammation leading not only to epithelial 
sloughing but also enteric neuronal and glial death. 
 
Intestinal inflammation leads to increased pro-inflammatory cytokine production in the 
lumbosacral region of the spinal cord 
 While much research has focused on the role of the vagus nerve as an important conduit for 
signaling along the gut-brain axis, limited research has been conducted with regards to the 
spinal cord (Van Der Zanden et al., 2009). The spinal cord is divided into 4 regions with the 
lumbar and sacral spinal afferents projecting in the ileum and colon. Following induction of 
UC, 2-3 fold increase in the mRNA of pro-inflammatory cytokines TNFα and IL-1β as well 
as iNOS was observed in the lumbosacral region of the spinal cord (Figure 4A). Despite 
presence of increase inflammatory transcripts, we did not observe an increase in the resident 
immune cells- the microglia or in astrocytes as there was no significant increase in Iba-1 or 
GFAP protein expression (Figure 4B).  
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Neuroinflammation and peripheral immune infiltration is observed in the midbrain 
following induction of DSS-induced ulcerative colitis 
Enteric inflammation is commonly observed in PD, autism and schizophrenia (Devos et al., 
2013; Schieve et al., 2012; Severance et al., 2012). However, it is not known whether 
intestinal inflammation precedes and drives neurological dysfunction or is a consequence of 
it (Engelender and Isacson, 2017). Hence we analyzed the substantia nigra pars compacta 
(SNpc)- an important region that regulates fine motor control and reward behavior and is the 
primarily affected in PD. SNpc from the DSS treated group showed increased mRNA 
transcripts of iNOS and IL-1β (Figure 5A). Both pro-inflammatory factors were increased 
about 2-fold when compared to SNpc samples from the untreated group. Interestingly, while 
we did not observe any gliosis or microglial activation in the SNpc (Figure 5B), we did 
observe more Iba-1+ microglia in the ventral hypothalamic nuclei (Figure 5C). Together, the 
data suggests that acute DSS-induced colitis potentially primes the SNpc where there is an 
increased transcript level of pro-inflammatory factors. 
 
Discussion 
Ulcerative colitis is a chronic intestinal inflammatory condition with intermittent recurrences 
despite proper medications. The disease is characterized by loss of colonic epithelia and 
inflammation in the mucosa and sub-mucosa. In most cases, the body is unable to regulate 
the sustained mucosal immune response resulting in greater production of inflammatory 
cytokines and chemokines leading to tissue damage (Parray et al., 2012). In most cases, the 
chronicity of intestinal inflammation leads to alterations in the autonomic nervous system 
(ANS) with nerve hyperplasia in the affected tissue and fluctuations in neurotransmitter 
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signaling (Neunlist et al., 2003). However, do the effects on the ANS lead to changes in the 
CNS? To answer this pertinent question, we used a known mouse model of UC. C3H mice 
given 3% DSS for 7 days followed by 3 days of normal drinking water mimics the acute 
phase of UC with distal colonic inflammation (Figures 1D and 1E), damage to the mucosa 
and sub-mucosa (Figure 2A) and shortening of the colon (Figures 1C and 1D). Influx of 
macrophages was evident in DSS treated colons (Figure 2C) and high production of iNOS 
and other pro-inflammatory factors (Figure 2B and 3F). Notably despite removal of DSS 
from drinking water in the last 3 days before completion of the study, the mice continued to 
loose weight (Figure 1B) and had peripheral inflammation as evidenced by high levels of IL-
6 and IL-12 in the serum of DSS exposed mice compared to untreated mice (Figure 1F). IL-6 
plays an important role in differentiation of Th17 cells and is vital in preventing intestinal 
epithelial apoptosis during inflammation. Hence elevated IL-6 levels in the serum might be a 
counteractive measure against loss of colonic epithelia. However, IL-6 is also involved in 
propagating inflammation and its continued presence is considered harmful in many chronic 
diseases such as rheumatoid arthritis, ischemia and PD (Chao et al., 2014; Liang et al., 2009; 
Zhang et al., 2015).  
Acute colitis also resulted in a decrease in serotonin (Figure 3A) and increased turnover in 
dopamine and serotonin metabolites (Figure 3B). Loss of enteric neuronal or glial terminals 
in the sub-mucosa and mucosa as well as loss of enterochromaffin cells present in this region 
might lead to a decrease altered neurotransmitter production. The increased monoamine 
neurotransmitter turnover might be due to loss of DA or 5-HT receptors. Hence we screened 
various neurotransmitter receptors present in the gut (data not known). We observed a down-
regulation of 5-HT4 receptor transcript in the distal colon (Figure 3C). This was an 
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interesting observation as we had also found a lack of formed fecal pellets in many colons 
from the DSS group (Figures 1D). 5-HT4 receptors are present mainly in the mucosa while a 
subset (5-HT4e and 5-HT4f) are mainly present on pre-synaptic terminals (Liu et al., 2005). 
The main function of these presynaptic 5-HT4 receptors is to increase excitatory 
neurotransmission thus inducing prokinetic effect on the smooth muscles. This initiates 
intestinal smooth muscle contraction. Even the 5-HT4 receptors present in the mucosa initiate 
motility and reduce visceral hypersensitivity (Hoffman et al., 2012). Thus a loss of 5-HT4 in 
the affected portion of the colon can reduce the propulsive action and contractility required 
for proper fecal pellet formation. However following loss of 5-HT4 receptor expression, the 
body might produce prokinetics that would directly act on smooth muscles leading to 
contraction. This might be the reason why increased PK-2 was observed in the same regions 
that had lower transcript level of 5-HT4 receptors. PK-2 is predominantly expressed by 
infiltrating macrophages and neutrophils at the site of intestinal lesion and can enhance GI 
motility (Watson et al., 2012). Increased production of PK2 might potentiate contraction 
allowing the non-inflamed regions the colon to come closer minimizing intestinal 
permeability. However, more work needs to be conducted with PK-2 knockout mice to 
validate this theory. 
 
Perhaps the most interesting observation made was the presence of increased inflammatory 
transcripts in the spinal cord and SNpc region in the brain following acute colitis.  A modest 
increase of iNOS, IL-1β and even TNFα was observed in both regions despite these areas not 
being the primary site of inflammation (Figures 4A and 5A). We did not observe such 
increase in pro-inflammatory transcripts in other parts of the brain (data not shown). Hence 
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intestinal inflammation possibly influenced neuroinflammation in the mid-brain possibly 
through the pelvic and sacral nerves that innervate the colon and rectum- incidentally the two 
regions most affected by UC. It is possible that the HPA axis is activated leading to stress 
and sickness behavior observed in other studies of DSS induced colitis (Melgar et al., 2008; 
Reichmann et al., 2015).  
The presence of peripheral inflammation might condition the host’s immune system to a pro-
inflammatory profile. Initially thought to be an immune privileged site, we now know that 
peripheral immune cells routinely patrol the CNS sampling antigens and surveilling the CNS 
much like the brains own resident immune cells- the microglia. While increased 
inflammation in the SNpc did not correspond to activation of the astrocytes, microglia or 
peripheral immune cells infiltration, we did observe a modestly elevated microglial density in 
DSS- treated ventromedial hypothalamus (Figure 5C). Villarán et al have shown that 
ulcerative colitis in mice exacerbated lipopolysaccharide induced SN damage (Villaran et al., 
2010). It is possible that the acute phase of this disorder primes the microglia to hyper 
vigilant state with exaggerated immune response that would be observed as the disease 
progresses. Serum IL-6 can increase the porosity of the blood brain barrier leading to influx 
of not only peripheral immune cells but also potential toxic substances and other pro-
inflammatory factors thus generating neuroinflammation in the CNS. Together the data 
points towards neuroinflammation in the mid-brain region brought on by intestinal 
inflammation that can lead to development of exaggerated microglial activation if the 
peripheral inflammation continues unabated. 
Future studies aimed at validating these findings in UC patients post-mortem is needed. 
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Figures 
 
Figure 1: Acute DSS-induced ulcerative colitis induces tissue damage to the colon 
(A) Treatment paradigm. (B) Body weight change. Body weight change was calculated for 
each mouse by dividing its body weight on the specified day by its weight at day 0 (C) Colon 
length in centimeters. (D) Representative photos of colon from control (upper panel) and 
DSS group (lower panel) at day 10. (E) Inflammation scoring based on gross observation of 
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the cecum and colon from each animal in both groups. (F) Analysis of serum IL-6 and IL-12 
levels from mice in each group in pictograms per milliliter serum. Data represented as the 
group mean ± SEM from n=10 or n=11. Asterisks (*p<0.05, **p<0.01 and ***p<0.001) 
indicate significant differences between DSS-treated group and control. 
 
 
Figure 2: Immune cell infiltration at site of inflammation in the colon 
(A) Representative 10x images of hematoxylin and eosin-stained colon sections from 
untreated and DSS-treated groups (n=3). Scale bar = 50 µm. (B) qRT-PCR analysis of TNFα, 
IL-1β and iNOS mRNA transcripts, normalized to 18S rRNA expression (n=7). (C) 
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Representative 60x immunofluorescence images showing increased iNOS production in the 
distal colon of DSS-treated mouse when compared to control. Scale bar = 25.4 µm. Arrows 
indicate presence of iNOS staining. Data represented as the group mean ± SEM. Asterisks 
(***p<0.001) indicate significant differences between DSS-treated group and control. 
 
 
Figure 3: Acute colitis leads to altered neurotransmitter and their receptor levels and 
increased prokineticin-2. (A) HPLC analysis of monoamine neurotransmitter levels in the 
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distal colon in nanograms per miligram tissue. (B) Turnover ratio of metabolite to its 
neurotransmitter. (C) q-RT PCR analysis of 5-HT4 receptor transcripts normalized to 18s 
rRNA expression (n=6) (D) q-RT PCR analysis of PK-2 transcripts normalized to 18s rRNA 
expression (n=7) (E) q-RT PCR analysis of GDNF receptor transcripts normalized to 18s 
rRNA expression (n=10) (F) Representative Western blots showing increased iNOS and PK-
2 expression in DSS treated colons compared to the untreated group. No significant change 
in GFAP expression is observed between the two groups. Data represented as the group mean 
± SEM. Asterisks (*p<0.05, **p<0.01 and ***p<0.001) indicate significant differences 
between DSS-treated group and control. 
 
 
Figure 4: DSS induced colitis potentiates inflammation in the spinal cord 
(A) qRT-PCR analysis of TNFα, IL-1β and iNOS mRNA transcripts, normalized to 18S 
rRNA expression (n=6). (B) Representative Western blots showing no significant difference 
in GFAP, TNFα or IBA-1 expression in the spinal cord between control and DSS groups. 
Data represented as the group mean ± SEM. Asterisks (*p<0.05, **p<0.01 and ***p<0.001) 
indicate significant differences between DSS-treated group and control. 
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Figure 5: Acute colitis potentiates inflammation in the mid-brain 
(A) qRT-PCR analysis of TNFα, IL-1β and iNOS mRNA transcripts, normalized to 18S 
rRNA expression (n=6). (B) Representative Western blots showing no significant difference 
in GFAP or IBA-1 expression in the substantia nigra between control and DSS groups. (C) 
Representative 30x images of microglia in the ventromedial hypothalamus. Modest increase 
in IBA-1 positive microglia present around the 3rd ventricle in the ventromedial hypothalamic 
region of DSS group compared to control. Data represented as the group mean ± SEM. 
Asterisks (*p<0.05) indicate significant differences between DSS-treated group and control. 
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S. Table 1: Inflammation scoring based on gross observations 
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GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
This section presents an overview of the results and findings of this dissertation, with 
special emphasis on their overall implications for the role of intestinal inflammation in 
priming the CNS to develop neuroinflammation. The major findings of each research chapter 
included in this dissertation are covered in the discussion section of the relevant chapter.  
CHRONIC EXPOSURE TO ENVIRONMENTAL TOXIN MANGANESE (Mn) 
LEADS TO INTESTINAL INFLAMMATION AND SUBSEQUENT ALTERATIONS 
IN GASTROINTESTINAL PHYSIOLOGY 
The enteric nervous system, which plays an important role in maintaining gut physiology, 
consists of enteric neurons and glia. Enteric glia cells (EGCs) share similar features with 
astrocytes present in the CNS, namely, presence of glial fibrillary acidic protein (GFAP) as 
well as S-100β as cell markers (Jessen and Mirsky, 1983). EGCs play an important role in 
supporting intestinal health by regulating the intestinal-epithelial barrier and acting as a 
bridge between neuronal and immune signaling circuits (Gulbransen and Sharkey, 2012). 
Hence, maintaining a healthy population of EGCs is necessary to maintain proper intestinal 
function. Manganese (Mn) is a an important divalent metal that is required in trace amounts 
for our normal body functioning (Avila et al., 2013), but chronic exposure to excessive Mn 
induces a Parkinsonian-like neurotoxic response.  The effect of low-dose Mn on EGCs has 
not been well characterized.  
In this chapter, we demonstrated that low nanomolar doses of Mn affect EGCs by 
compromising mitochondrial health. Notably, the low doses caused only cell stress rather 
than cell death, a point of particular importance because human exposure to Mn occurs 
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mainly in low doses rather than a single high dose. Typically, at higher doses of Mn exposure 
we found both caspase-3-mediated apoptosis as well as necrotic cell death.  
However, the gut is made up of different cell types present in distinct layers. Hence, to get a 
better sense of how Mn affects GI tissues, we developed methods for a new primary enteric 
culture representing all major cell types in the GI tract. The kinetics of Mn-induced toxicity 
changed considerably in this mixed culture with a 100-µM Mn exposure inducing metabolic 
stress in the cell population as a whole. Specifically, it caused production of inflammatory 
factors such as TNFα, IL-1β and iNOS, culminating in neuronal cell death. 
In an in vivo model of chronic exposure, we observed that even a low dose of Mn causes 
modest but definite changes in the GI tract. Specifically, 15 mg/kg/day Mn for 30 days 
induced mild colonic inflammation without causing any overt tissue damage. Chronic 
exposure to this metal down regulated expression of the Mn exporters ferroportin and 
SLC30A10 with no change in the Mn importer DMT1. This indicates that Mn was 
accumulating in the gut tissue during chronic low-dose exposure. ICP-MS of colonic tissue 
further confirmed that Mn-exposed animals had significantly higher Mn content in the 
intestine compared to unexposed controls. Importantly, Mn-exposed mice required more time 
for food to be absorbed and removed as waste compared to control mice, suggesting that 
normal intestinal peristalsis was affected following Mn treatment. Finally we showed that 
Mn exposure alters intestinal physiology affecting carbohydrate and especially fatty acid and 
amino acid synthesis with more pro-inflammatory-provoking short chain fatty acids produced 
in the presence of elevated Mn. While gut microbial populations did not differ significantly 
between groups, we did observe an increase in Gammaproteobacteria at Day 20, incidentally 
at the same time we observed increases in whole gut transit time. It is important to note that 
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the concentration of Mn that we administered to mice was comparable to the elevated levels 
found in groundwater (Bouchard et al., 2011).  
Future studies will be aimed at decoding the molecular and biochemical signaling 
pathways that stressed EGCs employ and how the presence of Mn skews the host’s 
physiology.  Utilization of cell culture models for mechanistic studies will provide new 
insights into the Mn-induced neurotoxicity response of the ENS. 
 
SPATIAL DIFFERENCES IN GUT MOTILITY IN THE MITOPARK MOUSE 
MODEL OF PARKINSON’S DISEASE 
In Chapter 2, we demonstrated for the first time how chronic exposure to even low doses of 
Mn affect intestinal physiology. Occupational exposure to Mn can lead to “manganism”, a 
neurological condition showing motor symptoms similar to Parkinson’s disease (PD) 
(Gunnarsson and Bodin, 2017). PD is thought to be a complex interplay of genetic and 
environmental factors (Warner and Schapira, 2003). While PD is defined by the presence of 
motor deficits such as muscle rigidity and a slow shuffling gait, incoordination, resting 
tremor and postural instability, recent studies have shown that sleep disturbances, 
constipation and anosmia are seen in most patients decades before actual disease diagnosis. 
Hence, it is important to understand whether these non-motor symptoms potentiate 
neurological dysfunction or are an early consequence, affected even by slight changes in 
neurological signaling. 
The MitoPark mouse model of PD mimics the adult onset and age-dependent dopaminergic 
neuron loss typically seen in PD patients (Ekstrand and Galter, 2009). Much emphasis has 
been given to this model’s use as a tool to study the progressive motor symptoms associated 
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with PD. However, characterization of its non-motor symptoms, especially GI dysfunction, 
has yet to be systematically carried out. In our study, we systematically observed CNS-
related behavior and GI motility in mice ranging in age from 8-24 weeks of age. MitoPark 
mice began to exhibit significant loss of dopaminergic neurons from 12-16 weeks of age, 
during which time we also observed lower reserves of dopamine in the colon. MitoPark mice 
showed increased colon transit time at 24 weeks compared to age-matched littermate controls 
(LCs), thus displaying a constipated phenotype similarly seen in PD patients. Paradoxically, 
the small intestine’s transit time seemed to be faster than that in LC mice, leading us to 
speculate that the effect of dopamine (dopamine signaling) on smooth muscle contraction 
differed between the small and large intestines. For instance, dopamine acting on DA1 
receptors on smooth muscles causes muscle relaxation, while the same neurotransmitter 
acting on DA2 receptors present on post-ganglionic sympathetic nerves counteracts the effect 
of norepinephrine-induced muscle relaxation, thereby inducing contraction (Kirschstein et 
al., 2009; Zizzo et al., 2010). We found no significant difference between D1 and D2 
receptor expression in the colon. We speculate that alpha- and beta-adrenergic receptors 
might play a more important role in dopamine-induced muscle contraction or relaxation as 
they are known to be part of the dopamine circuitry (Bech et al., 1982; Seiler et al., 2005). 
More studies need to be conducted to understand how PD-related dopamine loss contributes 
to opposing motility behavior in the small and large intestine. Despite the loss of 
dopaminergic neurons, we did not observe significant differences in the enteric neuronal 
population, suggesting that other neuronal sub-types might be altered in response to reduced 
dopamine to counteract the effects brought upon by dopamine loss. An interesting 
observation that needs further investigation is the role of the hypothalamus-pituitary axis 
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(HPA) in the context of PD. We observed increased levels of neuropeptide Y, a peptide that 
plays an important role in regulating hunger. We observed increased NpY in the 
hypothalamus of MitoPark mice displaying normal feeding behavior despite prominent 
weight loss. Such weight loss in animals with an otherwise normal appetite relative to LCs 
brings us back to the motility deficits in these animals. Small intestine motility affects 
digestion and absorption of nutrients, while colonic peristalsis is required for water and 
electrolyte absorption. Hence, faster motility in the small intestine means that nutrients are 
not optimally absorbed despite a healthy diet. These results have implications for PD 
treatment and diet and hence future studies will focus on understanding the neurochemical 
differences between the small and large intestines and how dopamine possibly plays dual 
roles in these regions. 
 
ULCERATIVE COLITIS INDUCES INFLAMMATION IN THE MID-BRAIN: 
IMPLICATIONS OF INTESTINAL INFLAMMATION AND THE GUT-BRAIN 
AXIS IN DRIVING NEUROINFLAMMATION IN THE CNS 
Intestinal inflammation has been observed in many neurological disorders, while 
neurological complications are found in patients with chronic intestinal inflammation. In 
chapter 4, we explore the role of intestinal inflammation in driving neuroinflammation in the 
CNS.  DSS-induced acute colitis resulted in the expected colonic inflammation and damage 
to the mucosa and sub-mucosa. Consistent with other studies, we observed immune cell 
influx at the sight of these lesions together with increased iNOS production (Camuesco et al., 
2004). The inflamed colons had lower levels of the neurotransmitter serotonin with increased 
metabolite turnover possibly due to decreased expression of 5-HT4 receptors. Serotonin and 
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5-HT4 are involved in contraction of smooth muscle cells (Spiller, 2001). This could explain 
why we observed fewer formed fecal pellets in the colons of DSS mice. DSS-treated animals 
also expressed high levels of prokineticin-2 (PK2) in the distal colon. Increased production of 
PK2 might potentiate contraction of GI tissue allowing the non-inflamed regions of the colon 
to develop toward ulcerative colitis (UC) (Catalano et al., 2010). Interestingly, we also 
observed more pro-inflammatory transcripts of TNFα, IL-1β and iNOS in the lumbosacral 
region of the spinal cord and in the substantia nigra with a slightly elevated microglial 
density in the ventromedial hypothalamus. Hence, intestinal inflammation may have 
influenced neuroinflammation in the mid-brain possibly through the pelvic and sacral nerves 
that innervate the colon and rectum. It is possible that the HPA is activated leading to the 
stress and sickness behavior observed in other studies of DSS-induced colitis.  Together, our 
data suggest a possible priming of the mid-brain region towards neuroinflammation 
following intestinal inflammation. 
Since it is difficult to differentiate peripheral immune infiltration from resident microglial 
populations in the brain due to overlapping cellular markers, peripheral cell influx following 
induction of UC needs to be studied using flow cytometry. Future studies should focus on the 
possible priming of the mid-brain to produce more inflammatory cytokines as well as on 
changes in blood-brain barrier porosity and peripheral immune infiltration. These three 
pathological changes are consistent with observations from post-mortem PD cases.  
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ABSTRACT 
A progressive loss of neuronal structure and function is a signature of many 
neurodegenerative conditions including chronic traumatic encephalopathy, Parkinson’s, 
Huntington’s and Alzheimer’s diseases. Mitochondrial dysfunction and oxidative and 
nitrative stress have been implicated as key pathological mechanisms underlying the 
neurodegenerative processes. However, current therapeutic approaches targeting oxidative 
damage are ineffective in preventing the progression of neurodegeneration. Mitochondria-
targeted antioxidants were recently shown to alleviate oxidative damage. In this work, we 
investigated the delivery of biodegradable polyanhydride nanoparticles containing the 
mitochondria-targeted antioxidant Mito-Apocynin (Mito-Apo) to neuronal cells and the 
ability of the nano-formulation to protect cells against oxidative stress. The nano-formulated 
Mito-Apo provided excellent protection against oxidative stress-induced mitochondrial 
dysfunction and neuronal damage in a dopaminergic neuronal cell line, mouse primary 
cortical neurons, and a human mesencephalic cell line. Collectively, our results demonstrate 
that nano-formulated Mito-Apo may offer improved efficacy of mitochondria-targeted 
antioxidants to treat neurodegenerative disease.  
 
Key words: Neurodegeneration; Oxidative stress; Polyanhydride nanoparticles; Mito-
Apocynin 
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Introduction 
Neurodegenerative diseases such as chronic traumatic encephalopathy (CTE), Alzheimer’s 
Disease (AD), Parkinson’s Disease (PD) and stroke are becoming more prominent as the 
world population ages (Tofaris and Schapira, 2015). These diseases typically manifest mid- 
to late-life and progressively worsen with increased morbidity. Chronic exposure to 
environmental toxins such as manganese in fertilizers and welding fumes (Harischandra et 
al., 2015), pesticides such as paraquat and rotenone, and brain trauma caused by a single or 
successive concussive blows to the head increase the risk of developing neurodegenerative 
disease (Goldstein et al., 2012). In terms of head trauma, Lehman et al. (Lehman et al., 2012) 
conducted a post-mortem review of the brains of ex-National Football League athletes, which 
revealed signs of protein misfolding and tauopathy seen in AD patients. Peskind et al. 
(Peskind et al., 2011) reported that soldiers exposed to improvised explosive devices showed 
cognitive impairment and deficits in speech and attention span. The economic burden 
associated with the increased medical management of neurodegenerative diseases and 
decreased individual productivity is projected to escalate steeply, making it increasingly 
urgent to develop effective medications. Currently, drugs are available on the market that 
manage the symptoms of CTE, AD, and PD. However, they do not slow disease progression.  
 
One of the major disease mechanisms of neurodegeneration is mitochondrial dysfunction, 
which contributes to oxidative stress through the build-up of reactive oxygen species and 
reactive nitrogen species. While anti-inflammatory and antioxidant drugs have been 
developed, the major factors compromising efficacy include reduced drug diffusion through 
the blood-brain barrier (BBB), limited availability due to drug metabolism, and undesirable 
218 
 
 
side effects. In this context, the non-toxic plant-derived molecule apocynin (4-hydroxy-3-
methoxyacetophenone) has been used as an antioxidant and an inhibitor of NADPH oxidase 
in pre-clinical models of PD (Anantharam et al., 2007; Cristovao et al., 2009; Gao et al., 
2003). At a high dose of 300 mg/kg, its dimer diapocynin is neuroprotective and anti-
neuroinflammatory in the MPTP and the progressively degenerative LRRK2R1441G 
transgenic (tg) mouse models (Dranka et al., 2014; Ghosh et al., 2012). To enhance efficacy 
at lower doses, we recently synthesized several more potent mitochondria-targeted apocynins 
with different carbon-chain lengths by conjugating with triphenylphosphonium cation 
moiety. The lipophilic chain and delocalized cationic moiety in the mitochondria-targeted 
apocynin (Mito-Apo) increases its cell permeability and sequestration into mitochondria 
(Dranka et al., 2014). We recently demonstrated that a low oral Mito-Apo dose (3 mg/kg) 
prevented hyposmia and loss of motor function in the LRRK2R1441G tg mouse model (11). 
The compound also showed moderate efficacy against dopaminergic neurodegeneration in 
the MPTP mouse model (Ghosh et al., 2016b). The next logical step is to enhance Mito-Apo 
bioavailability by using nano-carriers to facilitate transport and delivery to the central 
nervous system (CNS). 
 
By combining the ability to cross highly selective biological barriers with intracellular 
targeting, nano-carriers can deliver diverse payloads to organelles with reduced toxicity and 
increased bioavailability (Ross et al.). Biodegradable nanomaterials have been extensively 
evaluated for drug delivery across the BBB (Mallapragada et al., 2015). In particular, 
biodegradable polyanhydride-based nano-carriers have been utilized to provide sustained 
delivery of diverse payloads (Binnebose et al., 2015; Brenza et al., 2015; Carino et al., 2000; 
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Carrillo-Conde et al., 2015; Determan et al., 2004; Determan et al., 2006; Haughney et al., 
2013; Masters et al., 1993; Park et al., 1998; Ross et al., 2015; Storm et al., 2002; Torres et 
al., 2007; Vela Ramirez et al., 2014; Weiner et al., 2008). Polyanhydride nanoparticles 
possess excellent biocompatibility and erodible surfaces, both of which are central to their 
utilization as delivery vehicles (Burkersroda et al., 2002). Polyanhydride-based carriers have 
been translated to the clinic as evidenced by the FDA-approved Gliadel® wafer, which is 
composed of sebacic acid (SA) and 1,3 bis(p-carboxyphenoxy)propane (CPP), and carries the 
anti-cancer drug, carmustine (Westphal et al., 2006). Copolymers based on SA, CPP, 1,6 
bis(p-carboxyphenoxy)hexane (CPH), and 1,8 bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) have been used for sustained delivery. A major advantage of polyanhydrides is that 
by chemically altering their copolymer composition, their degradation rates can be varied 
from days to months, offering exceptional control of the release rate of encapsulated 
payloads (Jain et al., 2008; Shieh et al., 1994; Tabata and Langer, 1993). Moreover, these 
particles can be functionalized with ligands to enable targeted delivery to specific types of 
cells and/or tissues (Chavez-Santoscoy et al., 2012; Narasimhan et al., 2015; Phanse et al., 
2014). However, little information exists on the interaction of these nanomaterials with 
neuronal cells. In this work, we demonstrate that polyanhydride nanoparticles can efficiently 
deliver Mito-Apo to a mesencephalic neuronal cell line and to primary cortical neurons. For 
these studies, 20:80 CPH:SA nanoparticles were utilized because of their dual capabilities to 
rapidly deliver payloads (Petersen et al., 2010; Shen et al., 2002) and to be internalized 
efficiently by phagocytic cells (Petersen et al., 2009). 
  
220 
 
 
Methods 
Materials 
Synthesis of 20:80 CPH:SA copolymer was performed as described previously (Kipper et al., 
2002; Shen et al., 2002). Proton NMR (VXR-300, Varian) was used to measure polymer 
molecular weight and purity. Quantum dots (QDs, λex = 554 nm, λem = 627 nm) were 
purchased from Sigma-Aldrich. Neurobasal medium, RPMI 1640 and Dulbecco’s modified 
Eagle’s media (DMEM), B27 supplement, fetal bovine serum (FBS), Trypsin-EDTA (TE), 
L-glutamine, penicillin, and streptomycin were purchased from Invitrogen. The MTS cell 
viability kit (Catalog# G3580) was acquired from Promega. Primary antibodies against 
cleaved caspase-3 (Catalog# 9661) and β-III tubulin (Catalog# 14545) were purchased from 
Cell Signaling and Millipore, respectively.  
 
Mito-apo synthesis 
Mito-Apo was synthesized by modifying a previous protocol for Mito-Q and long-chain 
Mito-Apo-C11 synthesis (Dranka et al., 2014; Ghosh et al., 2010; Kelso et al., 2002). Briefly, 
acetylvanillic acid chloride was synthesized by first mixing acetylvanillic acid with thionyl 
chloride, and then dissolving the mixture in methylene chloride, 
aminoethyltriphenylphosphonium bromide, and pyridine. The acetylated Mito-Apo was 
purified on a silica gel column followed by removal of the acetyl protective group. The final 
product was purified and characterized by HPLC and LC-MS (Dranka et al., 2014; Ghosh et 
al., 2010; Kelso et al., 2002). 
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Nanoparticle synthesis 
Either 0.5 wt% QD or 5 wt% Mito-Apo were incorporated into polyanhydride nanoparticles 
by a modified anti-solvent nano-encapsulation method (Ulery et al., 2009). Briefly, the 
synthesized polymer (100 mg), QD, or Mito-Apo (0.1 or 0.2 mg) were dispersed in 4 mL of 
methylene chloride (Fisher Scientific) and sonicated for 60 s with a sonication probe (Sonics 
and Materials) (Gendelman et al., 2015). The solution was poured into 1 L of pentane (Fisher 
Scientific) and the particles were recovered by vacuum filtration. The particle morphology 
and particle size were determined using scanning electron microscopy (Quanta 250 FE-SEM, 
FEI). ImageJ 1.43u (National Institutes of Health) was utilized to quantify primary particle 
sizes for construction of the particle size distribution. 
 
Folic acid surface functionalization 
Functionalization of polyanhydride nanoparticles with folic acid (FA) was performed using a 
two-step amine-carboxylic acid coupling reaction. We performed studies using this reaction 
with other molecules to functionalize polyanhydride nanoparticle surfaces (Carrillo-Conde et 
al., 2011; Chavez-Santoscoy et al., 2012), and the optimized conditions were used in the FA 
functionalization as described below. 
 
The coupling reaction was performed by incubating a nanoparticle suspension (33 mg/mL) in 
ultrapure water with 10 equivalents of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC), 12 equivalents of N-hydroxysuccinimide (NHS), and 10 equivalents of 
ethylenediamine. The first incubation was carried out for 1 h at 4°C and a constant agitation 
of 350 rpm. Next, the nanoparticle suspension was centrifuged at 10,000 rpm for 10 min. 
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After removing the supernatant, an equal amount of ultrapure water was added to the 
nanoparticles, vortexed, centrifuged again to remove excess reactants, and the new 
supernatant was removed. The second step was performed by mixing 10 equivalents of EDC, 
12 equivalents of NHS, and corresponding equivalents of FA in ultrapure water under 
constant agitation of 350 rpm for 1 h at 4°C. Particles were centrifuged and the washing step 
was performed as previously described. Next, nanoparticles were vacuum-dried for 1 h. 
During the functionalization process, probe sonication was used before and after incubation 
to break agglomerated particles.  
 
Experiments with varying amounts of FA were performed to optimize the amount of FA 
needed to functionalize the nanoparticles. Surface-functionalized nanoparticles were 
characterized by measuring the zeta potential using quasi-elastic light scattering (QELS, 
Zetasizer Nano, Malvern Instruments Ltd.) and XPS analysis (PHI 5500 MultiTechnique 
system, Physical Electronics, Inc.). Binding energies were referenced to the aliphatic 
hydrocarbon peak (285.0 eV). High-resolution C1s peaks were collected and fitted using 
CasaXPS software (RBS Instruments). 
 
Mito-Apo release 
Quantification of Mito-Apo encapsulation efficiency and release kinetics was carried out. For 
these studies, the Mito-Apo-containing nanoparticles were suspended in phosphate buffered 
saline (PBS, pH 7.4) at 37°C on a shaking incubator. At specific time points, the particles 
were separated from the aqueous media by centrifugation, and after collecting each 
supernatant, the remaining nanoparticles were resuspended in fresh PBS. The supernatants 
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were analyzed by HPLC (Agilent Technologies 1200). 20 µL samples were injected and 
separation was performed with a Kinetex C18 column (Phenomenex) using a gradient elution 
comprising of solvent A (90% water and 10% acetonitrile) and solvent B (100% acetonitrile) 
for seven min at a flow rate of 1.5 mL/min at 40°C. Mito-Apo was quantified by UV 
absorbance at a wavelength of 262nm.  
 
For clarity, henceforth NP will refer to non-functionalized nanoparticles, while particles 
functionalized with 0.25 eq. of FA will be designated as FA-NP and particles functionalized 
with 2 eq. of FA will be designated as 2FA-NP. Mito-Apo-encapsulated particles will be 
designated as M:(NP) or M:(FA-NP) depending on the absence or presence of FA 
functionalization. 
 
Cell culture 
Immortalized rat mesencephalic cells (N27) were grown in RPMI media supplemented with 
10% FBS, 1% L-glutamine, penicillin (100 units/mL) and streptomycin (100 units/mL), and 
maintained at 37°C in a humidified atmosphere of 5% CO2 as described elsewhere 
(Harischandra et al., 2015; Song et al., 2011). 
 
Primary cortical neurons were isolated and prepared as described previously (Ghosh et al., 
2013). Briefly, cortical neurons were isolated from mouse embryos on gestational days 14-15 
and maintained in ice-cold DMEM followed by dissociation using 0.25% TE at 37°C for 15 
min. The action of TE was stopped by DMEM containing 10% FBS. Single cell suspension 
was achieved by triturating the neurons several times through a 10 mL pipette. Neurons were 
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plated at 0.1 x 106 cells per well on 96-well plates (Costar) coated with poly-D-lysine (PDL, 
50 µg/mL). Cultures were grown in neurobasal media with B27 neuronal supplement, 500 
mM L-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin. Primary neurons were 
maintained in a humidified atmosphere with 5% CO2 at 37°C for seven days with half the 
media changed every two days. 
 
The Lund human mesencephalic (LUHMES) cell line, derived from female human 
embryonic ventral mesencephalic cells by conditional immortalization (tetracycline-
controlled v-myc-overexpression) and subsequent clonal selection, was obtained from the 
American Type Culture Collection. This cell line can be differentiated into post-mitotic 
neurons with a dopaminergic phenotype (Ay et al., 2015; Jin et al., 2014). Undifferentiated 
LUHMES cells were propagated in Advanced DMEM/F12 supplemented with 1× N-2 
supplement, 2 mM L-glutamine, and 40 ng/mL recombinant bFGF on multi-well plates pre-
coated with 50 µg/mL poly-L-ornithine and 1 µg/mL fibronectin. Differentiation of 
LUHMES cells was initiated by the addition of differentiation medium containing Advanced 
DMEM/F12, 1× N-2 supplement, 2 mM L-glutamine, 1 mM dibutyryl cAMP, 1 µg/mL 
tetracycline and 2 ng/mL recombinant human GDNF. After two days, cells were trypsinized 
and seeded onto multi-well plates at a density of 1.5 × 105 cells/cm2. LUHMES cells 
differentiate into a dopaminergic phenotype after being cultured an additional three days in 
differentiation medium. For 6-hydroxydopamine (6-OHDA) treatment studies, at day five 
differentiated LUHMES cells were pre-treated in the presence or absence of the respective 
treatments for 12 h and co-incubated with 30 µM of 6-OHDA for another 12 h. 
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Cell viability 
To evaluate if the nanoparticles are toxic to neurons, N27 cells and primary cortical neurons 
were incubated for 24 h with 100 µg/mL of NP, FA-NP and 2FA-NP. Cell viability was 
measured by Cell Titer 96® AQueous Non-radioactive Cell Proliferation Assay (MTS assay, 
Promega G5430) as described previously (Jin et al., 2014). Briefly, 20 µL of MTS reagent 
was added to each well 1.5 h prior to incubation. Next, 25 µL of 1% SDS was added to each 
well to dissolve the formazan crystals. Absorbance was measured at 490nm using a 96-well 
plate reader (SpectraMax 190, Molecular Devices). A reference wavelength of 670nm was 
used to eliminate background.  
 
Treatment with Mito-Apo-encapsulated NPs 
We seeded 0.1 x 106 primary cortical neurons onto a PDL-coated 96-well plate. Seven days 
post-seeding, cells were pre-treated with either 10 µM Mito-Apo alone or 100 µg/mL of 
M:(NP) or M:(FA-NP) for 24 h. The cells were challenged with 50 µM H2O2 for 1.5 h. Cell 
viability was evaluated by the MTS assay.  
 
Mitochondrial superoxide production 
LUHMES cells (~250,000 per well) were grown in glass bottom dishes 16-18 h prior to 
treatments and exposed to 100 µg/mL of the nano-formulations for 12 h. We added 30 
µg/mL 6-OHDA to all the wells except control wells for another 12 h. Mitochondrial 
superoxide production in the cells was measured using MitoSOX fluorescence probe in 
Hank’s buffered salt solution (HBSS) containing calcium and magnesium, according to the 
manufacturer’s protocol. MitoSOX was added to a final concentration of 5 µM in HBSS. 
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Cells were incubated with MitoSOX for 30 min and washed twice with HBSS. Absorbance 
was measured at 580nm using a 96-well plate reader. 
 
Nanoparticle internalization 
Flow cytometry was used to quantify cellular internalization of QD-containing nanoparticles. 
Briefly, 1.0 x 106 N27 cells seeded in T25 flasks (Corning) were treated with 100 µg/ml of 
CdSeS/ZnS-alloyed QD (λem 490 nm) containing particles (NP, FA-NP or 2FA-NP) 
suspended in 2% RPMI. After 24 h, media was removed and the cells were washed twice 
with sterile PBS (Invitrogen) to remove excess QDs. Cells harvested by trypsinization were 
collected in 2-mL centrifuge tubes and fixed with 2% paraformaldehyde (PFA) for 20 min. 
Internalization of QD-containing nanoparticles was analyzed using a FACScantoTM flow 
cytometer (BD Biosciences, excitation - UV spectrum, emission - 490nm). Results are 
reported as percentage of total cell population normalized to control (cells without QDs).  
 
Confocal microscopy 
N27 cells (15,000/well) were plated on PDL-coated coverslips and particles were added. 
After 24 h, cells were washed several times with sterile PBS and fixed in 4% PFA. Non-
specific binding was blocked using 2% bovine serum albumin (BSA, (Sigma) in PBS with 
0.1% Triton-X (Sigma) and 0.01% Tween-20 (Bio-Rad) for 30 min. Cells were stained for 20 
min with 10 µM phalloidin (Invitrogen). Nuclei were stained with 2 µg/mL Hoechst 33342. 
Images were taken using an inverted Leica TCS NT confocal microscope.  
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Transmission electron microscopy (TEM) imaging of nanoparticles 
Primary cortical neurons were incubated for 24 h with 100 µg/mL QD-containing NP, FA-
NP and 2FA-NP. After treatment, cells were washed several times with sterile PBS and fixed 
with 2% glutaraldehyde (w/v) and 2% PFA (w/v) in PBS (pH 7.4) for 24 h at 4°C. The 
samples were washed in buffer and subsequently fixed in 1% osmium tetroxide in 0.1 M 
cacodylate buffer for 1 h at RT. Following fixation, the samples were dehydrated in a graded 
ethanol series and infiltrated and embedded using a modified EPON epoxy resin (Embed 
812). Resin blocks were polymerized for 48 h at 70°C. Thick and ultrathin sections were 
prepared using a Leica UC6 ultramicrotome (Leeds Precision Instruments). The ultrathin 
sections were collected onto copper grids and images were collected using a JEM 2100 200 
kV scanning and transmission electron microscope (Japan Electron Optic Laboratories).  
 
Immunocytochemistry 
Primary cortical neurons were seeded on PDL-coated coverslips at 0.2 x 106 neurons/well. 
After pre-treatment for 24 h with 100 µg/mL of M:(NP) or M:(FA-NP), neurons were 
challenged with 50 µM H2O2. After 1.5 h, media was aspirated and cultures were washed 
twice with sterile PBS. Cells were fixed in 4% PFA for 20 min followed by blocking with 
3% BSA containing 0.1% triton-X and 0.01% Tween-20 for 1 h. Primary antibodies to 
cleaved caspase-3 (rabbit monoclonal at 1:1500) and β-III tubulin (mouse monoclonal at 
1:2000) were added to each well and incubated overnight at 4°C. The next day, each well 
was washed five times with PBS and incubated at RT for 1.5 h with the secondary antibodies 
Alexa-488 conjugated (1:10,000) donkey-anti mouse and Alexa-555 conjugated donkey anti-
rabbit (1:10,000). Nuclei were counterstained for 7 min with Hoechst (1:5000, Invitrogen). 
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Cells were mounted and coverslipped on clean slides (Colorfrost, Fisher) with Fluoromount. 
Neurons were imaged with a SPOT digital camera (Diagnostic Instruments) attached to a TE-
2000U inverted fluorescence microscope (Nikon). 
 
High affinity [3H] dopamine uptake assay 
Dopamine uptake measurements were measured as described previously (Ay et al., 2015; 
Harischandra et al., 2014) with modifications. Briefly, differentiated LUHMES cells grown 
in 6-well plates were washed twice with Krebs-Ringer buffer (16 mM NaH2PO4, 120 mM 
NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM MgSO4, 1.3 mM EDTA, and 5.6 mM glucose, 
pH 7.4), followed by incubation with 10 nM [3H] dopamine for 30 min at 37°C. Next, the 
cultures were triple-washed with fresh ice-cold Krebs-Ringer buffer and lysed with 1N 
NaOH. Radioactivity was measured with a liquid scintillation counter (Tri-Crab 4000, 
Packard) after adding a 5-mL scintillation cocktail to each vial. Specific dopamine uptake 
was expressed as mean values of counts.  
 
Statistical analysis 
Data analysis was performed using Prism 4.0 (GraphPad). One-way ANOVA was applied to 
compare control and treatment groups. Differences with p<0.05 were considered significant 
from three or more independent experiments, which were performed in triplicate. 
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Results 
Nanoparticle synthesis and characterization 
The anti-solvent nano-encapsulation method resulted in polydisperse spherical particles 
(Table 1). The surface functionalization of the nanoparticles with FA was performed with a 
low and high FA surface concentration. The functionalized particles were characterized by 
QELS and XPS (Table 1). All three formulations (with or without functionalization) resulted 
in negatively charged particles. The degree of FA attachment increased with percent 
nitrogen, which was quantified using XPS.  
 
The nanoparticles were formulated with QDs for imaging purposes or Mito-Apo for 
evaluating therapeutic efficacy (electron microscopy images in Table 1). These particles were 
subsequently functionalized with FA, and no statistically significant primary particle size 
differences were observed between the various formulations (Table 2). The Mito-Apo-
containing particles were subjected to complete degradation to determine the encapsulation 
efficiency. The encapsulation efficiency (Table 2) indicated a loss of Mito-Apo during 
functionalization, from 57% for NP to 43% for FA-NP to 37% for 2FA-NP. 
 
The cumulative release profile of Mito-Apo from the particles over the first three days is 
shown in Fig. 1. After two hours of degradation, a greater amount of Mito-Apo was released 
as a burst from the non-functionalized particles. This initial burst could account for the lower 
encapsulation efficiency of the surface-functionalized particles since this would occur during 
the functionalization process. After 24 h of degradation, approximately 35% of the Mito-Apo 
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was released from the functionalized particles. A near linear release of drug was observed 
from all the nano-formulations. 
 
Nanoparticle toxicity and internalization 
Prior to encapsulation of Mito-Apo into the nano-formulations, their toxicity was assessed 
using the N27 dopaminergic neuronal cell line. None of the nano-formulations synthesized 
had any effect on cell viability at any of the doses tested (Fig. 2a). Next we determined if 
N27 cells differentially internalized the various nano-formulations using QD-loaded 
particles. Cellular uptake was determined by two independent methods: flow cytometry and 
confocal microscopy. Flow cytometric analysis revealed uptake of both NP and FA-NP. 
Functionalization with FA improved nanoparticle internalization, with 32% of N27 cells 
internalizing FA-NP compared to only 25% of cells internalizing NP (Fig. 2b). However, the 
amount of FA on the particle surface may have affected the internalization, because only 10-
15% of N27 cells internalized 2FA-NP.  
 
We further confirmed nanoparticle internalization in N27 cells by confocal microscopy, with 
consecutive z-stack images revealing that most of the particles were internalized and not 
attached to the surface of cells (Fig. 2c). Consistent with the flow cytometry results, N27 
cells internalized a significantly higher number of FA-NP compared to NP or 2FA-NP. 
Together, these results indicate that FA-NP were internalized more efficiently by neuronal 
cells than NP. 
Next, we evaluated the potential toxicity of the nano-formulations in primary cortical cells. 
As a positive control for cell death, some cells were treated with 50 µM of H2O2. Treatment 
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of primary cortical neurons with the oxidative stress inducer H2O2 alone reduced cell 
viability by more than 30%. Similar to the results obtained with N27 cells, none of the 
treatments had any effect on the viability of primary cortical cultures (Fig. 3a). Treating the 
cells with Mito-Apo alone also did not reduce cell viability.  
Intracellular localization of QD-loaded NP and FA-NP in primary cortical neurons was 
evaluated using TEM. Both NP and FA-NP were internalized by neurons (Fig. 3b). The 
images (Fig. 3b) indicate that both nano-formulations were located within the cytosol (shown 
by black arrows) and not associated with mitochondria (indicated by black stars).  
 
Mito-Apo-encapsulated particles protect neurons against oxidative stress-induced death 
Since FA-NP was internalized more efficiently compared to 2FA-NP, FA-NP was evaluated 
for its therapeutic efficacy and NP was used as a control. In these experiments, we tested the 
neuroprotective effect of M:(NP) and M:(FA-NP) in primary cortical neurons. While H2O2 
treatment reduced cell viability by >50%, pre-treating cells with either Mito-Apo alone, 
M:(NP), or M:(FA-NP) significantly protected against H2O2-induced toxicity (Fig 4a). 
However, M:(FA-NP) was more efficacious than M:(NP) or Mito-Apo alone. Together, these 
results indicate that encapsulation of Mito-Apo into FA-NP facilitates Mito-Apo 
internalization by neurons and increases its efficacy.   
 
Next, we evaluated caspase-3 activation using immunofluorescence since the proteolytic 
activation of caspase-3 is widely used as a marker of apoptotic cell death (Kaul et al., 2003; 
Porter and Janicke, 1999; Tadokoro et al., 2010). Primary cortical neurons were incubated 
with the nano-formulations and treated with 50 µM H2O2 as described previously. Very 
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strongly cleaved caspase-3 immunostaining (red) was evident in the H2O2-treated primary 
cortical neurons (Fig. 4b). However, neurons co-treated with M:(NP), M:(FA-NP) or Mito-
Apo alone showed less cleaved caspase-3 immunostaining. The cleaved caspase-3 
immunostaining in the H2O2-treated neurons increased three-fold compared to untreated 
controls (Fig. 4b), whereas treating the cells with Mito-Apo-encapsulated nano-formulations 
(with or without FA) and Mito-Apo alone limited the H2O2-induced increase in cleaved 
caspase-3 immunostaining to 1.5-, 2.0- and 2.5-fold, respectively. Together these results 
indicate that M:(FA-NP) effectively inhibited H2O2-induced cell death, especially compared 
to M:(NP) or Mito-Apo alone. 
 
Neuroprotective effect of M:(FA-NP) against 6-OHDA-induced superoxide production, 
caspase-3 activation, and dopaminergic cell loss 
For these studies, we used human mesencephalon-derived neuronal LUHMES cells, which 
are used to model human dopaminergic degeneration (Zhang et al., 2014). With the addition 
of cAMP and GDNF, LUHMES cells differentiate by forming long axons with relatively 
dense interconnections typically seen in the mesencephalic region in the brain (Scholz et al., 
2011). One of the early responses of stressed neurons is the retraction of their axons followed 
by loss of membrane integrity as the neurons undergo apoptosis. Superoxide production, 
caspase-3 cleavage, and dopamine uptake are markers of mitochondrial dysfunction, 
apoptosis and tyrosine hydroxylase (TH) neuronal loss respectively. Pre-treatment with Mito-
Apo alone or M:(NP) failed to reduce superoxide production in LUHMES cells challenged 
with 6-OHDA (Fig. 5a). In contrast, LUHMES cells pre-treated with M:(FA-NP) had 
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significantly lower production of superoxide following 6-OHDA treatment, similar to the 
untreated controls.  
 
Next, we counted TH-positive neurons by a [3H] dopamine uptake assay. Healthy 
dopaminergic neurons can re-uptake dopamine while stressed neurons have reduced 
dopamine uptake. As expected, 30 µM 6-OHDA caused a significant loss of dopaminergic 
neurons compared to untreated controls. However, pre-treatment with M:(FA-NP) 
significantly attenuated the 6-OHDA-induced loss of dopaminergic neurons. In contrast, pre-
treatment with M:(NP) or Mito-Apo alone did not significantly protect dopaminergic neurons 
(Fig. 5b). 
 
Finally, we determined proteolytic activation of caspase-3 using cleaved caspase-3 antibody 
in immunofluorescence experiments. Significantly more cleaved caspase-3 stained cells were 
observed in 6-OHDA-treated LUHMES cells compared to untreated controls (Fig. 5c). 
Similar to the results observed with cortical neurons, pre-treatment with M:(FA-NP) 
significantly protected LUHMES cells incubated with 6-OHDA compared to cells exposed to 
6-OHDA alone (p<0.001). Cells pre-treated with M:(NP) and Mito-Apo alone also showed 
fewer cleaved caspase-3-positive neurons compared to the 6-OHDA-alone group (p<0.05). 
However, the neuroprotection provided by pre-treatment with M:(FA-NP) was more 
effective at preventing dopaminergic neuronal degeneration compared to the other 
treatments. Together, these results demonstrate that M:(FA-NP) is more efficacious in 
protecting human mesencephalic neurons against mitochondrial damage and apoptotic cell 
death. 
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Discussion 
New drugs are urgently needed to slow the progression of debilitating brain disorders, such 
as CTE, AD, and PD. We previously demonstrated the effectiveness of Mito-Apo against 
oxidative stress (11). In this work, we demonstrate that Mito-Apo efficacy can be further 
enhanced with its incorporation into targeted biodegradable nano-carriers. Nano-formulated 
Mito-Apo provided excellent protection against oxidative stress-induced mitochondrial 
dysfunction and neuronal damage in a rat dopaminergic neuronal cell line, mouse primary 
cortical neurons, and a human mesencephalic cell line. 
 
A significant advantage provided by the polyanhydride nanoparticles is the slow and 
controlled erosion of the particles, enabling a sustained release of the encapsulated cargo 
(Binnebose et al., 2015). The FA functionalization of Mito-Apo-containing nano-
formulations lowered the encapsulation efficiency as expected because of exposure to 
aqueous conditions. However, a near-linear Mito-Apo release profile was observed from the 
nano-formulations (Fig. 1). This is important because it indicates that the drug release rate 
over time to neurons will be constant, potentially leading to increased bioavailability. Adding 
to the vast literature on the biocompatibility of polyanhydride particles, functionalized or 
otherwise (Adler et al., 2009; Huntimer et al., 2013a; Vela-Ramirez et al., 2015), our work 
shows that these nanoparticles were non-toxic to dopaminergic or primary cortical neurons 
(Figs. 2a and 3a).  
 
Unlike other cells, neuronal uptake of exogenously added compounds such as xenobiotics or 
drugs is very limited (Sun et al., 2013). However, treating neuronal cell lines with FA-
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functionalized polyanhydride particles significantly increased the percentage of neurons 
internalizing these particles in comparison to cells internalizing non-functionalized particles 
(Fig. 2c). This is likely due to the uptake of the functionalized nanoparticles by receptor-
mediated endocytosis via folate receptors present on neurons and is consistent with previous 
studies on folate-modified nano-carriers (Kanmogne et al., 2012; Li et al., 2015; Puligujja et 
al., 2015; Puligujja et al., 2013). It was observed (Fig. 2c) that particles functionalized with 2 
eq. FA were internalized by fewer cells compared to particles functionalized with 0.25 eq. 
FA or even non-functionalized particles. While not specifically investigated herein, this 
could be attributed to oversaturation of the folate receptors by excess FA, which might 
reduce that receptor’s ability to carry out endocytosis (Saul et al., 2003). Thereafter, we 
investigated nano-formulations functionalized with 0.25 eq. of FA (FA-NP), using non-
functionalized particles (NP) as an internal control. 
 
Even with 43% encapsulation efficiency and 35% of the Mito-Apo being released over the 
first 24 hours, M:(FA-NP) provided equivalent if not better protection than Mito-Apo alone 
against apoptosis (Fig. 4) and dopaminergic neuronal degeneration (Fig. 5). The amount of 
Mito-Apo required to confer protection to neurons might be much less than the 10 µM of 
Mito-Apo used in the in vitro protection studies. Our hypothesis is that a steady supply of the 
antioxidant in small (but appropriate) quantities – enabled by the nanoparticles – is more 
beneficial than delivering a large bolus of Mito-Apo alone. This may explain why M:(FA-
NP) is more efficacious in neuroprotection over Mito-Apo alone. The encapsulation 
efficiency coupled with the equivalent protection as compared to Mito-Apo alone also 
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indicates that the nano-formulations provide dose-sparing, which has been observed 
previously (Binnebose et al., 2015; Huntimer et al., 2013b). 
 
While encapsulating Mito-Apo within nanoparticles, it is possible that a fraction of the Mito-
Apo segregated to the nanoparticle surface, which may guide the particles to the 
mitochondria. However, TEM images (Fig. 3b) showed very few internalized particles 
(regardless of functionalization) inside the mitochondria, which suggests that the enhanced 
cellular internalization compensates for the lower amount of Mito-Apo released within the 
cells. Consequently, M:(NP) and M:(FA-NP) were more effective at preventing H2O2-
induced cell death when compared to Mito-Apo alone in both N27 cells and primary cortical 
neurons (Figs. 3 and 4). Similarly, cells pre-treated with M:(FA-NP) were protected against 
6-OHDA-induced superoxide production, caspase-3 activation, and TH neuronal loss (Fig. 
5). These observations support the hypothesis that the actual amount of Mito-Apo required 
for neuroprotection is small. Thus, to protect neurons from oxidative stress, the sustained 
release of small amounts of Mito-Apo over a period of 24 hours is more effective than 
delivering a single bolus of a larger amount of the antioxidant.  
 
Conclusions 
Our studies demonstrate that intracellular delivery of the mitochondria-targeted antioxidant, 
Mito-Apo, using FA-modified polyanhydride nanoparticles effectively protected against 
oxidative stress-induced neuronal damage in neuronal cell types across three species, 
including humans. While nanoparticle-mediated delivery of antioxidants for treatment of 
neurodegenerative disorders is promising, the ability of these particles to transverse the BBB 
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and deliver this cargo needs to be evaluated in animal models. Recent work demonstrated 
that monocyte-internalized FA-functionalized particles efficiently traversed the BBB 
(Kanmogne et al., 2012). Ongoing studies are focused on delivery of Mito-Apo-encapsulated 
FA-functionalized polyanhydride nanoparticles to the CNS.  
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Figures 
Table 1. Characterization of non-functionalized and folic acid functionalized 20:80 CPH:SA 
nanoparticles. 
 
Nano- 
formulation 
SEM  
Photomicrographs 
ζ potential 
     (mV) 
Carbon  
   (%) 
Oxygen  
   (%) 
Nitrogen  
   (%) 
20:80 CPH:SA 
nanoparticles 
 (NP) 
 
-25.7 ± 4.7 74.5 ± 0.1 25.5 ± 0.1 0.0 ± 0.0 
0.25 eq. FA-NPs 
 (FA-NP) 
 
-12.5 ± 4.7 71.8 ± 2.0 21.6 ± 0.4 6.5 ± 1.7 
2.0 eq. FA-NPs 
(2FA-NP) 
 
-25.4 ± 7.1 64.7 ± 1.2 21.6 ± 0.1 13.7 ± 1.2 
 
Fig. 1. Mito-Apo release kinetics from 20:80 CPH:SA nanoparticles. The amount of 
Mito-Apo released at each time point was normalized by the total amount of Mito-Apo 
encapsulated within the particles. The experiments were performed in triplicate and are 
reported as means	± SEM. 
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Table 2. Characterization of QD- and Mito-Apo-loaded 20:80 CPH:SA nanoparticles. 
Payload Formulation Geometric Mean 
          (nm) 
Geometric SD Encapsulation  
Efficiency (%) 
     
QD NP 254 1.33 N/A 
 FA-NP 315 1.21 N/A 
 2FA-NP 346 1.21 N/A 
Mito-Apo M:(NP) 324 1.26 56.5 ± 3.8 
 M:(FA-NP) 385 1.17 42.7 ± 1.8 
 M:(2FA-NP) 346 1.21 36.6 ± 3.7 
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Fig. 2. Nanoparticle interactions with N27 neuronal cells. Cells were treated with 20:80 
CPH:SA particles for 24 h. a) Cell viability was measured by using the MTS reagent. Data is 
expressed as percent viability compared to H2O2-treated controls. QD-loaded NPs were 
added separately to N27 cells for 24 h. Internalization was measured by flow cytometry (b) 
249 
 
 
and confocal microscopy (c). 40% of the cells internalized QD-loaded FA-NP as compared to 
only 25% of the cells that internalized QD-loaded NP. 
 
 
Fig. 3. Assessment of neuronal viability and nanoparticle internalization. Primary 
cortical cells were pre-treated for 24 h with NP, FA-NP, and 2FA-NP. a) MTS assay was 
used to measure the mitochondrial conversion of the tetrazolium salt to a water-soluble 
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formazan salt. Neurons treated with H2O2 for 1.5 h were used as a control for oxidative 
stress-induced cell death. b) TEM photomicrographs show presence of QD-loaded NP and 
FA-NP in the cytosol of cortical cells. Scale bar: 100 nm. 
 
Fig. 4. Efficacy of Mito-Apo-encapsulated nano-formulations on primary cortical 
neurons. Neurons were pre-treated with the various nano-formulations for 24 h and 
challenged with H2O2 for 1.5 h. a) Cell viability was measured by MTS reagent. Data is 
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expressed as percent viability compared to untreated controls. b) Neurons were stained for β-
III tubulin (green) and cleaved caspase-3 (red). Cell death was quantified by the presence of 
cleaved caspase-3 and by the reduction in neurite length. Caspase-3-positive cells were 
quantified as shown in the graph. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Neuroprotective role of M:(FA-NP) against 6-OHDA-induced dopaminergic 
neuronal degeneration. a) LUHMES cells were treated with 6-OHDA and superoxide levels 
were measured as fluorescence intensity. b) Neuronal function was assessed by dopamine 
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uptake. Cells were pre-treated with various formulations and exposed to 6-OHDA. Dopamine 
uptake was measured using a high affinity [3H] assay and expressed as mean values of 
counts. c) Cell death was quantified by the presence of cleaved caspase-3 in cells exposed to 
various treatments. Caspase-3-positive cells were quantified as shown in the graph. 
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